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Summary
Summary
In comparison to cell division, the mechanisms underlying cell growth are poorly 
understood. Progress towards understanding the latter requires systems in which 
cell growth can be studied independently from proliferation. Cardiomyocytes 
terminally differentiate and lose the capacity to divide shortly after birth in 
mammals. Enlargement of existing cardiomyocytes accounts for the increase in 
heart size that occurs during post-natal development. This increase in cell size, in 
the absence of proliferation, is known as hypertrophy. Cardiomyocyte 
hypertrophy also occurs in the adult heart in response to a range of physiological 
stimuli, allowing the heart to adjust its contractile capacity according to demand. 
However, if sustained, cardiomyocyte hypertrophy is associated with several 
serious cardiovascular disorders, and is an independent risk factor for heart 
disease.
One of the key hallmarks of hypertrophy is an increase in protein synthesis; 
however, the mechanisms responsible for this increased translation are not fully 
understood. RNA polymerase III (pol III) plays a vital role in protein synthesis 
by producing several components of the cellular biosynthetic machinery, 
including transfer (t)RNAs and 5S ribosomal (r)RNA. Thus, this project aimed to 
investigate whether pol III transcription is upregulated during hypertrophic 
growth, and if so, to elucidate the mechanisms responsible for such control.
Various stimuli induce hypertrophy in primary cultures of rat cardiomyocytes. 
Data presented in this thesis show that this hypertrophic growth accompanies a 
substantial increase in transcription by pol III, along with markedly elevated 
levels of various pol III products, including tRNAs and 5S rRNA. Furthermore, 
analysis of mouse ventricular tissue demonstrated that pol III transcription is also 
enhanced during hypertrophy in the myocardium in situ.
Several proteins are known to regulate transcription by pol III in proliferating 
cell lines. These include activators, such as c-Myc and extracellular signal- 
regulated kinase (ERK), and repressors, such as the retinoblastoma protein (RB).
Ill
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Summary
In addition, these molecules have been implicated in the regulation of 
cardiomyocyte hypertrophy; therefore, their involvement in pol III transcriptional 
control was investigated in these terminally differentiated cells. This revealed 
that c-Myc and ERK, which are known to promote hypertrophic growth, can 
activate pol III transcription in cardiomyocytes. On the other hand, although 
normally associated with controlling the cell division cycle, RB has recently been 
implicated as a negative regulator of hypertrophy, and in the present study, RB 
was shown to attenuate transcription by pol III in the heart. The activation or 
inhibition of pol III transcription by these proteins is likely to contribute to their 
ability to induce or repress hypertrophic cell growth.
Therefore, proliferating and non-dividing terminally differentiated cells appear to 
use some common means to regulate pol III transcription, and hence cellular 
biosynthetic capacity. However, a novel pol III transcriptional control 
mechanism was also identified in this study, namely the hypertrophy-associated, 
ERK-mediated induction of the pivotal pol III-specific transcription factor Brfl. 
Further work is required to establish whether Brfl induction contributes to 
increased pol III transcription during the growth of other terminally differentiated 
cell types, or whether this mechanism is unique to cardiomyocytes. Thus, 
numerous mechanisms contribute to the control of transcription by pol III in 
cardiomyocytes, suggesting that such regulation is a critical determinant of 
hypertrophic cell growth.
In summary, this thesis has identified a previously undescribed means by which 
hypertrophic stimuli could increase the protein synthetic capacity of 
cardiomyocytes, and has delineated the mechanisms responsible. This has 
important implications for understanding the molecular basis of pathological 
cardiomyocyte hypertrophy, and cell growth in general.
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1 Introduction
CHAPTER 1 
Introduction
1.1 Eiikarvotic transcription and cell growth
Cellular functions, including growth, division, differentiation and death, are 
ultimately determined by the appropriate expression of specific genes. The first 
stage of gene expression is transcription, a process by which large, complex 
RNA polymerase enzymes synthesise RNA using specific DNA templates. In 
eukaryotic cells, the task of transcribing nuclear genes is shared by RNA 
polymerases I, II and III (White, 1998). Each of these polymerases is dedicated 
to the transcription of a different set of genes, known as class I, II or III genes, 
accordingly. RNA polymerase I (pol I) transcribes genes encoding the 45S 
ribosomal (r)RNA, which serves as a precursor for the 5.8S, 18S and 28S rRNAs 
(Grummt, 2003). This accounts for up to 60% of cellular RNA synthesis (Moss 
and Stefanovsky, 2002). RNA polymerase II (pol II) produces messenger 
(m)RNAs, which code for cellular proteins, and many small nuclear (sn)RNAs, 
which are involved in mRNA processing (White, 1998). RNA polymerase III 
(pol III) is responsible for 10 to 20% of all nuclear transcription (Moss and 
Stefanovsky, 2002), and synthesises a variety of small, untranslated RNAs with 
essential roles in metabolism, including transfer (t)RNAs and 5S rRNA (White, 
2002). Tight regulation of these polymerases, and their respective transcription 
machineries, dictates gene expression patterns, and hence cell function. Although 
the proteins encoded by class II genes function in a diverse array of processes, 
the untranslated RNAs produced by pols I and III are primarily involved with
_______ __________________________________
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biosynthesis. This thesis is specifically concerned with pol III transcription and 
its relevance to cell growth.
Cell growth is fundamental to eukaryotic life. Although cell growth and division 
are often considered together, these processes are distinct, with growth resulting 
in an increase in cell mass, and division leading to increased cell number. 
Without cell growth, division could not be sustained, as cells would become 
progressively smaller. Thus, in general, cell growth is rate-limiting for cell 
division (Johnston et al, 1977; Nurse, 1975). In fact, several studies have shown 
that cells must reach a sufficient mass before they will duplicate their DNA and 
divide (Johnston et al, 1977; Killander and Zetterberg, 1965; R0iining et al, 
1981; reviewed by Conlon and Raff, 1999; Fingar et al, 2002). Knowledge of the 
cell division cycle has increased enormously in the last three decades, following 
extensive studies with yeast models, then complementary investigations in 
mammalian cells. However, by comparison, the current understanding of cell 
growth control is fairly limited, despite its primary importance. Therefore, the 
focus of research is turning towards elucidating the mechanisms underlying cell 
growth.
Cell growth is largely due to protein accumulation, which usually occurs as a 
result of increased rates of protein synthesis (Baxter and Stanners, 1978). 
Ribosomes constitute the core of the protein synthetic machinery; consequently, 
ribosome content is a critical determinant of protein accumulation 
(Brandenburger et al, 2001; Camacho et al, 1990; Siehl et al, 1985; Zetterberg 
and Killander, 1965). The abundance of ribosomes within a cell depends on the
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availability of rRNA (Liebhaber et al, 1978), which, as mentioned above, is 
produced by pols I and III. Furthermore, along with ribosomes, the accurate and 
efficient execution of translation requires many specialised, pol Ill-produced 
tRNA species, which, accordingly, also impinge upon cell growth rate (Francis 
and Rajbhandary, 1990). Moreover, pol III synthesises an array of additional 
RNAs that also function in various aspects of cellular biosynthesis, as discussed 
in the following sections. Therefore, regulating class III gene expression clearly 
has the potential to influence the capacity for cell growth.
Although cell division does not usually occur without prior growth, cell growth 
can occur independently of proliferation. For example, mutations that 
specifically block the cell division cycle do not always halt cell growth (Johnston 
et al, 1977; Neufeld et al, 1998; Weigmann et al, 1997). Furthermore, some 
terminally differentiated animal cells that have lost the capacity to divide (such 
as heart and skeletal myocytes and nerve cells), continue to grow during 
development and in adults in response to growth stimuli (Conlon and Raff, 
1999). This type of cell growth is known as hypertrophy, and because it occurs in 
the absence of cell division, provides a useful means for studying mechanisms 
contributing directly to growth. The hypertrophic growth of cardiomyocytes has 
received considerable attention in recent years. These cardiac muscle cells, which 
constitute the bulk of heart mass, withdraw from the cell cycle in the neonate, but 
continue to grow during post-natal development in order to attain the appropriate 
adult heart size (Bugaisky et al, 1992; Hannan and Rothblum, 1995; Leu et al, 
2001; Zak, 1974). Cardiomyocyte hypertrophy can also occur in the adult heart 
as an adaptive response to increased workloads and hormonal cues (Chien et al.
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1991). However, aberrant cardiomyocyte growth is an independent risk factor for 
cardiovascular disease, thus prompting intensive investigation into the molecular 
mechanisms underlying this response (Harjai et al, 1999; Kannel, 1990; Levy et 
al, 1990; Vakili et al, 2001). Although this has led to the characterisation of 
initiating stimuli and intracellular signalling pathways involved, it remains 
unclear how these induce hypertrophy. This thesis explores the possibility that 
changes in pol III transcription contribute to this cell growth control. Before 
addressing this issue, it is important to appreciate the various biosynthetic 
functions of pol IILsynthesised RNAs, the transcription machinery involved in 
their production, and how such transcription can be regulated. These aspects of 
class III gene expression are discussed in this introduction.
1 Introduction
1.2 Class III genes
The genes transcribed by pol III encode a variety of RNAs, typically less than 
400 nucleotides in length. These RNAs, and their functions, are listed in Table 1. 
The sections that follow discuss some of these transcripts in more detail.
Table 1: Summary of class III gene products and their functions*
Pol III Product Known Functions
5S rRNA 
tRNA 
U6 snRNA 
7SLRNA
HI RNA 
MRP RNA
7SK RNA 
vault RNA 
SINE transcripts 
VA RNAs 
EBER RNAs
Involved in protein synthesis as a component of ribosomes 
Involved in protein synthesis as a translational adaptor 
Involved in mRNA splicing
Involved in intracellular protein transport (component of signal 
recognition particle)
Involved in tRNA processing (RNase P component)
Involved in large rRNA splicing and mitochondrial RNA 
processing
Involved in controlling transcriptional elongation by pol II
Component of cytoplasmic vault ribonucleoproteins
Not well defined. Potential role in cellular stress responses
Involved in adenovirus translational control
Thought to be involved in Epstein-Barr virus translational control
*this information is reviewed in White, 2002.
1.2.1 5S rRNA
Along with approximately 80 proteins (Doudna and Rath, 2002), and the 5.BS, 
IBS and 2BS rRNAs produced by pol I, the 120 nucleotide 5S rRNA is an 
essential component of ribosomes in every eukaryotic organism, and therefore is 
vital for protein synthesis (Wool, 1979). As with all class III genes, 5S is
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transcribed in the nucleoplasm. However, following synthesis, 5S rRNA is 
transported to the nucleolus where it is processed and incorporated into the large 
ribosomal subunit, which specifically catalyses the formation of peptide bonds 
(Lafontaine and Tollervey, 2001). Eukaryotic genomes contain multiple 5S 
genes, ranging from 140 in the haploid genome of the yeast Saccharomyces 
cerevisiae, to more than 20 000 copies in Xenopus laevis (Brown, 1971; Elion 
and Warner, 1984). The majority of these X. laevis 5S genes are only expressed 
in the oocyte in order to sustain the rapid growth required during this 
developmental stage (Wolffe and Brown, 1988). Human cells are thought to 
contain 200 to 300 5S genes present in tandem an'ays (International Human 
Genome Sequencing Consortium, 2001). In addition, 5S gene variants and 
untranscribed pseudogenes have been described in some species (White, 2002).
1.2.2 tRNAs
As with 5S rRNA, tRNAs play an essential role in mRNA translation. These 
molecules serve as adaptors, allowing the genetic information carried in a 
particular nucleotide sequence to be translated into the appropriate amino acid 
sequence by the ribosome. Following their initial synthesis, tRNA transcripts are 
processed, and in some cases covalently modified, resulting in mature tRNAs 
which range in length from 70 to 90 nucleotides, and adopt a highly structured L- 
shaped conformation (Creighton, 1997; Hopper and Phizicky, 2003). As 
indicated in Table 1, the class III gene product HI participates in this tRNA 
processing as part of the RNase P endoribonuclease (Bartkiewicz et al, 1989; Lee 
and Engelke, 1989; Lee et al, 1991). There are approximately 50 to 100 distinct 
tRNA species within a eukaryotic cell (Sharp et al, 1984); in the haploid human
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genome, these ai'e encoded by around 500 genes (International Human Genome 
Sequencing Consortium, 2001). Although each of the expressed tRNA species 
has a similar, L-shaped structure, their unique nucleotide sequences allow 
functional specificity. For example, each tRNA will just recognise one particular 
amino acid and deliver this to the growing polypeptide chain only if matched to a 
complementary codon in the mRNA. Thus, tRNAs are vital for the fidelity of 
protein synthesis.
1.2.3 U6 snRNA
Following their initial synthesis by pol II, pre-mRNAs are extensively processed 
prior to translation. For example, 5’ and 3’ end modifications take place and, in 
addition, splicing is required to remove non-coding intron regions, thus 
producing a continuous coding sequence compatible with the translation 
machinery. Pre-mRNA splicing occurs in the nuclei of all eukaryotic cells and is 
performed by spliceosomes. Spliceosomes are abundant complexes, containing 5 
separate snRNA species and many proteins (Hastings and Krainer, 2001). Four 
of these snRNAs are produced by pol II; however, the smallest (106 nucleotides), 
most highly conserved snRNA U6 is manufactured by pol III (Reddy et al, 
1987). The high degree of U6 conservation between different organisms likely 
reflects the prominant role this particular RNA plays in directly catalysing the 
splicing reaction (Nilsen, 2000; Southeimer, 2001; Yean et al, 2000).
1.2.4 7SL RNA
The class III gene 7SL encodes the 300 nucleotide RNA component of the signal 
recognition particle (White, 2002). This signal recognition particle, which also
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contains six polypeptides, is responsible for the appropriate targeting of 
ribosomes engaged in translation to the endoplasmic reticulum, thus delivering 
nascent polypeptide chains to this organelle, where they are modified, correctly 
folded and then further directed to their final destinations (Creighton, 1997).
1,2.5 SINEs
In higher eukaryotes, pol III transcribes several short interspersed elements or 
SINEs. In humans, the most predominant SINEs are the Alu genes, whereas in 
rodents the B1 and B2 SINE families are most abundant. B1 genes are highly 
homologous to Alu genes, and both appear to have evolved from the 7SL gene; 
however, B2 genes are rodent-specific, and are thought to have evolved from 
tRNA genes (White, 2002). These SINE families constitute a significant fraction 
of mammalian genomes: over a million copies of Alu are encoded by the haploid 
human genome (International Human Genome Sequencing Consortium, 2001), 
and approximately 384 000 copies of B1 and 328 000 copies of B2 are present 
per haploid rat genome (Rat Genome Sequencing Project Consortium, 2004). 
Retrotransposition is believed to account for SINE amplification and dispersal 
throughout the genome. Despite the considerable proportion of genetic material 
assigned to these SINE families, little is known about the function, if any, of 
their encoded transcripts. It has been proposed that some SINE families are 
involved in cellular stress responses, as several stress stimuli, including heat 
shock and DNA-damaging agents, induce the production of SINE transcripts (Li 
et al, 1999; Liu et al, 1995; Rudin and Thompson, 2001). In fact, recent studies 
have demonstrated that the 180 base pair (bp) B2 RNA is involved in the 
repression of class II gene expression in response to heat shock, through a direct
1 Introduction
interaction with pol II (Allen et al, 2004; Espinoza et al, 2004). Furthermore, a 
role for Alu in mediating the response of human cells to heat shock has also been 
shown (Chu et al, 1998). This challenges a traditionally held concept that SINEs 
are merely ‘junk DNA’.
i#
1|1.2.6 Viral genes transcribed by pol III
Certain viruses utilise the cellular pol III transcription machinery to transcribe
■ishort transcription units within their genomes. For example, the adenovirus VAI #
and VAII genes are transcribed by pol III (Soderlund et al, 1976; Weinmann et 
al, 1974). High levels of these transcripts, which are approximately 160 
nucleotides in length, aie produced during the late stages of adenoviral infection 
(Akusjarvi et al, 1980; Soderlund et al, 1976; Weinmann et al, 1974). VAI 
influences host cell protein synthesis to promote the efficient translation of viral 
mRNAs, thus being essential for the productive expression of the viral genome 
(Svensson and Akusjarvi, 1984; Thimmappaya et al, 1982). The role of VAII is 
less clear, as mutants lacking this gene have relatively normal life-cycles 
(Thimmappaya et al, 1982). However, it has been demonstrated that VAII 
interacts with and inhibits cellular RNA helicase A, which may be involved in 
the defence against viral infection (Liao et al, 1998). Similar RNAs are encoded 
by the Epstein-Barr virus EBERl and EBER2 genes: these genes share regions of 
homology with the VA genes, and the resulting RNAs are predicted to have 
similar secondary structures (Rosa et al, 1981). Furthermore, EBERs can 
functionally substitute for VAI during adenovirus infection (Bhat and 
Thimmappaya, 1985). This suggests that EBERs might also act by subverting the 
host cell translation machinery towards the efficient manufacture of viral
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proteins. In addition, transfection of EBERs into mammalian cells has been 
shown to increase interleukin-10 expression and repress the cellular antiviral 
interferon response (Kitagawa et al, 2000; Komano et al, 1999). EBERs are 
sufficient to induce growth in soft agar and tumours in mice, thus providing the 
first example of an oncogenic RNA (Kitagawa et al, 2000; Komano et al, 1999; 
Ruf et al, 2000).
Thus, the majority of RNAs synthesised by pol III impinge either directly or 
indirectly on protein synthesis, and therefore contribute to cell growth capacity. 
Figure 1.1 illustrates how the best characterised of these class III transcripts 
participate in various steps leading from mRNA to protein in eukaryotic cells.
The genes discussed above are transcribed solely by pol III. The selective 
transcription of genes by pols I, II and III is dictated by their distinct promoters, 
which contain specific sequence elements that direct the recruitment of the 
appropriate transcription factors and RNA polymerase through multiple protein- 
DNA and protein-protein interactions. The following section describes the 
promoter structures specifically recognised by the pol III transcription 
machinery.
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Figure 1.1; Various pol III transcripts are involved in the production and 
targeting of cellular proteins. Several steps are involved in the route from an 
initially synthesised pre-mRNA to a functional protein in the appropriate cellular 
location. Pol Ill-synthesised RNAs are essential for many of these steps, as 
indicated in the figure with red arrows. U6 snRNA is required for mRNA 
splicing as part of the spliceosome, both 5S rRNA and tRNAs directly participate 
in mRNA translation, and 7SL forms part of the signal recognition particle, 
which directs nascent polypeptide chains to the endoplasmic reticulum. In 
addition, the HI and MRP RNAs are part of ribonucleoprotein particles required 
for pre-tRNA and pre-rRNA processing, respectively, and thus indirectly 
contribute to cellular protein synthesis.
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1.3.1 Type 1 promoters
Type 1 promoters are unique to 5S rRNA genes and require three internal 
promoter elements for efficient transcription: an A-block, an intermediate 
element (IE) and a C-block (Figure 1.2). The nature of this internal control 
region (ICR) has been extensively studied in X. laevis, revealing that the A-block 
is located between +50 and +64 relative to the transcription start site, the IE is 
found at +67 to +72, and the C-block from +80 to +97 (Pieler et al, 1987). 
Transcriptional efficiency is markedly reduced by mutations in these specific 
sequence elements or if the spacing between them is altered (Bogenhagen, 1985; 
Pieler et al, 1985a, b; Pieler et al, 1987).
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1.3 Class III gene promoters
■1
The promoters utilised by pol III can be divided into three main types. The most 
notable feature of the majority of these promoters is that the crucial sequence 
elements aie found downstream of the transcription start site, within the 
transcribed region, rather than upstream, as with class I and II genes. Promoters 
with such a structure are referred to as type 1 or 2, However, a small minority of 
pol Ill-transcribed genes in vertebrates lack any requirement for internal 
promoter regions, with important sequence elements being found exclusively 
upstream of the transcription start site. Such promoters are known as type 3.
Each of these promoter types is described in more detail below, and depicted in 
Figure 1.2.
I
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Type 1 promoter
5S rRNA genes
C-blockA-block
Tn
Type 2 promoter
e.g. tRNA genes
A-block B-block+ 1 Tn
Type 3 promoter
e.g. vertebrate U6 genes
PSEDSE TATA
Figure 1.2: Promoter types utilised by pol III. The transcription start site 
on each promoter is indicated by ‘+1’ and ‘Tn’ indicates the termination 
site. The important sequence elements o f each promoter type are 
represented by coloured boxes, and are explained in detail in the text. 
Abbreviations: DSE, distal sequence element; IE, intermediate element; 
PSE, proximal sequence element; TATA, TATA box. This figure was 
adapted from White, 2001.
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1.3.2 Type 2 promoters
The majority of pol III transcribed genes, including those for tRNAs, major SINE 
families and VA RNAs, have type 2 promoters (White, 2002). These consist of 
two essential, highly conserved sequence elements of about lObp each: an A- 
block and a B-block (Figure 1.2; Galli et al, 1981). The A-block is highly 
homologous to the type 1 promoter A-block, and in some species these elements 
are functionally interchangeable (Ciliberto et al, 1983). However, in type 2 
promoters the A-block is found further upstream, generally within 20bp of the 
transcription start site (White, 2002). The spacing between the A- and B-blocks 
is not as restricted as the spacing between type 1 promoter sequence elements. In 
fact, the position of the B-block is highly variable: an A- to B-block separation of 
30-60bp is optimal; however, a distance of up to 365bp can still support 
transcription (Baker et al, 1987; Fabrizio et al, 1987).
1.3.3 Type 3 promoters
Class III genes with type 3 promoters include the vertebrate U6, 7SK and MRP 
genes (Das et al, 1988; Murphy et al, 1987; Yuan and Reddy, 1991). In contrast 
to class III templates with type 1 and 2 promoters, efficient transcription of these 
genes by pol III requires three extragenic promoter elements: a TATA box, a 
proximal sequence element (PSE) and a distal sequence element (DSE) (Figure 
1.2). The best characterised type 3 promoter is that of a human U6 gene, in which 
the TATA box, PSE and DSE are found centred approximately 27, 56 and 229bp 
upstream of the transcription start site, respectively (Das et al, 1988; Kunkel and 
Pederson, 1988; Kunkel and Pederson, 1989; Lobo and Hernandez, 1989). 
Although transcribed by different polymerases, the human U6 and U2
15
1 Introduction
(transcribed by pol II) snRNA gene promoters share considerable homology in 
their DSE and PSE sequence elements (Kunkel and Pederson, 1988). Unlike 
vertebrates, yeast Ü6 genes require an ICR with functional A- and B-blocks for 
transcription, rather than the extragenic elements typical of type 3 promoters. 
This suggests that type 3 promoters have arisen relatively recently in evolution 
(Paule and White, 2000).
Thus, each of these distinct promoter types can specify a class III gene and direct 
its transcription by pol III. However, regardless of the promoter type, pol III 
itself has little affinity for these promoter sequence elements, and its accurate 
recruitment to the appropriate genes relies on specific accessory proteins known 
as transcription factors. The following sections describe the properties and 
functions of the various components required for the transcription of a class III 
gene.
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1.4 Transcription of class III genes
The process of transcription involves initiation, elongation and termination. 
Before transcription can proceed, a pre-initiation complex must assemble at the 
appropriate promoter, ultimately leading to polymerase recruitment.
1.4.1 Transcription initiation complex assembly on class III genes
The route to pol III recruitment varies depending on the promoter type of the 
gene to be transcribed, as discussed below (and reviewed by Geiduschek and 
Kassavetis, 2001; Schramm and Hernandez, 2002).
Type 2 promoters
Figure 1.3 shows a simplified illustration of the formation of a transcription 
initiation complex on the most commonly used class III gene promoter type (type 
2). This process requires two pol Ill-specific, basal transcription factors: TFIIIC 
and TFIIIB.
TFIIIC is one of the most complex transcription factors ever studied, having six 
subunits in yeast, with an aggregate mass of more than 500 kDa (Geiduschek and 
Kassevetis, 2001; Paule and White, 2000; Schramm and Hernandez, 2001). Each 
of these subunits has been cloned from S. cerevisiae and shown to be essential 
for cell viability. In isolation, these subunits cannot specifically bind DNA. 
However, when combined to form TFIIIC, the resulting complex specifically 
recognises and binds directly to the A- and B-block elements of type 2 
promoters. In fact, photocrosslinking experiments have revealed that this 
enormous and flexible transcription factor can span the entire length of a tRNA
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TFIIIC
TFIIIC
A-block B-block
TFIIIB
A-block
TFIIIC
B-block
pol III
TFinC
A-block B-block
Figure 1.3: Pol III transcription initiation complex assembly on a type 2 
promoter. TFIIIC recognises and binds the A- and B-block promoter 
elements directly. Once bound to the DNA, TFIIIC then recruits TFIIIB via 
protein-protein interactions. TFIIIB can then recruit pol III to the promoter 
and transcription is initiated. The transcription start site is indicated by ‘+1’. 
This figure was adapted from White, 2002.
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gene (Bartholemew et al, 1990). Although both A- and B-blocks are contacted by 
TFIIIC, the latter is the predominant determinant of binding affinity (Baker et al, 
1986).
Human TFIIIC was originally described as an activity in a HeLa cell 
phosphocellulose fraction required for class III gene expression (Segall et al, 
1980), which could be further resolved into two separate components termed 
TFIIIC 1 and TFIIIC2 (Yoshinaga et al, 1987). Both of these are required for 
transcription from type 1 and 2 promoters in vitro; however, only the TFIIIC 1 
fraction is required by type 3 promoters (Lagna et al, 1994; Oettel et al, 1997; 
Yoon et al, 1995). The identity of TFIIIC 1 is unknown, and a precise function for 
this factor has yet to be demonstrated unequivocally. In contrast, TFIIIC2 has 
been well characterised both structurally and functionally, and plays an 
orthologous role to the yeast TFIIIC factor, in that it binds type 2 promoter DNA 
directly (Geiduschek and Kassavetis, 2001; Kovelman and Roeder, 1992; 
Schramm and Hernandez, 2002; Yoshinaga et al, 1989). Despite this, there is 
little sequence homology between most of the TFIIIC subunits from these 
species. Human TFIIIC2 is composed of 5 polypeptides, known as TFIIIC220, 
110, 102, 90 and 63, according to their molecular masses (Kovelman and Roeder, 
1992), TFIIIC220 and 110 primarily generate the DNA-binding surface of 
TFIIIC, with TFIIIC220 interacting specifically with the B-block (Schramm and 
Hernandez, 2002; Shen et al, 1996; Yoshinaga et al, 1987, 1989). Specific 
TFIIIC-DNA interactions aie also likely to be contributed by TFIIIC63, via the 
A-block (Hsieh et al, 1999a). TFIIIC90 is pivotal to the integrity of the TFIIIC 
complex, as it bridges two distinct subdomains formed by the other four subunits
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(Hsieh et al, 1999b). In addition, three of these TFIIIC subunits (220, 110 and 
90) have been shown to possess histone acetyltransferase (HAT) activity, which 
may serve to remodel chromatin in the vicinity of class III genes (Hsieh et al, 
1999b; Kundu et al, 1999).
Regardless of the species, the key function of TFIIIC is to recruit TFIIIB, 
positioning this factor just upstream of the transcription start site. TFIIIB consists 
of three proteins: TATA box-binding protein (TBP) and two TBP-associated 
factors, known as Brfl (TFIIB-related factor 1; so-called because of its N- 
terminal homology to the pol Il-specific transcription factor TFIIB) and Bdpl 
(Schramm and Hernandez, 2002). In humans, TBP, Brfl and Bdpl have apparent 
molecular masses of approximately 34, 90 and 160kDa, respectively. TBP is also 
used by the transcription machineries of pols I and II, and is therefore essential 
for all nuclear transcription in eukaryotes (Cormack and Struhl, 1992). 
Conversely, Brfl and Bdpl are specifically involved in the transcription of class 
III genes. Brfl forms a tight association with TBP in solution; however, Bdpl is 
only weakly associated with this complex, if at all, in the absence of a DNA 
template (Geiduschek and Kassavetis, 2001; Huet et al, 1994; Kassavetis et al, 
1991; Schramm and Hernandez, 2002; Schramm et al, 2000). Several 
alternatively spliced Bdpl cDNAs have been identified in human cells (Schramm 
et al, 2000). The involvement of each of these in pol III transcription is unclear. 
However, one of these splice variants encodes a protein of approximately 
250kDa, which has been proposed to constitute at least part of the 
uncharacterised TFIIIC 1 activity mentioned above (Weser et al, 2004).
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TFIIIB is essential for the recruitment of pol III to the transcription start site of 
class III genes. All three TFIIIB subunits are required for polymerase
The recruitment of TFIIIB to class III gene promoters by TFIIIC has been 
extensively studied in S. cerevisiae. During transcription initiation complex 
formation, DNA-bound TFIIIC initially contacts the Brfl subunit of TFIIIB, and 
this is thought to occur via the S. cerevisiae equivalent of human TFIIIC 102
,(Kassavetis et al, 1992; Schramm and Hernandez, 2002). Several subsequent 
interactions that occur between each of the TFIIIB subunits and various TFIIIC 
components are also likely to participate in the formation of a stable pre­
initiation complex (Schramm and Hernandez, 2002). In human cells, it has been 
confirmed that TFIIIC90 interacts with Brfl, and that TFIIIC 102 and 63 interact 
with both Brfl and TBP (Hsieh et al, 1999a, b).
recruitment; however, only Brfl and TBP have been shown to make direct 
contacts (Schramm and Hernandez, 2002). Of these contacts, an interaction 
between Brfl and the yeast pol III-specific subunit C34 (RPC39 in humans) 
appears particularly important (Brim et al, 1997). Furthermore, it has recently 
been demonstrated that various TFIIIC subunits are capable of interacting with 
pol III, suggesting that this DNA-binding complex may also contribute to pol III 
recruitment (Flores et al, 1999; Hsieh et al, 1999a, b).
Type 1 (5S rRNA) promoters
Figure 1.4 shows a transcription initiation complex on a typical 5S rRNA 
promoter. As with type 2 promoters, the recruitment of pol III relies on TFIIIB, 
which is positioned just upstream of the transcription start site by TFIIIC.
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Figure 1.4: Type 1 promoter transcription initiation complex.
Recruitment o f TFIIIC, and hence TFIIIB and pol III, to type 1 promoters 
requires TFIIIA, which binds promoter elements within the ICR o f 5S 
rRNA genes as shown. The transcription start site is indicated by ‘+1’.
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However, type 1 promoters lack a functional B-block (Figure 1.2), which is the 
major determinant of TFIIIC DNA-binding affinity. Consequently, the gene- 
specific transcription factor TFIIIA is required for the productive association of 
TFIIIC with 5S rRNA genes (Engelke et al, 1980; Segall et al, 1980). TFIIIA 
was the first eukaryotic transcription factor to be purified (Engelke et al, 1980) 
and cloned (Ginsberg et al, 1984). It consists of a single polypeptide of 
approximately 40kDa, and has nine zinc finger domains that bind the ICR DNA 
of 5S genes. Three of these zinc fingers specifically recognise the C-block, and 
this constitutes the majority of TFIIIA DNA-binding energy (Paule and White, 
2000). TFIIIA-bound 58 genes are competent to recruit TFIIIC. However, it is 
unclear how TFIIIA promotes this TFIIIC binding (Schramm and Hernandez, 
2002).
Type 3 promoters
As shown in Figure 1.5, TFIIIB also forms part of the transcription initiation 
complex on vertebrate type 3 promoters. However, the TFIIIB entity involved in 
transcription from these promoters does not contain Brfl, but instead Bdpl, TBP 
and a Brfl-related factor known as Brf2 constitute an alternative, type 3 
promoter-specific TFIIIB activity (Schramm et al, 2000). Furthermore, the way 
in which TFIIIB is recruited to the transcription start site differs from type 1 and 
2 promoters, and does not require TFIIIC2 or TFIIIA (Lagna et al, 1994; 
Schramm and Hernandez, 2002). Type 3 promoters contain two upstream 
sequence elements in the vicinity of the transcription start site: a TATA box and 
a PSE. These elements are directly recognised by the TBP subunit of TFIIIB, and 
a five-subunit factor known as SNAPc, respectively (Lobo et al, 1991; Murphy et
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TATA
Figure 1.5: Type 3 promoter transcription initiation complex in the 
vicinity of the transcription start site. TFIIIB and SNAP^ bind 
cooperatively to the TATA box and PSE o f type 3 promoters, 
respectively. Interactions between DSE-bound Oct-1 and SNAP^ (not 
shown) enhance this SNAP/TFIIIB recruitment. Pol III is recruited to 
the transcription start site (indicated by ‘+1’) following SNAP/TFIIIB 
binding, and transcription commences.
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al, 1992). Alone, TFIIIB and SNAP, bind poorly to DNA; however, protein- 
protein interactions between these complexes enhance their recruitment to the 
promoter (Mittal and Hernandez, 1997). In addition, the DSE of type 3 promoters 
(found further upstream, see Figure 1.2) binds an additional transcription factor 
known as Oct-1, which further stimulates TFIIIB/SNAP, recruitment through 
protein-protein interactions between Oct-1 and SNAP, (Mittal et al, 1996, 
Murphy et al, 1992). However, although stimulatory, Oct-1 is not essential for 
basal transcription from type 3 promoters in vitro (Hu et al, 2003). Once 
TFIIIB/SNAP, have assembled on the promoter, pol III can be recruited. The 
interactions responsible for pol III recruitment to these promoters have yet to be 
defined.
Therefore, the components of the pre-initiation complexes utilised by pol III vary 
depending on the promoter type. However, TFIIIB is essential for polymerase 
recruitment to, and hence the transcription of, all class III genes. Therefore, 
TFIIIB is regarded as the central pol III transcription initiation factor.
1.4.2 Pol III
Pol III is a huge 600-700kDa complex composed of 17 subunits in yeast and 
humans, making it the largest of the three eukaryotic nuclear RNA polymerases 
(Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002; White,
2002). Genetic studies in yeast have indicated that at least 16 of these 17 subunits 
are essential for pol III function and yeast viability (Geiduschek and Kassavetis, 
2001; Schramm and Hernandez, 2002; White, 2002). Five of the 17 subunits are
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shared by all three RNA polymerases, a further two are common to both pols I 
and III, and ten subunits are unique to the pol III complex (Geiduschek and 
Kassavetis, 2001; Schramm and Hernandez, 2002; White, 2002). All three 
polymerases perform the same fundamental function: they catalyse the covalent 
attachment of ribonucleotides to form an RNA chain that is complementary to 
the gene template being transcribed. Therefore, it is not surprising that these 
enzymes share some common subunits. However, the polymerases transcribe 
distinct genes with different characteristics, and so they also have several unique 
properties. The subunits unique to pol III are presumed to contribute to pol Ill- 
specific properties, such as its distinct nucleoplasmic localisation (Pombo et al,
1999), its interaction with specific transcription initiation factors (as described 
above), and its ability to perform elongation and termination of transcription 
independently of accessory factors (as discussed below).
1.4.3 Transcription initiation, elongation and termination by pol III
Following pol III recruitment, the two strands of DNA around the transcription 
start site are separated to form a transcription bubble (Geiduschek and 
Kassavetis, 2001; White, 2002). This melting of the DNA helix allows the 
polymerase to access the template strand, and is required before transcription can 
proceed. DNA melting is performed by the polymerase, although the Brfl and 
Bdpl components of TFIIIB also play an active role (Geiduschek and Kassavetis, 
2001; Kassavetis et al, 1998, 2001; Schramm and Hernandez, 2002). Thus, 
TFIIIB serves not only to recruit pol III, but also participates in the formation of 
an open promoter complex.
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Once the DNA strands have been separated, RNA synthesis can be initiated, and 
the polymerase progresses into the gene and dissociates from promoter-bound 
TFIIIB (White, 2002), The transcription bubble moves downstream with the 
elongating polymerase. Although TFIIIC assembles within the transcribed 
regions of the majority of class III genes, this large factor is not dissociated from 
promoters during elongation (White, 2002). It is unclear at present how the 
polymerase passes DNA-bound TFIIIC during transcription. However, unlike 
pols I and II, pol III does not require any accessory factors for efficient chain 
elongation (Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002; 
White, 2002). Furthermore, termination by pol III also occurs independently of 
other factors: four or more T residues within the template strand of a class III 
gene are sufficient to signal the accurate and efficient termination of transcription 
(Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002; White, 
2002).
'I4
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Following the synthesis of the first transcript, pol III is known to be recycled on 
the same DNA template for several further rounds of transcription (Dieci and 
Sentenac, 1996). As a consequence, the slow initial step of polymerase 
recruitment is avoided, making the production of subsequent RNAs by pol III 
more efficient (Dieci and Sentenac, 1996). TFIIIB participates in this pol III 
recycling and under certain circumstances, TFIIIC is also required (Ferrari et al, 
2004).
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1.5 Pol III transcription can be stringently regulated
Many pol III products are involved in cellular biosynthesis, as detailed in section 
1.2, and are therefore constitutively available to perform a variety of 
‘housekeeping’ functions. However, the levels of these transcripts vary 
considerably in accordance with changing metabolic requirements as a result of 
tightly regulated pol III transcription. For example, pol III transcription is low 
when nutrients or mitogens are limiting, but upregulated when the availability of 
growth stimuli increase (Clarke et al, 1996; Johnson et al, 1974; Mauck and 
Green, 1974; Sethy et al, 1995). Furthermore, growth inhibitory agents, such as 
cyclohexamide and rapamycin, downregulate the production of tRNA and 5S 
rRNA, whereas growth-promoting agents, such as phorbol esters, induce pol III 
transcription (Garber et al, 1991; Gokal et al 1986; Zaragoza et al, 1998). Pol III 
transcription is also regulated in response to other cellular stresses, throughout 
the cell cycle, and during metazoan cellulai' differentiation and development (as 
outlined in the following sections). Various mechanisms contributing to this 
stringent control have been described, some of which are discussed below.
1.5.1 Regulation of pol III transcription in proliferating cells
The regulation of pol III transcription has been particularly well characterised in 
proliferating mammalian cells. Mitogenic stimulation of quiescent eukaryotic 
cells results in the activation of several intracellular signalling cascades, which 
can initiate a proliferative response. Some of these cascades have been shown to 
mediate an accompanying activation of pol III transcription. For example, CK2, a 
highly conserved growth-promoting eukaryotic protein kinase, has been shown to 
phosphorylate and activate TFIIIB, thus increasing pol III transcription, in both
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yeast and mammalian cells (Ghavidel and Schultz, 1997; Hockman and Schultz, 
1996; Johnston et al, 2002). Furthermore, the mitogen-activated extracellular 
signal-regulated kinase (ERK), which is activated via the ras signalling pathway 
in mammalian cells, can induce pol III transcription through phosphorylation of 
the Brfl component of TFIIIB (Felton-Edkins et al, 2003a). In addition to these 
kinases, the proto-oncogene product c-Myc is a crucial regulator of cell growth 
and proliferation in metazoans (Grandori et al, 2000; Schmidt, 1999). c-Myc 
specifically activates pol III transcription, again by targeting TFIIIB, leading to 
an increase in tRNA and 5S rRNA production (Felton-Edkins et al, 2003b; 
Gomez-Roman et al, 2003).
Another important regulator of mammalian proliferation is the retinoblastoma 
protein (RB). One of the main functions of RB is to ensure that cells only 
progress through the cell cycle and divide in response to the appropriate external 
stimuli (Kaelin, 1999; Weinberg, 1995). Loss of RB function results in aberrant 
cellular proliferation and tumour formation (Sherr, 1996). RB is therefore known 
as a tumour suppressor protein. In resting cells, RB is primarily found in an 
underphosphorylated form capable of interacting with several cellular targets, 
including TFIIIB (Scott et al, 2001). RB-bound TFIIIB is unable to interact with 
other components of the pol III transcription machinery, and thus in this way, RB 
represses class III gene expression (Sutcliffe et al, 2000). However, in response 
to growth stimuli, the cell cycle regulatory proteins cyclins D and E accumulate 
and activate their specific cyclin-dependent kinase (CDK) partners, which in turn 
phosphorylate and inactivate RB (Hulleman and Boonstra, 2001). This is 
essential for progression into the DNA synthesis (S) phase of the cell cycle.
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Hyperphosphorylated RB dissociates from TFIIIB leading to the activation of pol 
III transcription and the accumulation of class III gene products prior to S phase 
entry (Scott et al, 2001). RB also regulates the transcription of certain genes by 
pol II, whose products are involved in DNA synthesis (Dyson, 1998), and 
transcription by pol I, which synthesises the large rRNAs (Cavanaugh et al, 
1995). Therefore, this common regulatory mechanism allows components of the 
DNA and protein synthetic machinery to be produced in a highly coordinated 
manner during the cell cycle. Following S phase, pol III transcription declines as 
cells reach mitosis. Again, TFIIIB appears to be the primary target for regulation; 
in this case, TFIIIB activity is inhibited by direct phosphorylation (Fairley et al, 
2003; Gottesfeld et al, 1994; Hu et al, 2004; Leresche et al, 1996; White et al, 
1995a).
1.5.2 Regulation of pol III transcription in response to cellular stresses
Various cellular insults, including genotoxic stress and nutrient deprivation, 
repress pol III transcription (Clarke et al, 1996; Crighton et al, 2003; Ghavidel 
and Schultz, 2001; Sethy et al, 1995; Upadhya et al, 2002). In mammalian cells, 
this is thought to be partly mediated by p53, which can induce cell cycle arrest or 
cell death in response to a variety of stresses including radiation, hypoxia and 
oncogenic stimuli (Vousden, 2000). As with RB, p53 is a tumour suppressor 
protein whose function is compromised in most human tumours (Vousden,
2000). Although unrelated to RB, p53 also represses pol III transcription by 
binding and inactivating TFIIIB (Cairns and White, 1998).
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Another negative effector of pol III transcription is MafL This protein was 
recently identified in S. cerevisiae, and shown to interact with TFIIIB and pol III 
(Pluta et al, 2001; Upadhya et al, 2002). Mafl represses pol III transcription in 
response to a range of cellular stresses, such as nutrient limitation and DNA 
damage (Upadhya et al, 2002). Although homologues of M afl have been 
identified in higher eukaryotes (Pluta et al, 2001), a role for Mafl in the 
regulation of pol III transcription has thus far only been demonstrated in yeast.
As mentioned above, CK2 is known to activate pol III transcription under normal 
growth conditions (Ghavidel and Schultz, 1997; Hockman and Schultz, 1996; 
Johnston et al, 2002). It was recently demonstrated that CK2 is also involved in 
transducing DNA damage signals to the pol III transcription machinery in yeast 
(Ghavidel and Schultz, 2001). Stimulatory CK2 activity is a complex of two 
catalytic and two regulatory subunits. In response to genotoxic stress, the 
catalytic subunits are released. The residual regulatory subunits remain bound to 
TFIIIB, but can no longer phosphorylate and activate this factor, thus resulting in 
the repression of class III gene expression (Ghavidel and Schultz, 2001; Schultz,
2003). The involvement of CK2 in the downregulation of pol 111 transcription 
under DNA-damaging conditions in mammalian cells has not yet been described.
1.5.3 Regulation of pol III transcription during differentiation
Cellular differentiation is accompanied by specific changes in gene expression, 
cellular morphology and a reduction or cessation of proliferation. Cell culture 
systems, which mimic the processes accompanying differentiation, have been 
used to investigate this developmental phenomenon. For example, F9 embryonal
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carcinoma cells can be induced to differentiate into cells resembling parietal or 
visceral endoderm, depending on the conditions used (Hogan et al, 1981; 
Strickland et al, 1980). Such differentiation is accompanied by a specific 
decrease in the level of class III transcripts (Meipner et al, 1995; Murphy et al, 
1983; White et al, 1989). In the case of parietal endoderm formation, this was 
shown to result from a decrease in TFIIIB activity, which could be at least partly 
attributed to a decline in the level of Brfl (Alzuherri and White, 1998; White et 
al, 1989). Tight developmental regulation of pol III transcription has also been 
suggested by in situ hybridisation analysis of class III transcripts at various 
stages of early mouse embryogenesis (Vasseur bt al, 1985). However, the 
regulation of pol III transcription in response to growth stimulation of 
differentiated cells has not been investigated.
1.5.4 Aberrant activation of pol III transcription in transformed cells
The precise regulation of pol III transcription is clearly a prominent feature of 
normal cellular growth and proliferation. In contrast, deregulated pol III 
transcription accompanies the aberrant proliferation characteristic of many 
transformed and tumour cell types (reviewed by White, 2004a, b). Various 
mechanisms have been proposed to cause this subversion of normal pol III 
transcriptional control. For example, as discussed above, pol III transcription can 
be restrained by two key tumour suppressors, p53 and RB, and activated by 
known proto-oncogene products, including CK2, ras and c-Myc. Inactivation of 
p53 and RB, and abnormal activation of proto-oncogenes, are common features 
of most human cancers, and are likely to contribute to the elevation of pol III 
transcripts frequently observed in tumour cells (White, 2004a, b). Furthermore,
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pol III transcription is stimulated by several viruses associated with cellular 
transformation and human cancers, through the activation of TFIIIB and/or 
TFIIIC (White, 2004a, b). Abnormally elevated expression of TFIIIB and TFIIIC 
subunits have been described in certain virally-transformed cells and tumour 
types, and this may contribute to the deregulation of class III gene expression 
under these circumstances (Daly et al, 2004, In press', Felton-Edkins and White, 
2002; Larminie et al, 1999; Wang et al, 1995; Winter et al, 2000). Therefore, 
various aberrations in cellular control mechanisms ensure pol III transcription is 
elevated in tumours, suggesting that such elevation is advantageous for rapid 
growth and proliferation.
The existence of a complex network of pol III regulatory mechanisms, as 
outlined above, suggests that the stringent control of class III gene expression is 
an important aspect of proper cellular function, and is likely to be fundamental to 
the appropriate regulation of cellular biosynthetic capacity and ultimately cell 
growth.
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1.6 Aims of PhD
The overall objective of this PhD was to investigate the regulation of pol III 
transcription, specifically during cardiomyocyte hypertrophy. As mentioned 
previously, the hypertrophic growth of cardiomyocytes occurs in the absence of 
cell division and is associated with cardiovascular disease, which is highly 
prevalent in many countries. Therefore, research into the mechanisms underlying 
this response is of considerable relevance to the fundamental appreciation of cell 
growth controls and numerous cardiac pathologies. The current understanding of 
cardiomyocyte hypertrophy is outlined in Chapter 3. One of the key hallmarks is 
an increase in protein synthesis, which underlies cell growth; however, the 
mechanisms responsible for this increased translation are not fully understood. 
As discussed in this introduction, pol III manufactures essential components of 
the cellular protein synthetic machinery (see Figure 1.1), and the production of 
these RNAs is subject to stringent control under a variety of cellular conditions. 
Therefore, it seemed likely that pol 111 transcriptional regulation would be a 
critical feature of the hypertrophic growth response. The first aim of the project 
was to determine whether cardiomyocyte hypertrophy is accompanied by 
enhanced pol III transcription. To date, investigations on pol III transcriptional 
activation in mammals have focused solely on undifferentiated, proliferating cell 
types. Thus, the remainder of the investigation was concerned with elucidating 
the mechanisms responsible for upregulating pol III transcription in these 
terminally differentiated cells, with a view to characterising pathways directly 
involved in inducing a disease-associated cell growth response, through 
increased class III gene expression.
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CHAPTER 2 
Materials and Methods
2.1 Cell culture
2.1.1 Cardiomyocytes
Primary cultures of rat neonatal cardiomyocytes were prepared as follows. Hearts 
were excised from 1- to 5-day-old Sprague Dawley rats by Central Biological 
Services (Institute of Biomedical and Life Sciences, University of Glasgow), and 
supplied in ADS buffer (120 mM NaCl, 20 mM HEPES, 0.8 mM NaH^PO^, 5 
mM glucose, 5.4 mM KCl, 0.8 mM MgS0 4 , 100 units/ml penicillin and 100 
gg/ml streptomycin, pH 7.35). All subsequent procedures were performed using 
aseptic technique and sterile equipment and reagents. Hearts were transferred to a 
petri dish on ice containing chilled ADS buffer in a class 11 hood. Ventricular 
tissue was isolated from the hearts using forceps, then minced using a razor 
blade. Minced tissue was transfeiTed to a falcon tube, and excess ADS buffer was 
removed. Myocytes were dissociated from ventricular tissue by multiple rounds 
of enzymatic digestion at 37°C, with gentle shaking, using 0.48 mg/ml 
collagenase (Worthington) and 0.6 mg/ml pancreatin (Sigma) dissolved in ADS 
buffer. Depending on the amount of starting material, 4 to 6  x 15 minute 
digestions were required to completely dissociate the tissue into its constituent 
cells. Chilled foetal calf serum (PCS) was used to inactivate the enzymes at the 
end of each digestion. Dissociated cells were separated from the enzyme/ECS 
solution by centrifugation at 350g (in a benchtop Labofuge 400R, Heraeus 
Instruments) for 10 minutes at 4°C. The enzyme solution was removed and the
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cells were washed once in Dulbecco’s modified Eagle’s medium/medium 199 
(DMEM/M199 at a ratio of 4:1 v/v) supplemented with 10% horse serum (HS), 
5% PCS, 100 units/ml penicillin and 100 |ig/ml streptomycin (all Sigma), again 
by centrifugation at 350g for 10 minutes. The cells were then resuspended in the 
same medium and pre-plated for 1 hour at 37°C in a humidified, 5% CO2  
incubator, on uncoated 100mm tissue culture dishes. This step was performed to 
separate myocytes, which do not adhere to uncoated dishes, from non-myocytes, 
which do. After 1 hour, unattached myocytes were removed and plated on to 24- 
well, 6 -well or 1 0 0 mm tissue culture dishes, that had been coated with a 1 % 
(w/v) gelatin (Sigma) solution, in the medium described above. Cells were plated 
at a density of approximately 10^  cells per mm^. After 24 hours, confluent 
myocytes were beating spontaneously. At this time, cells were washed in 
DMEM/M199 (4:1) supplemented with 4% HS, 100 units/ml penicillin and 100 
gg/ml streptomycin (maintenance medium), then maintained in this medium until 
use (usually 24 hours).
Por experiments, cardiomyocytes were serum-starved in DMEM/M199 (4:1) 
supplemented with 100 units/ml penicillin and 100 gg/ml streptomycin. PCS was 
used at a final concentration of 10%. Endothelin-1 (ET-1) and phenylephrine 
(PE) (both Sigma) were dissolved in sterile distilled H2 O. ET-1 was used at a 
final concentration of 100 iiM, and PE was used at a final concentration of 100 
pM. PD98059 (Calbiochem), 5-bromodeoxyuridine (BrdU) (Sigma) and MG 132 
(Calbiochem) were dissolved in dimethylsulphoxide (DMSO) and used at final 
concentrations of 50 gM, 0.1 mM and 10 gM, respectively. Where DMSO was
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used as a vehicle, final DMSO concentrations were 0.1% in the tissue culture 
medium.
2.1.2 Rat lA  fibroblasts
As above, rat lA  cell culture was performed in a class 11 hood, using aseptic 
technique and sterile equipment and reagents. Rat lA  fibroblasts were 
maintained in DMEM supplemented with 5% PCS, 400 gg/ml Geneticin, 100 
units/ml penicillin and 100 gg/ml streptomycin (all Sigma), and incubated in 
serum-free medium for 24 hours prior to stimulation with 10% PCS. Cells were 
passaged when subconfluent (approximately every 2 to 3 days) using buffered 
trypsin (0.05% trypsin, 0.02% EDTA; Sigma). Cells were also stored by cryo- 
freezing. For cryo-freezing, trypsinised cells were resuspended in 70% DMEM 
(plus penicillin and streptomycin), 20% PCS and 10% DMSO. 1 ml aliquots 
were transferred to cryo-tubes, and frozen overnight at -80°C, before transferring 
to liquid nitrogen for permanent storage.
2.2 RNA extraction
2.2.1 RNA extraction from cultured cells
Total cellular RNA was extracted from cardiomyocytes grown on 6 -well tissue 
culture dishes using TRl reagent (Sigma), according to the manufacturer’s 
instructions. Media was aspirated from the cells, then cells were scraped into TRI 
reagent and transferred to sterile 1.5 ml microfuge tubes. 1 ml of TRI reagent 
was used per 2 to 3 wells of a 6 -well plate. Samples were incubated for 5 minutes 
at room temperature, to allow the complete dissociation of nucleoprotein
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complexes, then 0.2 ml of chloroform was added to each. Thorough mixing of 
chloroform and TRI reagent was ensured by vortexing each sample for 15 
seconds. Samples were incubated at room temperature for a further 5 minutes, 
then centrifuged (in an Eppendorf Centrifuge 5415R) at 16000g for 15 minutes at 
4°C. This centrifugation separated the samples into 3 phases: a lower organic 
phase containing proteins, a middle interphase containing DNA, and an upper 
aqueous phase containing RNA. The RNA-containing phase was carefully 
removed, and transferred to a fresh microfuge tube. To precipitate RNA, 0.5 ml 
of isopropanol was added, samples were mixed by vortexing for 1 0  seconds, then 
incubated for 10 minutes at room temperature. Subsequently, samples were 
centrifuged at 16000g for 10 minutes at 4°C. Following centrifugation, the 
supernatant was discarded, and the remaining RNA pellet was washed using 1ml 
of 75% ethanol, made using diethylpyrocarbonate (DEPC)-treated H2 O (0.1% 
DEPC). Samples were centrifuged for a further 5 minutes at 16000g (4°C), then 
the supernatant was aspirated off, and RNA pellets left to air dry for 
approximately 10 minutes. Once dry, RNA was resuspended in 10-30 gl of 
DEPC-treated H2 O. To aid resuspension, pre-warmed DEPC-treated H2 O was 
used, and samples were incubated at 65°C for 15 minutes. Following 
resuspension, a spectrophotometer was employed to measure the absorbance of 
each sample at 260 nm, and the following formula was used to calculate the 
RNA concentration: RNA concentration (gg/ml) = absorbance at 260 nm x 40 x 
dilution factor. All RNA samples were stored at -80°C.
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2.2.2 RNA extraction from whole hearts
Total RNA was also extracted from tissue samples, all of which were obtained 
from Dr WR MacLellan, Cardiovascular Research Laboratories, Department of 
Physiology, University of California at Los Angeles School of Medicine, USA. 
Animals were handled and tissue removed according to institutional guidelines. 
Following removal, hearts were immediately snap-frozen in liquid nitrogen, and 
shipped on dry ice. Tissue was crushed using a pestle and mortar in liquid 
nitrogen, then transferred to sterile microfuge tubes. 1 ml of TRI reagent was 
added per 50-100 mg of tissue, then tissue homogenised using a Polytron 
homogeniser. Subsequently, the homogenate was centrifuged at 12000g for 5 
minutes to remove any insoluble material. The supernatant (containing RNA) 
was transferred to a fresh microfuge tube, and RNA was extracted as outlined in 
section 2 .2 . 1  above.
2.3 Northern blot analysis
10 gg of RNA was diluted in DEPC-treated H2 O to give a total volume of 10 gl. 
A further 10 gl of 2 X RNA sample buffer (1 X MOPS [20 mM MOPS (pH 7.0), 
8  mM sodium acetate, 1 mM EDTA (pH 8.0)], 4.4 M formaldehyde, 54% 
formamide) was added to this, then samples were incubated at 65°C for 15 
minutes to denature RNA secondary structure. Subsequently, samples were 
immediately cooled on ice to prevent any renaturation of the RNA. 2 gl of 1 
mg/ml ethidium bromide and 2 gl of 10 X RNA loading dye (50% glycerol, 1 
mM EDTA, 0.25% bromophenol blue, 0.25% xylene cyanol) were added to each 
sample, prior to loading onto a denaturing formaldehyde 1 % agarose gel ( 1 %
39
2 Materials and Methods
agarose, 2.2M formaldehyde, 1 X MOPS) that had been pre-run at 40V in 1 X 
MOPS for 30 minutes. Electrophoresis was performed for 4 to 5 hours at 40V in 
1 X MOPS, then the gel was visualised under a UV transilluminator to ensure 
effective RNA separation and equal loading.
The gel was then washed in 20 X SSC (3 M NaCl, 0.3 M sodium citrate pH 7.0) 
with gentle shaking for 10 to 15 minutes. For capillary transfer of the RNA, the 
gel was inverted and placed on a wick of Whatmann 3MM chromatography 
paper, which had been pre-soaked in and was fed from a resevoir of 20 X SSC. A 
gel-sized piece of pre-soaked Hybond N nylon membrane (Amersham), followed 
by 2 pieces of pre-soaked Whatmann paper, were placed on the gel ensuring no 
air bubbles between layers. A stack of folded paper towels was then added 
followed by a 0.5 kg weight, to ensure efficient transfer of RNA to the membrane 
by capillary action. Pieces of autoradiography film were placed at the edges of 
the gel to prevent the paper towels from contacting the wick. The transfer was 
allowed to proceed for 16 to 18 hours, and then RNA was fixed to the membrane 
by UV crosslinking at 1200 gJ. The membrane was rinsed for 5 minutes in 
DEPC-treated H2 O and stored in Saran wrap until use.
To specifically detect the RNA of interest, radiolabelled complementary DNA 
probes were used: the B2 gene probe was prepared from a 240bp EcoRI-PstI 
fragment of pTB14, and the probe for acidic ribosomal phosphoprotein PO 
(ARPP PO) was prepared from a Ikb EcoRI-Hindlll fragment of the mouse 
cDNA. A Megaprime DNA Labelling Kit (Amersham) was used to label the 
probes by random oligonucleotide priming, according to the manufacturer’s
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instructions. Random hexamer oligonucleotides were mixed with 25 ng of the 
DNA fragment to be probed, and made up to a total volume of 50 gl with DEPC- 
treated H2 O. This was heated at 95°C for 5 minutes to denature the DNA. Slow 
cooling of the mixture to room temperature allowed the random hexamer 
oligonucleotides to anneal to the DNA. 10 gl of reaction buffer (dATP, dGTP, 
dTTP in Tris pH 7.5, (3 -mercaptoethanol and MgCb), 2 gl (2U) of DNA 
polymerase I Klenow fragment, and 50 gCi of [a-^^P] dCTP (Amersham) were 
added, and labelling was allowed to proceed at 37°C for 1 hour. The labelled 
DNA was then denatured by heating at 100°C for 5 minutes, and then stored on 
ice until use.
Prior to hybridising the membrane with an appropriate radiolabelled probe, it was 
pre-hybridised in a hybridisation oven at 45°C for 45 minutes by rotating in 25 
ml of hybridisation buffer (0.2 M sodium phosphate buffer pH 7,2, 1 mM EDTA, 
1 % bovine serum albumin (BSA), 7% sodium dodecyl sulphate (SDS), 45% 
formamide in DEPC-treated H 2 O). The radiolabelled probe was then added to 25 
ml of fresh hybridisation buffer, and incubated with the membrane overnight at 
45°C with rotation. The following day, the membrane was washed with rotation 
in hybridisation wash buffer (40 mM sodium phosphate buffer pH 7.2, 1 mM 
EDTA and 1% SDS) twice for 5 minutes at 65°C, then twice for 15 minutes at 
65°C, to remove any non-specific radioactivity. The membrane was then exposed 
to autoradiography film for an appropriate length of time at -80°C. To reprobe 
the membrane, it was boiled in DEPC-treated H2 O for 4 minutes, then pre­
hybridised and probed as before.
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2.4 Reverse transcriptase-polvmerase chain reaction 
(RT-PCR)
2.4.1 Preparation of cDNAs
3 gg of RNA (or 1.2 gg if derived from tissue, see below) and 200 ng of random 
hexanucleotide primers (Roche) were diluted in DEPC-treated HgO to give a 
final volume of 24 gl. Primer annealing was carried out for 10 minutes at 80°C. 
Following this, samples were transferred to ice then 1 gl (200 U) of Superscript II 
reverse transcriptase (Invitrogen Life Technologies), 8  gl of 5 X First Stand 
Buffer (Invitrogen Life Technologies), 4 gl of 0.1 M dithiolthreitol (DTT) 
(Invitrogen Life Technologies) and 2 gl of a mix containing 10 mM of each of 
the four dNTPs (Promega) were added to each. Reverse transcription was then 
allowed to proceed for 1 hour at 42°C. The reaction was stopped by heating at 
70“C for 15 minutes. cDNAs were stored at -20°C.
RNA derived from tissue was DNase I-treated prior to cDNA synthesis using a 
lyNA-free kit (Ambion), according to the manufacturer’s instructions. 10 gg of 
RNA was diluted with DEPC-treated H2 O to give a final volume of 25 gl. To 
this, 2.5 gl of 10 X DNase I Buffer (Ambion) and 1 gl (2 U) of DNase I 
(Ambion) were added. Samples were incubated at 37°C for 30 minutes. To 
inactivate the DNase I, 5 gl of DNase Inactivation Reagent slurry (Ambion) was 
added, and samples incubated for 2 minutes at room temperature. Subsequently, 
samples were centrifuged (in an Eppendoif Centrifuge 5415R) at lOOOOg for 1 
minute to pellet the Inactivation Reagent. The supernantant containing DNA-free 
RNA was transferred to a fresh sterile microfuge tube, and stored at -80°C. 1.2 
gg of this RNA was used for cDNA synthesis, as described above.
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2.4.2 PCR
PCRs were performed using a Techgene thermal controller (TECHNE). Each 
reaction had a total volume of 20 gl and contained 2 gl of cDNA, 20 pmol of the 
appropriate primers, 0.5 U of Tag DNA polymerase (Promega), 1 X Tag DNA 
polymerase buffer (Promega), 1.5 mM MgCb, 0.2 mM of each non-radioactive 
dNTP, and 1.8 gCi of [a-^^P] dCTP (Amersham). Table 2.1 lists the primers used 
for PCR, and their sequences. The cycling parameters employed and product size 
obtained for each primer set are indicated in Table 2.2. Reaction products were 
diluted 1:1 with formamide loading buffer (98% formamide, 0.01% bromophenol 
blue, 0.01% xylene cyanol, 5 mM EDTA), and resolved on 7% polyacrylamide 
sequencing gels containing 7 M urea and 0.5 X TBE (45 mM Tris, 45 mM boric 
acid, 0.625 mM EDTA pH 8.0). Gels were pre-run at 40W for 30 minutes in 0.5 
X TBE prior to loading samples (1.5 gl of each). Before loading, samples were 
heated at 95°C for 2 minutes, then quenched on ice. Electrophoresis was carried 
out for 1 hour at 40W in 0.5 X TBE, then gels were vacuum-dried for 1 hour at 
80°C. Radiolabelled PCR products were visualised by autoradiography.
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Table 2.1: PCR primers
Transcript Forward (F) and reverse (R) primers
ARPP PO F: 5’-GCA CTG GAA GTC CAA CTA CTT C-3’ 
R: 5’-TGA GGT CCT CCT TGG TGA AC A C-3’
tRNA^" F: 5’-GTC AGG ATG GCC GAG TGG TGT AAG GCG CC-3’ 
R: 5’-CCA CGC CTC CAT ACG GAG ACC AG A CCC-3’
tRNA^ y' F: 5’-CCT TCG ATA GCT CAG CTG GTA GAG CGG AGG-3’ 
R: 5’-CGG AAT TGA ACC AGC GAC CTA AGG ATG TCC-3’
tRNA '^G F: 5’-GGC TCT GTG GCG CAA TGG ATA-3’
R: 5’-TTC GAA CCC ACA ACC TTT GAA TTG CTC-3’
5S rRNA F: 5’-GGC CAT ACC ACC CTG AAC GC-3’ 
R: 5’-CAG CAC CCG GTA TTC CCA GG-3’
U 6  snRNA F: 5’-GCT CGC TTC GGC AGC ACA TAT AC-3’ 
R: 5’-TAT CGA ACG CTT CAC GAA TTT GCG-3’
Brfl F: 5’-CTA CTT GGT TTG CCG AAC G-3’ 
R: 5’-TCC TCT GTC CAG CGG TGT A-3’
atrial
natriuretic 
factor (ANF)
F: 5’-ATG GGC TCC TTC TCC ATC AC-3’ 
R: 5’-TCT TCG GTA CCG GAA GCT G-5’
c-Myc F: 5’-CCA GTG AGG ATA TCT GGA AG-3’ 
R: 5’-TTC ACC ATG TCT CCT CCA AG-3’
cyclin D2 F: 5’-TTA CCT GGA CCG TTT CTT GG-3’ 
R: 5’-TGC TCA ATG AAG TCG TGA GG-3’
nucleolin F: 5’-CGC GTC CGA GGC AGT G-3’
R: 5 -TCC ATC TAC CGT CAC GGT CAG-3’
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Table 2.2: PCR cycling parameters and product sizes
Transcript Cycling parameters Product size
ARPP PO 95°C for 2 minutes, 18 to 22 cycles of [95°C for 1 
minute, 58°C for 30 seconds, 72°C for 1 minute], 
72°C for 3 minutes.
265bp
tRNA^" 95°C for 3 minutes, 25 to 29 cycles of [95°C for 
30 seconds, 6 8 °C for 30 seconds, 72°C for 30 
seconds], 72°C for 5 minutes.
8 8 bp
tRNA^y 95°C for 3 minutes, 25 to 29 cycles of [95®C for 1 
minute, 62°C for 30 seconds, 72°C for 30 
seconds], 72°C for 5 minutes.
84bp
tRNA '^: 95°C for 2 minutes, 30 cycles of [95°C for 30 
seconds, 65°C for 30 seconds, 72°C for 15 
seconds], 72°C for 5 minutes.
74bp
5S rRNA 95°C for 3 minutes, 18 to 22 cycles of [95°C for 
30 seconds, 58°C for 30 seconds, 72°C for 1 
minute], 72°C for 5 minutes.
107bp
U 6  snRNA 95°C for 3 minutes, 25 cycles of [95°C for 1 
minute, 60°C for 30 seconds, 72°C for 1 minute], 
12°C for 5 minutes.
96bp
Brfl 95°C for 5 minutes, 21 to 25 cycles of [95°C for 1 
minute, 61°C for 30 seconds, 72°C for 1 minute], 
12°C for 5 minutes.
490bp
ANF 94°C for 1 minute, 20 to 25 cycles of [94°C for 45 
seconds, 63°C for 45 seconds, 72°C for 90 
seconds], 72°C for 2 minutes.
455bp
c-Myc 95°C for 2 minutes, 20 to 23 cycles of [95°C for 
30 seconds, 55.3°C for 30 seconds, 72°C for 1 
minute], 72°C for 5 minutes.
185bp
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Table 2.2: PCR cycling parameters and product sizes (continued)
Transcript Cycling parameters Product size
cyclin D2 95°C for 3 minutes, 23 cycles of [95°C for 30 
seconds, 55.3°C for 30 seconds, 72°C for 30 
seconds], 72°C for 5 minutes.
240bp
nucleolin 95°C for 3 minutes, 35 cycles of [95°C for 1 
minute, 65°C for 30 seconds, 72°C for 30 seconds], 
72°C for 5 minutes.
1 ‘
105bp
2.5 Preparation of whole cell extracts
All steps were performed on ice or at 4°C. Buffers, reagents and plastic-ware 
were kept chilled.
2.5.1 Preparation of extracts for in vitro transcription assays 
Extracts for in vitro transcription assays (IVTs) were prepared from 
cardiomyocytes grown on 100mm tissue culture dishes. Cells were placed on ice 
then washed twice in phosphate-buffered saline (PBS; 170 mM NaCl, 3.4 mM 
KCl, 1 mM Na2HP 0 4 , 2 mM KH2PO4 , pH 7.2). Cells were then scraped into PBS 
(5ml/dish), and collected in 50ml Falcon tubes. Cells were pelleted by slow 
centrifugation at 500g (in a Sorvall RT 6000 D), then the PBS was discarded, A 
small amount of fresh PBS (approximately 1ml) was then added to the cells to 
aid transfer into sterile microfuge tubes. This PBS was then also removed 
following centrifugation (in an Eppendorf Centrifuge 5415R) at 12000g for 1 
minute. The remaining cell pellets were gently resuspended in freshly made 
microextraction buffer (450 mM NaCl, 50 mM NaF, 20 mM HEPES pH 7.8,
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25% glycerol, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 
mM EDTA, 40 gg/ml bestatin, 1 gg/ml trypsin inhibitor, 0.7 gg/ml pepstatin, 0.5 
gg/ml aprotinin, 0.5 gg/ml leupeptin). The volume of microextraction buffer used 
was equivalent to the volume of the cell pellet. Following resuspension, samples 
were immediately snap-frozen on dry ice, then thawed at 30°C. When just 
thawed, samples were again returned to dry ice. This freeze-thaw procedure was 
performed a total of 3 times to ensure optimal cell lysis. Following the final 
thaw, cell debris was collected by centrifugation at 12000g for 10 minutes. The 
supernatant was promptly aliquoted, then snap-frozen. Samples were stored at - 
80°C. Aliquots were not used more than twice for IVTs.
2.5.2 Preparation of extracts for polyacrylamide gel electrophoresis
Extracts for polyacrylamide gel electrophoresis were prepared from 
cardiomyocytes grown on 6 -well plates. Cells were placed on ice then washed 
twice in PBS. Cells were then scraped directly into cell lysis buffer (20 mM 
HEPES (pH 7.8), 150 mM NaCl, 25% glycerol, 50 mM NaF, 0.2 mM EDTA, 
0.5% Triton X-100, 0.5% NP-40, 10 mM (3-glycerophosphate, 1 mM sodium 
orthovanadate, 1 mM PMSF, 1 mM DTT, 0.5 gg/ml leupeptin, 1.0 gg/ml trypsin 
inhibitor, 0.5 gg/ml aprotinin and 40 gg/ml bestatin) and transferred to sterile 
microfuge tubes. 100 gl of buffer was used per well. The cell lysates were 
incubated on ice for 15 minutes, and then passed through a 26-guage needle three 
times. Cell debris was collected by centrifugation at 16000g for 10 minutes, and 
the supernatants were aliquoted, snap-frozen on dry ice, then stored at -80°C.
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2.5.3 Determination of protein concentrations
The protein concentrations of whole cell extracts were determined using 
Bradford’s reagent (BioRad) diluted 1 in 5 with distilled HgO. The colour change 
produced upon mixing this reagent with protein can be quantified by measuring 
absorbance at 5 9 5  nm, and is directly proportional to the concentration of protein 
in the sample. For each experiment, a standard curve was constructed by 
measuring the absorbance (using a spectrophotometer) of 1, 2, 4, 6 , 8 , 10 and 12 
gg of BSA in 1ml of Bradford’s reagent. Whole cell extracts were diluted 1 in 10 
with microextraction buffer, then 10 gl added to 1 ml of reagent. Absorbance 
readings at 595 nm were performed in triplicate, and the protein concentration of 
each sample determined from the standard curve.
2.6 Storage, propagation and preparation of plasmid 
DNA
2.6.1 Transformation of competent cells
For plasmid storage and propagation, E.coli XL-1 blue supercompetent cells 
(Stratagene) were transformed. These cells were stored at -80°C and were 
thawed on ice prior to use, to prevent loss of transformation efficiency. 1 0 - 2 0  ng 
of plasmid DNA was added to 50 gl of thawed cells and mixed gently. The 
mixture was incubated on ice for 30 minutes, with occasional gentle agitation. 
Following this time, cells were heat-shocked for exactly 45 seconds at 42°C, then 
transferred to ice for a further 2 minutes. 450 gl of SOC medium (LB broth, 
0.04% glucose, 10 mM MgS0 4 , 10 mM MgCL), which had been pre-heated to 
42°C, was then added and cells were incubated at 37°C for 1 hour on an orbital
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shaker (225-250 rpm). Subsequently, 150 gl of the transformation mixture was 
plated on LB-agar (2% LB, 2% agar) containing 50 gg/ml of the selective 
antibiotic ampicillin, and then incubated at 37°C overnight to allow colony 
formation.
2.6.2 Preparation of plasmid DNA
An isolated bacterial colony was selected from a streaked LB-agai* plate, and 
used to inoculate 4 ml of LB medium containing 50 gg/ml ampicillin. This mini­
culture was incubated at 37°C for approximately 6  hours on an orbital shaker 
(300rpm), then used to inoculate 250 ml of LB medium containing 50 gg/ml 
ampicillin. This larger culture was incubated overnight under the same 
conditions. The following day, plasmid DNA was purified from the bacterial 
cells using the QIAGEN Plasmid Maxi Kit, according to the manufacturer’s 
instructions.
Bacterial cells were harvested by centrifugation (in Sigma Laboratory Centrifuge 
4K15) at 6000g for 15 minutes at 4°C, then resuspended in 10 ml of Buffer PI 
(500 mM Tris pH 8.0, 10 mM EDTA, 100 gg/ml RNase A). Cell lysis was 
performed by adding 10 ml of Buffer P2 (200 mM NaOH, 0.1% SDS). This 
reaction was allowed to proceed at room temperature for 5 minutes before lysates 
were neutralised by adding 10 ml of chilled Buffer P3 (3 M potassium acetate, 
pH 5.5). Addition of Buffer P3 caused the precipitation of potassium dodecyl 
sulphate, SDS-denatured proteins, chromosomal DNA and cell debris. 
Precipitation was enhanced by a 20 minute incubation on ice. Plasmid DNA is 
circular, and therefore renatured correctly and remained in solution.
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Centrifugation at 20000g for 30 minutes was performed (at 4°C) to separate 
precipitated debris from soluble material. Following this centrifugation, the 
supernatant containing plasmid DNA was promptly removed and applied to a 
QIAGEN-tip 500, pre-equilibrated with 10 ml of Buffer QBT (750 mM NaCl, 50 
mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X-100). Plasmid DNA binds 
tightly to QIAGEN-tip resin, while the remainder of the supernatant passes 
through by gravity flow. The resin was then washed twice with 30 ml of buffer 
QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol), before eluting the 
purified plasmid DNA into a Falcon tube with 15 ml of buffer QF (1.25 M NaCl, 
50 mM Tris pH 8.5, 15% isopropanol). DNA was precipitated with 10.5 ml of 
isopropanol. The sample was then centrifuged at 15000g for 30 minutes at 4°C. 
Following this, the supernatant was carefully decanted out leaving the pelleted 
plasmid DNA, which was then washed with 70% ethanol and recentrifuged. The 
pellet was air-dried for approximately 1 0  minutes, then resuspended in an 
appropriate volume of sterile distilled H2 O. DNA concentration was determined 
by measuring absorbance at 260 nm, and using the following calculation: DNA 
concentration (gg/ml) = absorbance at 260 nm x 50 x dilution factor. All plasmid 
DNA stocks were stored at -20°C.
2.7 Pol III in vitro transcription assay
IVTs were performed using 15 to 20 gg of cell extract (prepared as described in 
section 2.5.1) and 250 ng of plasmid DNA (prepared as described in section 2.6) 
containing the class III templates tRNA^" (pLeu: a 240bp EcoRI-Hindlll 
fragment of human genomic DNA carrying a tRNA^'’^  gene subcloned into
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pAT153), VAI (pVAI: a 221 bp Sall-Ball fragment of adenovirus 2 DNA 
containing the VAI gene subcloned into pUC18), B2 (pTB14: a 0.2kb Bglll 
fragment containing the B2 gene from TP2 subcloned into pUC18) or 5S rRNA 
(pMOSSl.l; a 436bp Sacl-Nhel fragment of mouse DNA cloned into pBluescript 
KS-). Transcription was carried out at 30°C for 1 hour in a total volume of 25 gl 
containing 12 mM HEPES pH 7.9, 60 mM KCl, 7.2 mM MgCb, 0.28 mM 
EDTA, 1.2 mM DTT, 10% glycerol, 1 mM creatine phosphate, 0.5 mM of each 
rATP, rCTP and rGTP, and 10 gCi of [a-^^P]UTP (Amersham). Transcription 
was stopped by the addition of 250 gl of 1 M ammonium acetate/0.1% SDS 
containing 20 gg of yeast tRNA (which stabilises the newly synthesised RNA in 
the samples). Phenol-chloroform extraction was then performed, to remove 
protein and DNA, by adding 250 gl of a 25:24:1 ratio solution of 
phenol/chloroform/isoamyl alcohol to each sample. Samples were mixed 
thoroughly by vortexing, then centrifuged at 13000g for 5 minutes. 200 gl of the 
resulting upper aqueous layer was then transferred to a fresh microfuge tube 
containing 750 gl of ethanol. The samples were mixed by repeated inversion, and 
left at -20°C overnight to precipitate RNA. The following day, samples were 
centrifuged at 13000g for 30 minutes to pellet the precipitated RNA. The 
supernatant was carefully removed and discarded, then pellets were washed 
using 750 gl of 70% ethanol (prepared using DEPC-treated H^O) and re­
centrifuged at 13000g for 5 minutes. Again, the supernatant was discarded. RNA 
pellets were dried at 50°C for 5 minutes. Once dry, 4 gl of formamide loading 
buffer was added to each sample. Samples were then vortexed for 30 minutes to 
ensure complete resuspension of the RNA, and heated at 95°C for 2 minutes.
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Electrophoresis and autoradiography of radiolabelled transcripts was performed 
as described in section 2.4.2 for PCR products.
2.8 Separation of proteins bv SDS-polvacrylamide gel
electrophoresis (SDS-PAGE) and detection by Western 
blotting
2.8.1 SDS-PAGE
Whole cell lysates (prepared as described in section 2.5.2) containing 75 gg of 
protein were resolved by denaturing SDS-PAGE on 7.8% (unless otherwise 
indicated) polyacrylamide minigels (375 mM Tris pH 8 .8 , 0.1% SDS), with 4% 
polyacrylamide stacking gels (125 mM Tris pH 6 .8 , 0.1% SDS). Prior to loading, 
samples were boiled for 4 minutes in 1 X protein sample buffer (62.5 mM Tris 
pH 6 .8 , 0.5% SDS, 5% p-mercaptoethanol, 10% glycerol, 0.125% bromophenol 
blue). Electrophoresis was performed in 1 X SDS running buffer (0.1% SDS, 
76.8 mM glycine, 10 mM Tris pH 8.3) at an initial voltage of 80V. Once the 
bromophenol blue die had moved through the stacking gel and reached the 
resolving gel, the voltage was increased to 140V and electrophoresis was 
continued for 60 to 90 minutes.
2.8,2 Western blot analysis
Following resolution by SDS-PAGE, proteins were transferred to a PVDF 
membrane (Amersham) using the BioRad Mini Trans-Blot Electrophoretic 
Transfer Cell system. Transfer was carried out in 1 X transfer buffer (76.8 mM
52
2 Materials and Methods
glycine, 10 mM Tris pH 8.3, 16.5% methanol) at 50V for 2 hours at room 
temperature. Membranes were then blocked in milk buffer (32.5 mM Tris, 150 
mM NaCl, 0.2% Tween-20, 5% skimmed milk powder (Marvel)) for 1 hour at 
room temperature, prior to incubation overnight at 4°C with the relevant primary 
antibody diluted in milk buffer. The primary antibodies utilised for Western 
blotting are listed in Table 2.3. The following day, membranes were washed 3 
times for 5 minutes in milk buffer, to remove excess primary antibody. 
Subsequently, membranes were incubated with the appropriate horseradish 
peroxidase-conjugated secondary antibody (Dako), diluted 1 in 1000 in milk 
buffer, for 1 hour at room temperature. Excess secondary antibody was then 
removed by three 10 minute washes in fresh milk buffer. Following a final 5 
minute wash in 1 X TBS (2.5 mM Tris pH 7.6, 15 mM NaCl), the bound 
antibodies were detected using the enhanced chemiluminescence (ECL) method 
(Amersham), as directed by the manufacturer.
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Table 2.3: Primary antibodies used for Western blot analysis
Protein Detected Antibody Supplier Dilution in 
milk buffer
Bifl 128 In house 1 : 1 0 0 0
Bdpl 2663 In house 1 : 1 0 0 0
TBP 58C9 Santa Cruz Biotechnology 1 : 1 0 0 0
TFIIICllO 4286 In house 1 : 1 0 0 0
TFIIIC220 A b7 In house 1 : 1 0 0 0
Active ERKl and 2 ElO Cell Signalling Technology 1 : 1 0 0 0
Total ERKl and 2 9102 Cell Signalling Technology 1 : 1 0 0 0
c-Myc 9E10 Santa Cruz Biotechnology 1:500
c-Myc C 8 Santa Cruz Biotechnology 1:500
RB phosphorylated on 
threonine 826
44-576 Biosource International 1:500
RB phosphorylated on 
serine 780
9307 Cell Signalling Technology 1:500
RB phosphorylated on 
serine 795
9301 Cell Signalling Technology 1:500
Total RB C15 Santa Cruz Biotechnology 1 : 1 0 0 0
Total RB G3-245 BD PharMingen Biosciences 1:500
Cyclin D1 72-13G Santa Cruz Biotechnology 1 : 1 0 0 0
p l^ lN K 4 a H-156 Santa Cruz Biotechnology 1 : 1 0 0 0
Haemagglutinin (HA) F-7 Santa Cruz Biotechnology 1 : 1 0 0 0
Actin C ll Santa Cruz Biotechnology 1 : 1 0 0 0
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2.9 Coulter 7,2 analysis of cardiomvocvte volume and 
number
Prior to analysis in the Coulter Z2 particle count and size analyser (Beckman 
Coulter), cardiomyocytes were dissociated from dishes using trypsin, then 
resuspended in DMEM/M199 (4:1) supplemented with 10% ECS, 100 units/ml 
penicillin and 1 0 0  pg/ml streptomycin. 1 0  ml of this medium was used per 
100mm tissue culture dish. 0.4 ml of this cell suspension was then added to a vial 
containing 10 ml of Isoton II electrolyte solution (filtered PBS solution,
Beckman Coulter), and analysed using the Coulter Z2 with a 100 gm aperture.
This aperture was pre-calibrated using spherical latex beads with 10 gm diameter 
(Beckman Coulter), according to the manufacturer’s instructions. For each 
analysis, the Coulter Z2 measured 0.5 ml of the electrolyte cell suspension. The j
Z2 determines cell number and volume by measuring the frequency and size of
1
electrical pulses generated as each cell enters the aperture. These changes in 
electrical current are collated by the Z2, and displayed as a histogram of cell 
number versus volume. From this, the number and mean volume of cells above a 
certain threshold could be obtained. This lower threshold was set to exclude any 
cell debris and dust particles from the analysis, and was in the range of 
approximately 400 to 500fl. Two 100mm dishes were analysed per condition for 
each experiment, and each sample was measured three times. The aperture was 
flushed with Isoton II before and after each analysis.
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2.10 DNA synthesis assay
For measurements of DNA synthesis, cardiomyocytes were plated on 24-well 
tissue culture dishes. Cardiomyocytes were treated accordingly (3 wells per 
condition), depending on the experiment, and pH]thymidine (0.1 gCi/ml) was 
added 16 hours prior to harvesting. Cells were then transferred to ice and washed 
twice in ice-cold PBS, three times in 5% trichloroacetic acid (TCA), and twice in 
ethanol. Samples were solubilized in 0.3 M NaOH and transferred to scintillation 
vials, to which 3ml of scintillation fluid (Fisher Scientific) was added. The 
incorporation of [%]thymidine into DNA was measured hy liquid scintillation 
counting.
2.11 Protein synthesis assay
Cardiomyocytes were grown on 24-well plates, and treated as required 
depending on the experiment. Three wells were used for each different condition. 
One hour prior to harvesting, 5 gCi of [^^S]methionine/cysteine (Amersham) was 
added per ml of medium to label cellular proteins. Cells were then washed twice 
with ice-cold PBS on ice, and scraped into 50 gl of cell lysis buffer (as defined in 
section 2.5.2). 10 pi of each extract was spotted onto a 2 x 2cm piece of 3MM 
Whatmann paper, in duplicate. The paper was dropped into 5% TCA containing 
a small amount of ‘cold’ methionine (Sigma), and boiled for 2 minutes. The TCA 
was discarded and replaced with fresh TCA/methionine before boiling again for 
2 minutes. Filters were then rinsed once in cold TCA, and once in ethanol. Filters 
were air-dried, then transferred to scintillation vials, and 3 ml of scintillation
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fluid was added. Incorporation of radiolabelled amino acids was determined by 
liquid scintillation counting.
2.12 Infection of cardiomvocvtes with replication- 
deficient recombinant adenoviruses
Cardiomyocytes were cultured in 6 -well plates for 48 hours after isolation, before 
infections were performed. Infections were carried out in a class II hood, and 
viral waste and contaminated equipment was discarded according to institutional 
guidelines. All viruses were stored in small aliquots at -80“C, and thawed at 
room temperature before use. Aliquots were not freeze-thawed more than twice.
2,12.1 MEKl-expressing adenovirus
Dr JD Molkentin (Departments of Medicine and Cell Biology, Einstein College 
of Medicine, The Bronx, New York, USA) provided equivalent titres of 
adenoviruses expressing p-galactosidase (p-gal) alone (control) or (3-gal and 
constitutively active MEKl (CAMEK). Viruses were shipped on dry ice. Prior to 
infection, cardiomyocyte medium was replaced with fresh maintenance medium 
(2 ml/well). Subsequently, control or CAMEK-expressing viruses were added 
(10, 25 or 40 pi per well, as indicated for each experiment), and infection was 
allowed to proceed for 16 hours at 37°C in a humidified, 5% CO2  incubator. 
Following this time, medium was aspirated off and replaced with serum-free 
medium (3 ml/well). Cells were incubated for a further 48 hours prior to 
harvesting for RNA and protein, as described in sections 2.2.1 and 2.5.2,
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respectively. Efficient expression of CAMEK was confirmed by Western blotting 
for active ERK.
2.12.2 p essing adenovirus
Dr S Mittnacht (Centre for Molecular and Cell Biology, The Institute of Cancer 
Research, Chester Beatty Laboratories, London, UK) supplied equivalent titres of 
adenoviruses expressing green fluorescent protein (GFP) alone (control) or GFP 
and p lô ’^ "^*". Again, viruses were transported on dry ice. Infection was carried out 
for 16 hours in 2 ml/well of fresh maintenance medium using 25 pi of control or 
p l 6 '^’^ '‘‘‘-expressing adenoviruses. Both viruses infected approximately 90% of 
cells, as confirmed using a fluorescent microscope (Axiovert 25, Carl Zeiss). 
Following 16 hours of exposure to virus, the maintenance medium was replaced 
with fresh (3 ml/well). 32 hours later, cells were changed into serum-free 
medium or medium containing 10% FCS. Cells were harvested after 16 hours for 
RNA and protein, as described in sections 2.2.1 and 2.5.2, respectively. p l 6 ‘^ '^*“ 
expression was confirmed by Western blotting.
2.12.3 HA-tagged Brfl (HA-Brfl)-expressing adenovirus
Adenoviruses expressing GFP alone (control) or GFP and HA-Brfl were 
generated, amplified and titred by Dr F Cairns (Division of Biochemistry and 
Molecular Biology, Institute of Biomedical and Life Sciences, University of 
Glasgow, UK). Cells were infected by adding 1.5 x 10*^  plaque forming units of 
control or HA-Brfl-expressing virus to wells containing 2 ml of fresh serum-free 
medium (giving a multiplicity of infection of 2). Cells were incubated for 4 
hours, then serum-free medium was replaced with fresh maintenance medium. 24
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hours later, cells were serum-starved or stimulated with 10% FCS for 16 hours. 
Cells were then harvested for RNA and protein, as described in sections 2.2.1 
and 2.5.2, respectively. Both viruses infected approximately 75% of cells, as 
determined using a fluorescent microscope. HA-Brfl expression was confirmed 
by Western blotting.
2.13 Chromatin immunoprécipitation (ChIP) assay
Cardiomyocytes were grown on 100mm tissue culture dishes for ChIP assays. 
Ten dishes were used per condition (serum-free or stimulated with 10% FCS). 
Medium was aspirated from the cells, then cells were washed once in pre­
warmed 37“C PBS. To crosslink cellular DNA and proteins, 7ml of pre-warmed 
PBS containing 1% formaldehyde was added to each dish. Crosslinking was 
allowed to proceed for 10 minutes at 37°C, then glycine was added at a final 
concentration of 0.125 M to stop the crosslinking, and plates were transferred to 
ice. Cells were then harvested in the PB S/formaldehyde/ glycine solution, and 
transferred to Falcon tubes. Tubes were centrifuged (in a Sorvall RT 6000 D) at 
500g for 5 minutes at 4°C, then cells were washed twice by resuspension in ice- 
cold PBS, followed by centrifugation at 500g for 5 minutes. Following removal 
of supernatant after the final wash, cells were resuspended in 40 ml of high salt 
buffer (0.5% NP-40/PBS, 1 M NaCl) and incubated on ice for 30 minutes. Cells 
were then centrifuged at 500g for 5 minutes, and washed once in 0.5% NP- 
40/PBS. Subsequently, hypotonic disruption was performed by resuspending 
cells in 40 ml of low salt buffer (0.1% NP-40, 10 mM Tris pH 8.0, 1 mM EDTA, 
0.1 M NaCl) and incubating on ice for 30 minutes. Following this, samples were
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centrifuged at 500g for 5 minutes at 4°C, and the resulting pellets resuspended in 
1  ml of low salt buffer. To obtain nuclei, samples were then passed through a 26- 
guage needle 3 times. The samples were re-centrifuged as before, but this time 
the pellets were resuspended in 2.7 ml of low salt buffer, then lysed with 300 gl 
of 20% sarkosyl. Subsequently, lysed nuclei were transferred to a sucrose 
cushion (40 ml low salt buffer/100 mM sucrose) and centrifuged at 4000g for 10 
minutes at 4"C. The supernatant was discarded, and the pellet was resuspended in 
3 ml of TE (10 mM Tris pH 8.0, 1 mM EDTA). This 3 ml was then applied to a 
second sucrose cushion and the centrifugation process repeated. The final pellet 
containing genomic DNA was resuspended in 2 ml of TE, and then the DNA was 
sheared into smaller fragments (Ikb on average) by sonication (Branson Sonifier 
250, 10 X for 10 second intervals, 30% duty cycle). 0.2 ml of 11 X NET buffer 
(1.65 M NaCl, 5.5 mM EDTA, 5.5% NP-40, 550 mM Tris pH 7.4) was added to 
2 ml of sonicated material, then this was transferred to microfuge tubes for 
centrifugation at 13000g for 5 minutes. The supernatants were then aliquoted 
evenly into microfuge tubes. Each aliquot was incubated in the presence of 5 gg 
(25 gl) of an appropriate antibody overnight at 4°C on a rotating wheel. 
Antibodies used for ChIP analysis are listed in Table 2.4. As a negative control, 
one aliquot was incubated in the absence of antibody. Also, 10% of the aliquot 
volume was retained for use as an input control.
The following day, Protein-A-Sepharose beads (Amersham) were added for a 
further 2 hours of incubation, and then recovered on Polyprep columns (BioRad). 
Columns were washed twice in 10 ml of RIPA buffer (50 mM Tris pH 8.0, 150 
mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40), twice in 10 ml of LiCl
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buffer (10 mM Tris pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 
mM EDTA pH 8.0) and twice in TE. These washes were performed at 4°C. 
Beads were then transferred to 1.5 ml microfuge tubes and immunoprecipitated 
material eluted by incubating the beads with 100 gl of 1% SDS/TE on a rotating 
wheel for 10 minutes at room temperature. This was performed twice, and each 
time the supernatant was collected following centrifugation at 13000g for 1 
minute. The pooled supernatants (and input DNA made up to a total volume of 
400 gl with 1% SDS/TE) were incubated overnight at 42°C with 0.125 mg/ml 
Proteinase K to degrade the antibodies and any other proteins present. 
Subsequently, genomic DNA was extracted twice using 400 gl 
phenol/chloroform/isoamylalcohol (25:24:1). Ethanol precipitation was 
performed overnight at -20°C. The immunoprecipitated DNA was then 
resuspended in 40 gl TE, and quantified by PCR. 1 gl of immunoprecipitated or 
input DNA was used per PCR reaction following the protocol outlined in section 
2.4.2. PCR primers and cycling parameters are indicated in Tables 2.1 and 2.2.
Table 2.4 Antibodies used for ChIP assays
Protein recognised Antibody Supplier
Brfl 128 In house
Bdpl 2663 In house
Largest pol III subunit (RPC 155) 1900 In house
TFIIICllO 4286 In house
TFIIIC220 A b7 In house
c-Myc 9E10 Santa Cruz Biotechnology
c-Myc N262 Santa Cruz Biotechnology
TFIIB C18 Santa Cruz Biotechnology
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2.14 Quantification and statistical analysis of data
Data were quantified by densitometry using TotalLab (photoretix) version 1.11. 
Statistical analysis was performed using a Student’s t-Test (Microsoft Excel; 
two-tailed distribution, unequal variance). A probability (p) value of less than 
0.05 was taken as a statistically significant difference between two groups.
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CHAPTER 3 
RNA Polymerase III transcription is activated 
during cardiomyocyte hypertrophy
3.1 Introduction
The mammalian heart is primarily composed of cardiomyocytes. As outlined in 
Chapter 1, these cells become terminally differentiated and largely lose the 
ability to proliferate shortly after birth (Brooks et al, 1998; Leu et al, 2001; Li et 
al, 1997; Soonpaa et al, 1996). As a result, myocardial hypertrophy, characterised 
by an increase in myocyte volume in the absence of cell division, is the major 
determinant of heart mass during post-natal development (Bugaisky et al, 1992; 
Hannan and Rothblum, 1995; Leu et al, 2001; Zak, 1974). In addition to this 
developmental role, cardiomyocyte hypertrophy can also occur in the adult heart 
under various circumstances. For instance, exercise training in athletes can lead 
to a modest increase in heart size through cardiomyocyte hypertrophy (Frey and 
Olson, 2002; Hunter and Chien, 1999; Linzbach, 1960; Selvetella et al, 2004). 
This beneficial adaptation increases the contractile capacity of the heart, allowing 
it to cope with the increased demands associated with intensive exercise. 
However, in industrialised countries, hypertrophy in adults is most commonly 
associated with cardiac disease, and is a well-established risk factor for 
cardiovascular mortality (Harjai et al, 1999; Kannel, 1990; Levy et al, 1990; 
Vakili et al, 2001). Therefore, the causes and molecular events underlying this 
pathological hypertrophic response have been the subject of intensive 
investigation.
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Cardiomyocyte hypertrophy develops during most cardiovascular disorders as a 
result of chronic mechanical and/or neuro-hormonal abnormalities. For instance, 
increased mechanical loading has been well documented to induce hypertrophy 
in the heart and in cultured cardiomyocytes (Komuro et al, 1990; Morgan and 
Baker, 1991; Sadoshima and Izumo, 1997; Sadoshima et al, 1992). In the 
physiological setting, this results from haemodynamic alterations, usually caused 
by high blood pressure or defects in contractile efficiency. Ion channels, integrins 
and receptor tyrosine kinases have all been implicated in detecting this 
mechanical load and converting it to intracellular signals (Ross, 2004; Sadoshima 
and Izumo, 1997; Sussman et al, 2002; Yamazaki et al, 1998). Although 
mechanical stress can induce hypertrophic growth directly (Komuro et al, 1990; 
Komuro et al, 1991; Yamazaki et al, 1998), the release of autocrine/paracrine 
factors may contribute to the development of this load-induced hypertrophy 
(Sadoshima and Izumo, 1993a; Sadoshima and Izumo, 1997; Yamazaki et al,
1998). In particular, the peptide hormones angiotensin II and ET-1 are thought to 
play important roles in mediating the hypertrophic response to increased 
workload (Ito et al, 1993; Ito et al, 1994; Rockman et al, 1994; Sadoshima et al, 
1993).
Hormonal signais are also capable of stimulating cardiomyocyte hypertrophy 
independently of load (Morgan and Baker, 1991; Simpson et al, 1982). The best 
characterised of these factors include ET-1, angiotensin II, and aj-adrenergic 
agonists, such as PE (Chien et al, 1991; Lee et al, 1988; Morgan and Baker, 
1991; Sadoshima and Izurao, 1993b; Shubeita et al, 1990). These bind to 
specific, seven-transmembrane G-protein coupled receptors found on the surface
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of cardiomyocytes, which couple to the intracellular second messenger Gq. The 
importance of Gq-coupled receptors in mediating the hypertrophic response has 
been demonstrated by numerous studies (reviewed in Dorn and Brown, 1999; 
and Molkentin and Dorn, 2001). For example, transgenic mice overexpressing 
these receptors, or Gq itself, in the heart, display myocardial hypertrophy, 
whereas cardiac-specific conditional inactivation of Gq ablates pressure overload- 
induced hypertrophy in adult mice (Akhter et al, 1998; D ’Angelo et al, 1997; 
Frey and Olson, 2002; Milano et al, 1994; Paradis et al, 2000). Other 
extracellular stimuli, which bind a range of cell-surface receptor types, have been 
reported to induce the hypertrophic growth of cardiomyocytes, including 
fibroblast growth factors, insulin-like growth factor 1, prostaglandin Fz  ^ and 
cytokines such as cardiotrophin-1 (Sugden, 1999).
Regardless of the nature of the initiating trigger, detection of a hypertrophic 
stimulus at the cell surface is followed by the activation of a wide array of 
intracellular signalling cascades. Impressive advances have been made towards 
characterising this extensive, hypertrophy-associated signalling network, now 
known to encompass a variety of signal transducing molecules, including the 
small G-protein ras, protein kinase C (PKC), various members of the mitogen- 
activated protein (MAP) kinase family, phosphatidylinositol 3-kinase (PI3K) and 
the calcium-regulated signalling proteins calmodulin and calcineurin (reviewed 
in Hoshijima et al, 2004, and Molkentin and Dorn, 2001). The activation of these 
pathways culminates with hypertrophic cardiac growth, which is largely due to 
an increase in protein content per individual cardiac myocyte, through increased 
rates of protein synthesis, in the absence of cell division (Chien et al, 1991;
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Morgan et al, 1987). In addition, other cardinal features specific to the 
maladaptive hypertrophic response accompany this cell growth, including 
characteristic morphological changes, such as increased sarcomere oiganisation, 
and alterations in gene expression. The latter includes the induction of immediate 
early genes (e.g c-fos, c-jun and c-myc), the re-expression of certain foetal genes 
(such as ANF, p-myosin heavy chain and skeletal muscle a-actin), and the 
upregulation of constitutively expressed contractile proteins (Chien et al, 1991). 
This programme of molecular events induced during hypertrophy is summarised 
in Figure 3.1.
One of the current goals of cardiovascular research is to understand how these 
signalling pathways influence downstream events, ultimately leading to the 
induction of the features of hypertrophy described above. The majority of studies 
in this regard, have so far focused on elucidating the processes involved in 
mediating characteristic changes in cardiomyocyte gene expression, such as the 
re-expression of foetal genes. This has revealed specific roles for MAP kinase 
and calcineurin pathways, which regulate gene expression by altering the activity 
of various transcription factors (reviewed in Hoshijima et al, 2004). However, 
less emphasis has been placed on determining the molecular mechanisms by 
which hypertrophy-inducing signalling cascades increase myocyte protein 
synthesis, a fundamental feature of hypertrophic growth.
A cell has the potential to increase its rate of protein synthesis through various 
means. Mechanisms proposed to facilitate the increased rates of protein synthesis 
required for the hypertrophic growth of cardiomyocytes, include enhanced
66
Figure 3.1: Summary of the molecular events induced by hypertrophic 
stimulation of cardiomyocytes. A range of hormonal and mechanical stimuli 
activate a wide array of receptors expressed on the surface of cardiomyocytes. 
This leads to the activation of numerous intracellular signalling cascades, which 
in turn cause an alteration in the cardiomyocyte gene expression programme, an 
increase in the overall rate of cardiomyocyte protein synthesis, and changes in 
cellular morphology. However, the precise mechanisms through which these 
signalling pathways regulate protein synthesis, which underlies cell growth, 
remain unclear, as indicated by ‘?’.
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translational efficiency and capacity (reviewed in Hannan et al, 2003). 
Translational efficiency is controlled at the levels of peptide chain initiation and 
elongation, which in turn are regulated by specialised translation factors (Proud, 
2004). Several lines of evidence suggest that the activities of certain translation 
initiation and elongation factors are regulated in response to hypertrophic 
stimulation of cardiomyocytes (Everett et al, 2001; Hardt et al, 2004; Nagatomo 
et al, 1999; Saghir et al, 2001; Wada et al, 1996; Wang and Proud, 2002a). 
Although initially this may contribute to increased rates of protein synthesis 
(Hannan et al, 2003; Nagatomo et al, 1999), it is widely accepted that this is not 
sufficient to account for sustained hypertrophic growth, and it has been shown 
that, in terminally differentiated cardiomyocytes, cell growth accompanies an 
increase in translational capacity (Chua et al, 1987; McDermott and Morgan,
1989; Morgan et al, 1987; Siehl et al, 1985).
Translational capacity is determined by the availability of components of the 
protein synthetic machinery, including ribosomes, tRNAs and translation factors. 
Transcription by pol I, which synthesises the large rRNAs, is increased during 
hypertrophy (Hannan et al, 1995; Hannan et al, 1996a; Luyken et al, 1996; 
McDei*mott et al, 1989; McDermott et al, 1991), and this is essential for the 
induction of cardiomyocyte growth (Brandenburger et al, 2001). Pol III 
synthesises 5S rRNA, which is found in the ribosome in equimolar amounts with 
the other, pol I-produced rRNAs (Wool, 1979). Furthermore, pol III generates 
other essential components of the protein synthetic machinery (as detailed in 
Chapter 1), including tRNAs. Because of the crucial involvement of class III 
gene products in various aspects of cellular metabolism, the rate of pol III
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transcription is tightly correlated with the growth state of cells (reviewed in 
Chapter 1). For example, several studies in various eukaryotic systems have 
demonstrated that pol III transcription is subject to stringent control during many 
fundamental cellular processes, which require changes in the rate of protein 
synthesis, such as during the cell cycle and differentiation, and in response to 
nutrients and mitogens (Leresche et al, 1996; Scott et al, 2001; Sethy et al, 1995; 
Tower and Sollner-Webb, 1988; White et al, 1989; White et al, 1995a, b). 
Therefore, it is highly likely that, as with pol I transcription, pol III transcription 
will also be activated during myocardial hypertrophy. However, pol III 
transcriptional regulation has not yet been thoroughly investigated in cardiac 
muscle cells. This is an important issue to address, in order to enhance 
understanding of the processes facilitating hypertrophic growth. The experiments 
described in this chapter aimed to determine whether increased pol III 
transcription is a feature of the hypertrophic response, through the use of well- 
defined model systems.
70
3 RNA polymerase III transcription is activated during cardiomyocyte hypertrophy
3.2 Results
3.2.1 Characterisation of cultured cardiomyocytes
The current understanding of the hypertrophic growth response has been greatly 
facilitated by the development and characterisation of cultured cardiomyocyte 
cell models by several investigators (reviewed in Chien et al, 1991). Most 
commonly, these cells are prepared directly from neonatal rat hearts. The 
suitability of these primary cells for studying the molecular events involved in 
myocardial growth has been well documented. Although prepared from neonates, 
numerous studies have demonstrated that exposure of these cells to various 
agents induces many features of hypertrophy seen in adult cardiomyocytes in the 
heart (Bishopric et al, 1987; Chien et al, 1991; Knowlton et al, 1991; Lee et al, 
1988; Meidell et al, 1986; Shubeita et al, 1990; Simpson et al, 1982; Starsken et 
al, 1986; Waspe et al, 1990). For example, ET-1, PE and also FCS induce 
morphological, structural, biochemical and transcriptional changes in these 
cultured cardiomyocytes characteristic of those induced in the myocardium.
In this study, cardiomyocytes were prepared from the hearts of neonatal Sprague 
Dawley rats, using previously described methods with minor modifications (as 
described in Chapter 2). Following dissociation of the various types of cardiac 
cell from rat heart tissue, procedures that selectively enrich for cardiomyocytes 
were employed. This resulted in spontaneously contracting cultures of 
cardiomyocytes of greater than 90% purity, as determined by microscopic and 
immunofluorescence analysis (data not shown), in accordance with what has 
been reported in the literature (Boluyt et al, 1997; Flink et al, 1998; Poolman and 
Brooks, 1998; Sadoshima et al, 1997; Starsken et al, 1986; von Harsdorf et al.
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1999). To further ensure that the myocyte isolation procedure used in this study 
produced a reliable model system, a series of experiments were performed to 
characterise the hypertrophic growth response of these cells, before examining 
the regulation of pol III transcription.
As discussed previously, several criteria typify the hypertrophic growth of 
cardiomyocytes. One of the cardinal features of this response is an increase in the 
rate of protein synthesis (Chien et al, 1991; Morgan et al, 1987). Because this 
occurs in the absence of cell division, DNA synthesis is not normally induced. 
Cultured cardiomyocytes were serum-starved for 24 hours, then treated for 16 
hours with classic hypertrophic stimuli, including FCS, ET-1 and PE. Control 
cells were maintained in serum-free media. The effects of these treatments on 
protein synthesis and DNA synthesis were assessed by measuring the 
incorporation of radiolabelled cysteine and methionine, or thymidine, 
respectively. As revealed in Figure 3.2, each of these stimuli caused a significant 
increase in the rate of protein synthesis compared to control cells, within the 
range previously reported in the literature (Boluyt, et al, 1997; Bueno et al, 2000; 
Nozato et al, 2001; Pham et al, 2001; Sano et al, 2002; Tamamori et al, 1998). 
DNA synthesis was not induced, as expected (Sadoshima et al, 1997; Tamamori 
et al, 1998).
Accelerated protein synthesis, and the resulting accumulation of protein, 
underlies the increase in cardiomyocyte size characteristic of hypertrophy. To 
confirm that increased protein synthesis was accompanied by cell growth in the 
present study, cardiomyocyte volume was measured using a Z2 Coulter counter.
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Figure 3.2: Various stimuli induce protein synthesis, but not DNA synthesis, in 
primary cardiomyocyte cultures. Cultured cardiomyocytes were serum-starved 
for 24 hours, then either maintained in serum-free media for a further 16 hours 
(control cells), or exposed to 10% FCS, 100 nM ET-1 or 100 gM PE for 16 hours. 
To determine protein synthesis rates, cells were labelled with 
P^S]methionine/cysteine 1 hour before harvesting. To measure DNA synthesis rates, 
pH]thymidine was added to cells 16 hours before harvesting. Relative p^S] and pH] 
incorporation was assessed by liquid scintillation counting. The fold increases 
represent the mean o f five separate experiments, each with three replicates per 
condition. The error bars indicate the standard deviation from the mean 
(*significantly different from control, p<0.02; **not significantly different from 
control).
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Figure 3.3 demonstrates that cardiomyocytes exposed to FCS for 16 hours were 
significantly larger (1.3-fold) than control, serum-stai'ved cells. Consistent with 
this being part of a hypertrophic growth response, cell number was unaffected.
The mammalian heart contains a variety of cell types, in addition to 
cardiomyocytes, including fibroblasts and endothelial cells. Although the 
cardiomyocyte isolation procedure minimises the content of these cells in the 
final cultures, it is veiy difficult to completely exclude these cells. Unlike 
cardiomyocytes, cardiac fibroblasts can divide rapidly, and so il proliferation of 
these cells takes place, they may eventually overgrow the cardiomyocytes. 
Therefore, it is important to limit the proliferation of any contaminating 
fibroblasts within cardiomyocyte cultures. In this study, and many others, high 
plating density was used to restrict fibroblast proliferation (Sadoshima and 
Izumo, 1995; Sadoshima et al, 1997). Additionally, prior to use, cultures were 
maintained in media containing horse serum only, which is low in mitogens, or 
no serum. Figures 3.2 and 3.3 show that FCS does not induce detectable DNA 
synthesis or cell division in these cultures. Not only does this confirm that the 
isolated myocytes were non-dividing, but also suggests that the measures 
outlined above were sufficient in preventing the proliferation of any 
contaminating fibroblast cells.
In addition to changes in protein synthesis and cell size, a specific feature of the 
pathological hypertrophic growth response is the re-expression of characteristic 
foetal genes. In particular, induction of ANF expression has been demonstrated
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Figure 3.3: Stimulation of cultured cardiomyocytes with FCS increases cell 
size but not cell number. Cardiomyocytes were cultured in the absence o f serum 
for 24 hours, then either maintained in serum-free media for a further 16 hours 
(control ceils), or stimulated with 10% FCS for 16 hours. Cells were dissociated 
from dishes, then cell volume and number were measured using a Z2 Coulter 
counter. The fold increases represent the mean o f three separate experiments, 
each with two replicates per condition. The error bars indicate the standard 
deviation from the mean (*significantly different from control, p<0.05; **not 
significantly different from control).
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in a wide variety of species, in response to many stimuli (Chien et al, 1991; 
Hoshijima et al, 2004; Hunter and Chien, 1999). As a result, ANF expression is 
often used as a marker of hypertrophy in the heart and in primary cultured cell 
models. RT-PCR analysis confirmed that ANF expression was increased in 
response to FCS, ET-1 and PE treatment of the primary cultures used in this 
study (Figure 3.4). This effect was specific, as there was no change in the control 
mRNA, ARPP PO.
Thus, these cells display several defining features of the hypertrophic growth 
response, and so provide an appropriate culture system to determine whether pol 
III transcription is activated during cardiomyocyte hypertrophy.
3.2.2 Hypertrophic stimulation of cultured cardiomyocytes induces pol III 
transcription
Several techniques were used to assess changes in pol III transcription in 
response to hypertrophic stimulation of cultured cardiomyocytes. For example, 
Northern blotting demonstrated that induction of hypertrophic growth, with FCS, 
ET-1 or PE, is accompanied by a significant increase in the level of class III 
transcripts derived from the B2 middle repetitive gene family (Figure 3.5). This 
effect is specific, since the level of ARPP PO mRNA is unaffected by these 
treatments. B2 transcripts have very short half-lives (less than 5 minutes (Bladon 
et al, 1990)), and therefore an increase in their abundance is indicative of an 
enhanced rate of ongoing transcription by pol III.
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Figure 3.4: Various stimuli induce re-expression of the foetal gene ANF in 
cardiomyocyte cultures. Cultured cardiomyocytes were serum-starved for 24 
hours, then either maintained in serum-ffee media for a further 16 hours (control 
cells), or exposed to 10% FCS, 100 nM ET-1 or 100 pM PE for 16 hours. Total 
RNA was extracted from these cells and 3 gg used to generate cDNAs by reverse 
transcription. Specific cDNAs were then amplified by PCR using ANF and 
ARPP PO primers. The figure shows a representative RT-PCR analysis.
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Figure 3.5: Hypertrophie stimulation of cultured cardiomyocytes induces B2 
expression. Cultured cardiomyocytes were serum-starved for 24 hours. 
Hypertrophy was then induced by treating cells with 10% FCS, 100 nM ET-1 or 
100 |iM PE for 16 hours. Control cells were maintained in serum-free media for 
these 16 hours. Total cellular RNA was extracted and 10 gg analysed by 
Northern blotting. A. Representative Northern blot. The upper panel shows the 
blot probed for B2, and the lower panel shows the same blot stripped and re­
probed for ARPP PO. B. The levels of B2 and ARPP PO in each sample were 
quantified using densitometry, and B2 levels normalised against ARPP PO levels. 
This was done for 3 separate experiments and the average fold increases 
obtained, along with standard deviations from the means, are represented in the 
graph (^significantly different from control, p<0.05).
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PCS has been shown to induce pol III transcription in proliferating fibroblast 
cells (Felton-Edkins et al, 2003a; Johnson et al, 1974; Mauck and Green, 1974; 
Scott et al, 2001). The lack of effect of PCS on DNA synthesis (Figure 3.2) and 
cell number (Figure 3.3) in this study indicated that there was no significant pool 
of proliferating fibroblasts within the cultures used, as discussed previously. 
Nonetheless, it was important to ascertain that the observed increase in class III 
transcripts, in response to PCS, was a feature of the hypertrophic growth of the 
myocyte population, and not associated with any contaminating fibroblast 
proliferation. In addition to high plating density and the use of mitogen-poor 
serum, some investigators also include BrdU in cardiomyocyte culture media 
(Bogoyevitch et al, 1993; Boluyt et al, 1997; McDermott et al, 1989; Sadoshima 
and Izumo, 1995; Simpson et al, 1982; Starsken et al, 1986). BrdU is toxic to 
dividing cells, and therefore ensures that fibroblast proliferation is inhibited 
(Simpson and Savion, 1982). However, BrdU does not influence the stimulation 
of cardiomyocyte hypertrophic growth (Simpson et al, 1982). Although BrdU 
was not routinely used in the current study, to rule out the possibility that the 
increase in pol III transcripts in response to PCS was due to contaminating 
fibroblast cells, the effects of PCS on B2 induction were compared in the 
presence and absence of BrdU (Figure 3.6). Inclusion of BrdU in the culture 
media had no significant effect on the induction of B2 by PCS, as determined by 
Northern blotting, thus confirming that proliferating cells do not contribute to 
this increase in class III transcripts.
As described in Chapter 1, pol III transcribes a variety of genes in addition to B2. 
To assess the effect of hypertrophic stimuli on the expression of a range of other
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Figure 3.6: BrdU has no effect on B2 induction by FCS in cultured 
cardiomyocytes. Following dissociation from neonatal rat hearts, 
cardiomyocytes were cultured in media containing 0.1 mM BrdU or vehicle 
alone (0.1% DMSO). BrdU and vehicle exposed cells were serum starved for 24 
hours, then treated with or without 10% FCS to induce hypertrophy. BrdU or 
vehicle were present throughout the course of the experiment. 10 gg of total 
RNA was analysed by Northern blotting. A. Representative Northern blot. The 
upper and lower panels show the blot probed for B2 then re-probed for ARPP PO, 
respectively. B. B2 and ARPP PO levels were quantified using densitometry, and 
B2 normalised against ARPP PO. This was done for 4 experiments and the 
average fold increases obtained are represented in the graph. The error bars 
indicate the standard deviation from the mean (*both are significantly different 
from control, p<0.05, but not significantly different from each other).
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pol ni-transcribed genes, semi-quantitative RT-PCR analysis was used. As 
before, hypertrophy was induced in cultured cardiomyocytes by exposing serum- 
starved cells to FCS, ET-1 or PE for 16 hours. Extracted RNA was then analysed 
by RT-PCR using primers specific for various pol III templates. This revealed an 
increase in all the pol III transcripts tested, in stimulated cells compared to 
control cells, including 5S rRNA, U6 snRNA and precursors for tRNAs tyrosine 
(pre-tRNA'^^') and leucine (pre-tRNA’^ *') (Figure 3.7). The primers used to 
measure tRNA levels were designed to hybridise to rapidly processed introns 
within the nascent tRNA transcripts (Winter et al, 2000). Therefore, whereas the 
5S rRNA and U6 snRNA primers measure steady-state transcript levels, the 
levels of pre-tRNA'^^' and pre-tRNA^" provide a direct measure of transcriptional 
output (Winter et al, 2000). The genes transcribed by pol III can be categorised 
depending on their promoter structure, of which there are three types (types 1-3). 
5S rRNA, tRNA and U6 snRNA genes have type 1, 2 and 3 promoters, 
respectively. Therefore, this analysis suggests that there is a general increase in 
pol III transcription during hypertrophic growth, which is not specific to one 
particular pol III template or promoter type.
The increase in various pol III transcripts following hypertrophic stimulation, as 
determined by Northern blotting and RT-PCR analysis, indicated that pol III 
transcription was activated during hypertrophic growth. In particular, the 
increase in intron-containing tRNAs directly demonstrated an induction of 
transcription by pol III (Figure 3.7). This may have been due to an increase in the 
inherent activity of the pol III transcription machinery or, for example, as a result 
of altered chromatin structure and hence increased accessibility to these
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Figure 3.7: Hypertrophic stimulation of cultured cardiomyocytes induces 
the expression of various class III genes. Cultured cardiomyocytes were treated 
as in Figure 3.5 to induce hypertrophy. 3 pg of total cellular RNA was used to 
generate cDNAs by reverse transcription. cDNAs were then PCR amplified using 
primers specific for 5S rRNA, pre-tRNA^", pre-tRNA^^', U6 snRNA and ARPP 
PO, as indicated. A. Representative RT-PCRs are shown. B, Transcript intensities 
were quantified and the level of class III gene products were normalised to ARPP 
PO. The average fold increases for each class III transcript are shown in the 
graph. The error bars indicate the standard deviation from the mean (*n=3 and 
significantly higher than control, p<0.05; *"^n=2).
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templates. To directly test whether the pol III transcription machinery was more 
active following hypertrophic stimulation, IVTs were performed. Whole-cell 
extracts were prepared from FCS-starved and FCS-stimulated cells and tested for 
their ability to support transcription of various pol III templates in vitro, 
including 5S rRNA, B2, tRNA^"“ and adenovirus VAÎ (Figure 3.8). This showed 
that pol III transcriptional activity was higher in extracts derived from 
hypertrophic cardiomyocytes, thus supporting the conclusion that pol III 
transcription is activated during cardiomyocyte hypertrophy in culture.
Increased transcription is often associated with augmented polymerase 
recruitment to target genes (White, 2001). To examine whether this was true for 
pol III in cardiomyocytes, ChlPs were performed using antibodies against the 
largest pol III subunit and, as negative controls, a TFIIB antibody or beads alone. 
Figure 3.9 shows that, although hypertrophic stimulation of cardiomyocytes had 
little effect on the level of input genomic DNA, there was a marked increase in 
pol III binding to 5S rRNA and tRNA genes in vivo. This is consistent with the 
hypertrophy-associated increase in transcription of these genes (Figures 3.7 and 
3.8).
Thus, hypertrophic stimulation of cultured cardiomyocytes enhances pol III 
binding to promoters in vivo, activates the pol III transcription machinery and 
hence induces the expression of various class III genes.
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Figure 3.9: Hypertrophie stimulation of cultured cardiomyocytes enhances pol 
111 binding to class 111 gene promoters in vivo. Hypertrophic growth was induced 
in cultured cardiomyocytes, as before, with 10% FCS. Chromatin was then isolated 
from control, serum-starved cells and FCS-stimulated cells. ChlPs were performed 
using Protein A Sepharose beads alone, as a control, or beads coupled to antibodies 
against TFIIB (irrelevant antibody control) or the largest pol III subunit, as 
indicated. Association o f pol III with 5S rRNA, tRNA^®“ and tRNA^y  ^promoters in 
unstimulated and hypertrophic cells was quantified by PCR with gene-specific 
primers. Input genomic DNA (10% and 2% o f that used in the ChlPs) was analysed 
in the same PCR reactions. The figure shown is representative o f at least 3 
independent ChIP experiments.
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3.2.3 Hypertrophic stimulation of the heart induces pol III transcription in 
mice
In addition to cultured cells, animal models are also invaluable for studying the 
causes and consequences of myocardial growth. Hypertrophy can be induced in 
the hearts of these animals by administering certain hormones, or by mimicking 
cardiac pressure overload using surgical procedures (Antos et al, 2001; Busk et 
al, 2002; Nozato et al, 2001; Rockman et al, 1994; Shioi et al, 2003). For 
example, pressure overload hypertrophy is commonly induced in mice by 
chronic constriction of the transverse aorta (Rockman et al, 1991). This causes an 
increase in cardiomyocyte size and hence myocardial mass, along with 
characteristic changes in gene expression (Rockman et al, 1991). To assess 
whether pol III transcription was activated during this hypertrophic response, 
hearts were obtained from adult mice in which pressure overload hypertrophy 
had been induced by transverse aortic constriction (TAC) for 2 weeks (in the 
laboratory of Dr WR MacLellan, UCLA, USA). Control mice were subjected to 
sham operation. RNA was extracted from these hearts and analysed by RT-PCR. 
TAC caused a clear increase in ANF mRNA levels, confirming that this 
procedure induced a hypertrophic response (Figure 3.10). This was accompanied 
by a significant increase in the level of pre-tRNA'^y" transcripts (Figure 3.10), thus 
demonstrating that pol III transcription is not only activated during 
cardiomyocyte hypertrophy in culture, but also in the heart.
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Figure 3.10: Hypertrophie stimulation of the heart activates pol III 
transcription in mice. Hearts were obtained from mice in which pressure- 
overload hypertrophy had been induced by TAC for 2 weeks. Control animals 
underwent sham operation (SHAM). RNA was extracted from whole hearts, 
DNase I-treated, then used for RT-PCR analysis with pre-tRNA^^', ANF and 
ARPP PO specific primers. A. RT-PCRs, using RNA derived from 2 separate 
animals per condition, are shown (SHAM (lanes 1 and 2) or TAC (lanes 3 and 
4)). B. Densitometry was used to quantify the amounts of pre-tRNA^^' and ARPP 
PO in each heart. Six hearts were analysed for each condition, and the average 
level of pre-tRNA^^", normalised to ARPP PO, is shown in the graph. The error 
bars indicate the standard deviation from the mean (^significantly higher than 
control, p<0.05). The hearts used for these analyses were provided by Dr WR 
MacLellan, University of California, Los Angeles, USA.
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3.3 Discussion
Heart growth in adults, in response to increased demands, occurs through 
cardiomyocyte hypertrophy. Accelerated rates of protein synthesis, leading to 
protein accumulation, facilitate this cell growth (Morgan et al, 1987). However, 
the mechanisms by which hypertrophic stimuli cause this increased synthesis are 
incompletely defined. Pol III produces essential components of the cellular 
biosynthetic machinery, such as 5S rRNA and tRNAs. Thus, by targeting the pol 
III transcriptional apparatus, hypertrophic stimuli could potentially increase the 
protein synthetic capacity of cardiomyocytes, making the pol III transcription 
machinery a likely candidate for regulation during hypertrophic growth. The data 
presented in this chapter confirmed that hypertrophic growth, characterised by 
increased protein synthesis and cell size in the absence of cell division, and the 
re-expression of the foetal gene, ANF, can be induced in primary cultured 
cardiomyocytes. Northern blotting, RT-PCR, IVTs and ChIP analysis revealed 
that this hypertrophic growth was accompanied by an activation of the pol III 
transcription machinery, enhanced binding of pol III to promoters in vivo, and a 
general increase in class III gene expression. Analysis of hearts from mice, in 
which TAC had induced pressure-overload hypertrophy, indicated that this 
activation of pol III transcription was physiologically relevant. Thus, this 
provides the first, comprehensive analysis of changes in pol III transcription 
occurring during hypertrophic growth, and may represent a novel mechanism 
contributing to the increased rates of protein synthesis necessary to sustain 
cai'diomyocyte hypertrophy (Figure 3.11). Not only does this add to the current 
understanding of a process with relevance to disease, but also indicates that
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activation of pol III transcription can be associated purely with cell growth, 
without cell division.
An eaiiy study by Cutilletta et al (1978) demonstrated that aortic constriction 
increased the activity of all three RNA polymerases in cardiomyocytes. These 
investigators exposed isolated nuclei to varying concentrations of a-amanitin 
(derived from the fungus Amanita phalloides) in order to distinguish between the 
activities of pols I, II and III, which have differential sensitivities to this toxin. 
This assay was relatively crude and, furthermore, the consequences of increased 
enzymatic activity on changes in class I, II or III gene expression were not 
addressed. A more recent investigation reported increased transcription of the 
MRP gene by pol III under hypertrophic conditions in cultured cardiomyocytes 
(Hannan and Rothblum, 1995). MRP is involved in processing the pre-rRNAs 
produced by pol I. However, the relevance of this observation to hypertrophic 
growth, or whether it was due to a general increase in pol III transcription, was 
not explored. The current study extends these limited observations described 
above, and presents a more thorough examination of hypertrophy-associated 
class III gene expression. Crucially, increased expression of 5S rRNA and tRNA 
was clearly demonstrated here, suggesting that the increase in pol III 
transcription is likely to have functional consequences for protein synthetic 
capacity.
Valions factors influence the extent of hypertrophic growth, including the nature 
and duration of the initiating stimulus. The former is exemplified in Figure 3.2: 
FCS increased protein synthesis by approximately 2.4-fold, whereas ET-1 and
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PE caused only 1.7- and 1.65-fold increases, respectively. This is consistent with 
previous studies, which have also demonstrated that FCS is a more potent 
inducer of hypertrophy than various individual agonists (Busk et al, 2002; 
Simpson et al 1982; Taigen et al, 2000). This may be due to the presence of 
several, synergistically acting hormones and growth factors in FCS (Simpson et 
al, 1982). Consequently, for all subsequent analyses of the mechanisms 
regulating pol III transcription in cultured cardiomyocytes, FCS was used as the 
hypertrophic stimulus.
Stimulation of cardiomyocytes in culture with 10% FCS for 16 hours caused a 
significant, 1.3-fold increase in cell volume in the current study (Figure 3.3). 
Hypertrophic stimulation of cultured cardiomyocytes with a variety of agents, for 
various lengths of time, has been reported to induce increases in cell surface area 
ranging from approximately 1.2- to 2.3-fold (Boluyt, et al, 1997; Brandenburger 
et al, 2001; Busk et al, 2002; Glennon et al, 1996; Haq et al, 2003; Nozato et al, 
2001; Taigen et al, 2000; Tamamori et al, 1998; Yanazume et al, 2003). 
Although direct comparisons of these values are not possible, as different 
conditions for inducing hypertrophy and techniques for measuring cell size were 
used, the fold-increase reported here does fall within this range. In studies where 
cell enlargement exceeded that observed here, cells had been exposed to 
hypertrophic stimuli for a minimum of 48 hours.
It is generally accepted that cardiomyocytes irreversibly withdraw from the cell 
cycle shortly after birth in mammals, and become terminally differentiated. 
However, recent studies have challenged this view, and have presented evidence
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to suggest that cardiomyocyte proliferation can occur in the adult heart (Anversa 
and Kajstura, 1998; Anversa and Nadal-Grinard, 2002; Beltrami et al, 2001). 
This issue remains controversial and, in the main, cardiomyocyte hyperplasia is 
considered to be a rare event, if occurring at all. For the purposes of this study, 
cardiomyocytes were cultured from neonatal rat hearts. Although it is possible 
that, under some conditions, these cells may show limited capacity to proliferate, 
analysis of changes in pH]thymidine incorporation (Figure 3.2) and cell number 
(Figure 3.3) in response to serum stimulation, confirmed that such cell division 
was not present in the primary cells used here. Likewise, no evidence of myocyte 
cell cycle re-entry was detected in hearts following TAC (MacLellan, 
unpublished data). Therefore, the systems used were bona fide  models for 
studying hypertrophic growth without cell division, thus validating the 
conclusion that pol III transcriptional activation was independent of proliferation.
The ways in which cardiomyocytes achieve increased rates of protein synthesis 
during hypertrophic growth are beginning to be elucidated, as summarised in 
Figure 3.11. In addition to reviewing the mechanisms previously implicated in 
mediating hypertrophic cell growth, this figure also illustrates the role pol III 
may play in this process. As previously discussed, it is an increase in 
translational capacity that is thought to be critical for sustained hypertrophic 
growth (Brandenburger et al, 2001; Morgan et al, 1987; Siehl et al, 1985). Along 
with pol I, enhanced pol III transcription will likely contribute to this increased 
capacity. Activation of transcription by pols I and III often coincide, in order to 
coordinate the production of ribosomes, tRNAs and other RNAs involved in 
cellular biosynthesis. This study suggests that the hypertrophic growth of
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Figure 3.11: Mechanisms likely to contribute to increased rates of protein 
synthesis during cardiomyocyte hypertrophy. Hypertrophic stimulation of 
cardiomyocytes leads to the activation of the translation initiation factors, eIF4E 
and eIF2Be, and the translation elongation factor, eEF2. This is likely to increase 
the efficiency with which existing ribosomes synthesise novel peptide chains. 
Other changes that occur following hypertrophic stimulation include increased 
pol I transcription, which is known to be essential for hypertrophic growth, and, 
as demonstrated in the current study, increased pol III transcription. The latter is 
also likely to contribute to an increase in translational capacity, and hence 
increased protein synthesis.
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cardiomyocytes provides no exception to this frequent co-regulation, and 
highlights the fundamental importance of such synchrony.
Having established that pol III transcription is activated during cardiomyocyte 
hypertrophy, the next aims of the project were to determine the mechanisms 
responsible for this increase. The following chapters examine whether the pol III 
transcription machinery is a target for vaiious known mediators of hypertrophy, 
that have been shown to activate pol III transcription in immortalised, 
proliferating cell types. Novel mechanisms for regulating pol III transcription in 
cardiomyocytes are also considered.
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CHAPTER 4 
Several mechanisms potentially regulate TFIIIB 
activity during cardiomyocyte hypertrophy
4.1 Introduction
The data presented in Chapter 3 demonstrate that pol III transcription is activated 
during the hypertrophic growth of cardiomyocytes. The mechanisms controlling 
this increase are investigated in the remainder of this thesis. This chapter 
considers a variety of potential regulatory mechanisms, and aims to establish 
whether any of these could be involved in the control of pol III transcription 
during cardiomyocyte hypertrophy. An understanding of these mechanisms 
might be useful when devising strategies to manipulate hypertrophic growth in 
disease. In addition, because the majority of studies on the regulation of pol III 
transcription in mammalian cells have focused on dividing, immortalised cell 
types, it will be interesting to determine whether the same or distinct mechanisms 
operate in non-dividing, primary cells.
4.1.1 Regulation of pol III transcription
The transcription of a class III gene can be divided into three main stages: 
initiation, elongation and termination. The rate of transcription is primarily 
regulated at the level of initiation. This is dependent on the productive assembly 
of a transcription initiation complex at the appropriate promoter, and the 
subsequent recruitment of pol III. For the majority of class III genes, this process 
requires two pol Ill-specific, basal transcription factors: the promoter-recognition 
factor, TFIIIC, and the polymerase recruitment factor, TFIIIB (see Chapter 1;
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Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002), Several 
components of these transcription factor complexes are regulated under various 
circumstances in eukaryotic cells, in order to modulate pol III transcriptional 
output, as detailed in Chapter 1. In particular, TFIIIB activity is stringently 
controlled by a variety of mechanisms.
In proliferating cells, control of TFIIIB activity is predominantly achieved 
through protein-protein interactions with various regulators. For example, the 
MAP kinase ERK can induce pol III transcription by binding and 
phosphorylating the Brfl subunit of TFIIIB (Felton-Edkins et al, 2003a). This 
enhances the interaction of TFIIIB with both TFIIIC and pol III, hence 
promoting pol III transcription (Felton-Edkins et al, 2003a). The proto-oncogene 
product c-Myc also activates pol III transcription, again by targeting TFIIIB 
(Gomez-Roman et al, 2003). In contrast to these positive regulators of pol III 
transcription, RB plays an important role in restraining pol III activity (White et 
al, 1996). In resting cells, RB binds and inactivates TFIIIB (Chu et al, 1997; 
Larminie et al, 1997; Sutcliffe et al, 2000), thereby preventing the unnecessary 
production of tRNAs, 5S rRNA and other pol III products. However, in response 
to mitogenic stimulation, RB becomes inactivated by CDK-induced 
hyperphosphorylation. This leads to the release of TFIIIB, and the activation of 
pol III transcription prior to S phase (Scott et al, 2001).
ERK, c-Myc and RB all play central roles in regulating mammalian cellular 
proliferation (for reviews see Chang et al, 2003; Dang, 1999; Kaelin, 1999; 
LUscher, 2001; Weinberg, 1995; Wilkinson and Millar, 2000). However, it is
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becoming increasingly apparent that these molecules are also important 
regulators of cell growth (Schmidt, 1999; White, 1998; Whitmarsh and Davis, 
2000; Wilkinson and Millai*, 2000), and in fact, under certain circumstances, this 
regulation can occur independently of cell division (Bueno et al, 2000; Glennon 
et al, 1996; Iritani and Eisenman, 1999; Johnston et al, 1999; Kim et al, 2000; 
MacLellan et al, unpublished results; Schuhmacher et al, 1999). This point is 
suitably illustrated by the fact that each of these proteins has been implicated in 
mediating the hypertrophic growth of cardiomyocytes (Bueno and Molkentin, 
2002; MacLellan et al, unpublished results; Nozato et al, 2001; Sadoshima et al, 
1997; Simpson, 1988; Tamamori et al, 1998; Xiao et al, 2001). The roles that 
these proteins play in the hypertrophic response are incompletely defined, but it 
seems highly possible that they will target the pol III transcription machinery in 
cardiomyocytes, and in this way regulate hypertrophic growth. Thus, ERK, c- 
Myc and RB are likely candidates for the regulation of pol III transcription 
during hypertrophy. To begin to address this possibility, this chapter examined 
the induction and/or phosphorylation of each of these potential regulators in 
cultured cardiomyocytes in response to hypertrophic stimulation.
In addition to changes in pol III transcription factor activity, alterations in 
transcription factor expression may also contribute to the regulation of pol III 
productivity. Changes in transcription factor abundance seem to be an important 
determinant of pol III transcription rates during certain instances of mammalian 
cell differentiation (Alzuherri and White, 1998), viral infection (Felton-Edkins 
and White, 2002; Larminie et al, 1999; Wang et al, 1995) and tumourigenesis 
(Winter et al, 2000; Daly et al, 2004, In press). Hypertrophy-associated changes
101
4 Several mechanisms potentially regulate TFIIIB activity during cardioniyocyte hypertrophy
in the levels of pol Ill-specific transcription factors will be explored in this 
chapter.
In summary, the objectives of this chapter were to examine changes in the pol III 
transcription machinery, and proteins known to interact with this machinery, in 
response to hypertrophic stimulation, in order to establish a potential basis for the 
regulation of pol III transcription during cardiomyocyte hypertrophy.
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4.2 Results
4.2.1 Interaction of the pol III transcription machinery with promoters in 
vivo during hypertrophic growth
Enhanced pol III transcription during hypertrophic growth accompanies an 
increase in polymerase binding to class III gene promoters in vivo (Figure 3,9), 
and this is likely to at least partly facilitate the observed activation of 
transcription by pol III. To investigate the basis of this increased pol III 
recruitment, ChIP assays were performed to examine the association of other 
components of the pol III transcription machinery with promoters during 
hypertrophy. As previously discussed, the recruitment of pol III to most target 
genes requires the transcription factor complexes TFIIIB and TFIIIC 
(Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002). To 
determine whether the binding of either of these factors to promoters was subject 
to regulation during hypertrophic growth, ChIP analyses were carried out using 
antibodies against two of the TFIIIB subunits (Brfl and Bdpl), and two of the 
TFIIIC subunits (TFIIIC 110 and TFIIIIC220). As shown in Figure 4.1, this 
demonstrated that, along with the previously described increase in pol III binding 
(Figure 3.9), hypertrophic stimulation (with FCS for 16 hours) also increases the 
level of TFIIIB bound to tRNA and 5S rRNA genes in vivo. Although in the 
example shown for tRNA'^ '^ the level of input DNA from serum-stimulated cells 
is also slightly higher, this difference is clearly less than the difference in TFIIIB 
immunoprecipitated under each condition. Increased TFIIIB binding is more 
striking for the tRNA genes than the 5S rRNA genes, and may reflect differences 
in the promoter types utilised by pol III to transcribe different templates (see 
Chapter 1). TFIIIC binding to each promoter type is unaffected. Figure 4.2
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Figure 4.1: Hypertrophic stimulation of cardiomyocytes enhances TFIIIB and pol 
111, but not T F lllC , binding to class 111 gene promoters in vivo. Cultured 
cardiomyocytes were treated with 10% PCS for 16 hours to induce hypertrophic growth. 
Control cells were maintained in serum-ffee medium. ChlPs were performed with 
antibodies against Brfl, Bdpl, TPIIICl 10, TPIIIC220 and the largest pol III subunit, as 
indicated. As negative controls, ChlPs were carried out using a TPIIB antibody and 
beads alone. Association o f each factor with 58 rRNA, tRNA^“ and tRNA^)  ^promoters, 
in unstimulated and hypertrophic cells, was quantified by PCR with gene-specific 
primers. Input genomic DNA (10% and 2% o f that used in the ChlPs) was analysed in 
the same PCR reactions. The figure shown is representative o f 3 independent ChIP 
experiments.
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Figure 4.2: Increased TFIIIB and pol III recruitment to class III gene 
promoters may contribute to the activation of pol III transcription during 
cardiomyocyte hypertrophy. Hypertrophic stimulation o f cardiomyocytes 
enhances the binding o f TFIIIB to class III gene promoters in vivo. This is likely to 
facilitate the increase in pol III recruitment, and hence the activation o f pol III 
transcription, that occurs during hypertrophic growth. A typical type 2 promoter is 
shown in this figure to illustrate these changes in promoter occupancy.
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summarises these changes in class III gene promoter occupancy. TFIIIB is 
directly responsible for polymerase recruitment (Geiduschek and Kassavetis, 
2001; Schramm and Hernandez, 2002); therefore, the increased association of 
TFIIIB with promoters is likely to account for the augmented polymerase 
binding, and hence the enhanced class III gene expression, that occurs during 
hypertrophic growth. This is consistent with TFIIIB being an important 
regulatory target for the control of pol III transcription in terminally 
differentiated cardiomyocytes.
4.2.2 Hypertrophic stimulation of cardiomyocytes influences known 
regulators of TFIIIB activity
As discussed above, TFIIIB activity may be a central determinant of the rate of 
pol III transcription during cardiomyocyte hypertrophy. Known regulators of pol 
III transcription in proliferating cells, which interact with TFIIIB, include ERK, 
c-Myc and RB (Chu et al, 1997; Felton-Edkins et al, 2003a; Gomez-Roman et al, 
2003; Larminie et al, 1997; Sutcliffe et al, 2000). PCS was shown to induce pol 
III transcription and hypertrophic growth in primary cardiomyocyte cultures 
(Chapter 3). To establish whether ERK, c-Myc or RB could potentially 
contribute to this regulation of pol III transcription, protein lysates were prepared 
from cultured cardiomyocytes before and after hypertrophic stimulation with 
FCS for 16 hours. Western blotting was performed to assess the activation of 
ERK, the induction of c-Myc, and the phosphorylation status of RB (Figure 4.3).
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Figure 4.3; Hypertrophie stimulation of cardiomyocytes influences known 
regulators of TFIIIB. Whole cell lysates were prepared from cultured 
cardiomyocytes that had been serum-starved for 24 hours, then either maintained 
in serum-free medium or exposed to 10% FCS for 16 hours. 75 pg of protein 
were then resolved by SDS-PAGE. Western blotting was performed with 
antibodies against the proteins, or phosphoproteins (indicated by ‘phos-’), 
specified. A. Hypertrophic stimulation induces ERK phosphorylation. B. 
Hypertrophic stimulation induces c-Myc expression. The anti-c-Myc antibody 
9E10 was used here. C. Hypertrophic stimulation induces the 
hyperphosphorylation of RB. The Western blots in the top three panels were 
probed with antibodies that specifically detect RB phosphorylated on serine (ser) 
795, threonine (thr) 826, or ser 780. Total RB levels were measured after 
electrophoresis on both 7.8% (with antibody C-15) and 6% (with antibody G3- 
245) polyacrylamide gels (bottom two panels).
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ERK activation results from the phosphorylation of two particular residues by 
upstream kinases (Carrington and Johnson, 1999). Using a phospho-specific 
antibody, that recognises the 44 and 42kDa isoforms of activated ERK, Western 
blotting demonstrated ERK activation in response to hypertrophic stimulation 
(Figure 4.3A, upper panel). The total level of ERK was unaffected, confirming 
that ERK activity, and not abundance, is influenced by FCS (Figure 4.3A, lower 
panel). Figure 4.3B (upper panel) shows that c-Myc is also induced by 
hypertrophic stimulation. The constant level of total ERK (Figure 4.3B, lower 
panel) indicates equal protein loading in both lanes. These observations are 
consistent with previous studies, which have shown ERK activation and c-Myc 
induction to be features of the hypertrophic growth response (Bogoyevitch et al, 
1993; Bogoyevitch et al, 1994; Izumo et al, 1988; Sadoshima and Izumo, 1993a; 
Sadoshima et al, 1995; Starsken et al, 1986), and support the proposed 
involvement of these proteins in regulating pol III transcription in 
cardiomyocytes.
Mitogenic stimulation of proliferating cells induces the phosphorylation of RB at 
multiple sites (Hulleman and Boonstra, 2001; Kaelin, 1999; Weinberg, 1995). 
This is a fundamental requirement for cell cycle progression (Hulleman and 
Boonstra, 2001; Kaelin, 1999; Weinberg, 1995). One of the consequences of RB 
hyperphosphorylation is the release of TFIIIB, which relieves pol III 
transcriptional repression (Scott et al, 2001). Although cardiomyocytes do not 
proliferate, RB phosphorylation is thought to occur in response to hypertrophic 
stimulation (Sadoshima et al, 1997). This was confirmed in the present study: 
Figure 4.3C shows that hypertrophic stimulation leads to the phosphorylation of
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at least three separate RB residues (serine 795, serine 780 and threonine 826), 
known to be important for RB function (Connell-Crowley et al, 1997; Kitagawa 
et al, 1996; Knudsen and Wang, 1996; Zarkowska and Mittnacht, 1997). 
Hypertrophic stimulation has little effect on the total level of RB.
Hyperphosphorylation can reduce the electrophoretic mobility of RB. Although 
this was not apparent when lysates were resolved on 7.8% SDS-polyacrylamide 
gels (Figure 4.3C, second panel from bottom), electrophoresis of protein samples 
using gels with a lower percentage acrylamide (6%) revealed that a portion of 
RB, derived from serum-exposed cells, displayed a mobility shift (Figure 4.3C, 
bottom panel). This provides further evidence to suggest that RB becomes 
hyperphosphorylated in response to hypertrophic stimulation. Therefore, this 
may contribute to the upregulation of pol III transcription during hypertrophy.
4.2.3 Hypertrophic stimulation of cardiomyocytes specifically induces Brfl 
expression
In dividing cells, pol III transcription is regulated primarily by proteins that 
interact with the transcription machinery, rather than through alterations in 
transcription factor abundance. To test whether the same were likely to be true in 
cardiomyocytes. Western blots were carried out to compare the effects of FCS- 
stimulation on the levels of TFIIIB and TFIIIC subunits in cultured fibroblast 
cells and cardiomyocytes. As expected, the levels of all the TFIIIB and TFIIIC 
subunits tested (Brfl, Bdpl, TBP and TFIIIC 110) were unchanged following 
FCS-stimulation of a rat fibroblast cell line (Figure 4.4A). In contrast, there was
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Figure 4.4: B rfl protein levels specifically increase in cardiomyocytes, but not 
fibroblasts, in response to growth stimulation. Whole cell lysates were prepared 
from cultured rat 1A fibroblasts (A) or cardiomyocytes (B) that had been serum-starved 
for 24 hours, then either maintained in serum-free medium or exposed to 10% FCS for 
16 hours. 75 gg o f protein were then resolved by SDS-PAGE. Western blotting was 
performed with antibodies against the proteins indicated.
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a significant induction of Brfl expression in response to the hypertrophic 
stimulation of cardiomyocytes (Figure 4.4B). This effect is specific to Brfl, as 
the levels of the other TFIIIB subunits, Bdpl and TBP, and the TFIIIC subunits, 
TFIIICllO and TFIIIC220, remained unchanged. The constant level of actin in 
Figures 4.4A and B indicate that protein was loaded equally in both cases. 
Potentially, increased Brfl expression may represent a mechanism for increasing 
TFIIIB activity in cardiomyocytes, distinct from mechanisms operating during 
cellular proliferation.
4.2.4 Comparison of pol III transcriptional activation, and changes in 
potential regulators of pol III transcription, over time
Thus, hypertrophic growth accompanies the activation of ERK and c-Myc, the 
hyperphosphorylation of RB, and the induction of Brfl. To gain further insights 
into the role these proteins may play in upregulating pol III transcription during 
hypertrophy, the kinetics of pol III activation and the induction or 
phosphorylation of each of these potential regulators were compared. Cultured 
cardiomyocytes were serum-starved for 24 hours then exposed to FCS for 
various lengths of time (ranging from 0 to 48 hours). Total cellular RNA or 
protein were then prepared and analysed by Northern or Western blotting, 
respectively. To assess the induction of pol III transcription over this timecourse, 
B2 levels were measured by Northern blotting (Figure 4.5). This indicates that 
pol III transcription increases significantly, as early as 2 hours following 
hypertrophic stimulation, and reaches maximum levels between 12 and 24 hours.
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Figure 4.5: Changes in pol III transcription over time following the hypertrophic 
stimulation of cultured cardiomyocytes. Total RNA was extracted from 
cardiomyocytes that had been cultured in serum-free medium for 24 hours, then 
stimulated with 10% FCS for the times indicated (0 to 48 hours). 10 pg o f this RNA was 
analysed by Northern blotting. A. Example o f such a Northern blot. The upper panel 
shows the blot probed for B2, and the lower panel shows the same blot stripped and re­
probed for ARPP PO. B. The levels o f B2 and ARPP PO in each sample were quantified 
using densitometry, then B2 normalised against ARPP PO. This was done for 4 separate 
experiments. The average fold increases obtained, along with standard deviations from 
the means, are represented in the graph (*signifrcantly different from control, p<0.05).
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B2 levels then decline again between 24 and 48 hours. The level of the control 
mRNA, ARPP PO, remains unchanged.
Figure 4.6 demonstrates how known regulators of TFIIIB are affected over this 
same time period. Both ERK and c-Myc are activated after 1 hour of 
hypertrophic stimulation, thus preceding the initial increase in pol III 
transcription (Figures 4.6A and B). Therefore, these proteins could potentially be 
involved in the early induction of transcription by pol III. RB phosphorylation 
occurs 6 to 12 hours after hypertrophic stimulation (Figure 4.6C). Consequently, 
this is unlikely to contribute to the initial activation of pol III transcription during 
hypertrophy. However, RB phosphorylation does coincide with the peak of B2 
levels, suggesting that release of TFIIIB from RB may be required for maximum 
pol III transcription. In addition, the level of phosphorylated RB decreases 
between 24 and 48 hours. Likewise, c-Myc levels decline towards the end of the 
timecourse. These effects may at least partly account for the reduction in pol III 
transcripts at this time. As expected, RB phosphorylation was preceded by the 
induction of cyclin D1 (Figure 4.6C, top panel), which is known to be directly 
responsive to growth factors, in both proliferating cells and cardiomyocytes, and 
is required for CDK4/6 activity (Hulleman and Boonstra, 2001; Nozato et al, 
2001; Sadoshima et al, 1997; Sherr, 1996; Tamamori et al, 1998). These cyclin 
D-dependent kinases are responsible for the initial RB phosphorylation events 
that occur following the mitogenic stimulation of dividing cells (Hulleman and 
Boonstra, 2001; Sherr, 1996). Levels of total ERK, actin and total RB (Figures 
4.6A, B and C, respectively) were constant throughout the timecourse.
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Figure 4.6: Changes in ERK, c-Myc and RB over time following the 
hypertrophic stimulation of cultured cardiomyocytes. Whole cell lysates were 
prepared from cardiomyocytes cultured in serum-free medium for 24 hours, then 
stimulated with 10% FCS for the times indicated (0 to 48 hours). Western 
blotting was performed with antibodies against the proteins specified. A. ERK 
activation precedes the initial induction of pol III transcription. B. c-Myc 
induction precedes the initial activation of pol III transcription. The anti-c-Myc 
antibody C8 was used here. C. RB phosphorylation coincides with the highest 
level of pol III transcription. RB phosphorylation was measured here using the 
antibody that specifically detects RB phosphorylated on thr 826. The anti-RB 
antibody C l5 was used to measure the level of total RB.
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Alterations in TFIIIB and TFIIIC subunit levels over time were also examined by 
Western blotting (Figure 4.7). As expected, Bdpl, TBP, TFIIICllO, TFIIIC220 
and actin levels do not change. In contrast, Brfl levels increase significantly after 
3 to 6 hours of exposure to FCS. Maximum levels of Brfl (approximately 2.4- 
fold higher than control cells) are attained after 16 hours of hypertrophic 
stimulation. As with RB phosphorylation, this correlates with the highest level of 
pol III transcription.
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Figure 4.7: Changes in TFIIIB and TFIIIC subunit levels over time 
following the hypertrophic stimulation of cultured cardiomyocytes. Whole 
cell lysates were prepared from cardiomyocytes cultured in serum-free medium 
for 24 hours, then stimulated with 10% FCS for the times indicated (0 to 48 
hours). Proteins were resolved by SDS-PAGE. A. Western blotting was 
performed with antibodies against the proteins indicated. B. Using densitometry, 
the level of Brfl was quantified at each timepoint and normalised to actin. This 
was done for 3 separate experiments. The average fold increases obtained, along 
with standard deviations from the means, are represented in the graph 
significantly different from control, p<0.05).
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4.3 Discussion
Transcription initiation complex assembly on class III genes is enhanced by 
hypertrophic stimulation of cardiomyocytes, as demonstrated by ChIP analyses. 
This appears to be regulated at the level of TFIIIB recruitment. The activities of 
known TFIIIB regulators were investigated in the current chapter. This 
demonstrated the activation of ERK and c-Myc, and the inactivation of the 
TFIIIB repressor RB in response to hypertrophic stimulation. In addition, the 
Brfl subunit of TFIIIB is specifically induced during hypertrophy. Temporal 
examination of these changes revealed that ERK and c-Myc induction precede 
the initial activation of pol III transcription, whereas RB phosphorylation and 
Brfl induction correlate with the later, maximum level of pol III transcripts. 
Thus, this chapter displays a variety of mechanisms potentially involved in the 
activation of pol III transcription during cardiomyocyte hypertrophy, and 
provides a basis for the further investigation presented in subsequent chapters.
Serum-induced changes in class III gene promoter occupancy have not 
previously been documented in mammalian cells in vivo. The data presented here 
demonstrate that enhanced TFIIIB recruitment coincides with increased pol III 
binding, and the activation of pol III transcription. Although this scenario has not 
previously been reported to accompany the serum stimulation of pol III 
transcription, decreases in TFIIIB, and not TFIIIC, promoter occupancy correlate 
with the reduction in pol III transcription associated with ERK inhibition (Felton- 
Edkins et al, 2003a), p53 induction (Crighton et al, 2003) and mitosis (Fairley et 
al, 2003) in mammals, and the transition from growth to stationery phase in yeast 
(Harismendy et al, 2003). This indicates that altered TFIIIB recruitment is a
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common means of regulating pol III transcription, and is consistent with the 
well-recognised role of TFIIIB as a target for numerous regulatory mechanisms.
Of these known control mechanisms, ERK, c-Myc and RB were considered 
likely candidates for the regulation of pol III transcription in cardiomyocytes. 
This was based on the fact that these proteins have been implicated in mediating 
hypertrophic growth (Bueno and Molkentin, 2002; MacLellan et al, unpublished 
results; Nozato et al, 2001; Sadoshima et al, 1997; Simpson, 1988; Tamamori et 
al, 1998; Xiao et al, 2001). Consistent with this, the current study demonstrated 
the hypertrophy-associated activation of ERK and c-Myc, and the 
phosphorylation of RB. ERK activation has been reported to occur after only 1 
minute of hypertrophic stimulation (Clerk et al, 1994), and can be sustained for 
up to 48 hours (lijima et al, 2002). Although such a rapid induction was not 
investigated here, ERK was found to be activated at the earliest timepoint tested. 
In addition, c-Myc induction and RB phosphorylation occurred with kinetics 
similar to those previously reported (Izumo et al, 1988; Sadoshima et al, 1997; 
Starsken et al, 1986). These molecular changes coincided with distinct phases of 
pol III transcriptional activation. Therefore, the significance of each of these 
proteins in regulating pol III transcription in cardiomyocytes was investigated 
further, as detailed in Chapter 5.
Although RB phosphorylation is significantly higher after 16 hours of 
hypertrophic stimulation than in the absence of FCS (Figure 4.2C), analysis of 
RB phosphorylation over time revealed an unexpectedly high level of 
phosphorylated RB in unstimulated cells compared to cells stimulated with FCS
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for 1 to 6 hours (Figure 4.5C, compare lane 1 with lanes 2-5). The significance of 
this surprising observation is unclear. However, it was a consistent feature of 
several timecourses, and may indicate that initially, basal CDK activity is 
inhibited by hypertrophic stimulation. Interestingly, the association of CDK 
activity with a D-type cyclin has been reported to decrease during the first 6 
hours of hypertrophic stimulation with FCS (Sadoshima et al, 1997). RB 
phosphorylation was monitored over time using an antibody that specifically 
detects phosphorylation of the cyclin D-dependent kinase target site, threonine 
826 (Zarkowska and Mittnacht, 1997). Possibly, the decrease in phosphorylation 
after 1 hour of FCS exposure may be specific to this particular residue. Whatever 
the explanation for the initial decrease in RB phosphorylation, it did not 
accompany a decline in pol III transcription.
Stimulation of undifferentiated fibroblast cells with FCS increases pol III 
transcription (Felton-Edkins et al, 2003a; Johnson et al, 1974; Mauck and Green, 
1974; Scott et al, 2001), but does not affect the levels of TFIIIB or TFIIIC, as 
shown in this chapter (Figure 4.4A) and by other investigators (Felton-Edkins et 
al, 2003a; Johnston et al, 2002; Scott et al, 2001; Winter et al, 2000). This 
indicates that the basal levels of these factors are sufficient to permit increases in 
transcription, in response to growth stimulation. As previously discussed, this is 
achieved through regulating transcription factor activity, rather than abundance. 
Cardiomyocytes are terminally differentiated cells. Differentiation of F9 
embryonal carcinoma cells has been shown to accompany a dramatic decrease in 
the rate of pol III transcription, specifically caused by a reduction in TFIIIB 
activity (White et al, 1989). This decrease in TFIIIB activity can be at least partly
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attributed to a decline in Brfl levels (Alzuherri and White, 1998). Thus, 
potentially, the low level of Brfl in unstimulated cardiomyocytes (Figures 4.4 
and 4.7) may reflect the differentiated nature of these cells, and could restrict the 
formation of functional TFIIIB complexes, and thereby restrain pol III 
transcription. If this were the case, an increase in the level of Brfl would be 
required to enhance pol III transcription in cardiomyocytes, in contrast to the 
situation in undifferentiated fibroblasts. In support of this proposed mechanism, 
Brfl levels do increase in response to the hypertrophic stimulation of 
cardiomyocytes (Figures 4.4 and 4.7). The relevance of this to the hypertrophy- 
associated activation of pol III transcription is addressed in Chapter 6.
Although hypertrophic stimuli do not induce cardiomyocyte proliferation, many 
of the responses they do initiate also occur in proliferating cells in response to 
mitogens and growth factors. Some of these changes, including RB 
phosphorylation and the activation of ERK and c-Myc, play important roles in 
the regulation of pol III transcription during cellular proliferation. It is possible 
that these same mechanisms are used to regulate pol III transcription in 
cardiomyocytes, in order to facilitate the rapid growth demands of these non­
dividing cells during hypertrophy. Distinct regulatory mechanisms may also 
contribute to the control of pol III transcription in fibroblasts and 
cardiomyocytes, possibly reflecting differences in their states of differentiation 
and proliferative capacity. For example, hypertrophic stimulation may increase 
pol III transcription in cardiomyocytes through the induction of Brfl. The 
following chapters address these possibilities.
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CHAPTER 5 
Regulation of pol III transcription by ERK, c-Myc 
and RB in cardiomyocytes
5.1 Introduction
The mechanisms regulating pol III transcription in terminally differentiated 
cardiomyocytes are unknown. The data presented in Chapter 4 are consistent 
with a role for ERK, c-Myc and RB in this regulation. The aim of this chapter 
was to test the hypothesis that these proteins, known to regulate pol III 
transcription in proliferating cells, are also involved in controlling the 
hypertrophy-associated increase in pol III transcription in cardiomyocytes. The 
potential involvement of each of these molecules is summarised in Figure 5.1.
5.1.1 ERK and cardiomyocyte hypertrophy
One of the most intensely studied groups of signalling pathways, activated by 
hypertrophic stimuli, are the MAP kinase cascades. The MAP kinase superfamily 
consists of several subfamilies, the best characterised of which are the ERKs (1 
and 2), the c-Jun N-terminal kinases (JNKs) and the p38-MAP kinases (p38s) 
(Chang and Karin, 2001; Carrington and Johnson, 1999; Wilkinson and Millar, 
2000). The latter two subfamilies are also known as the stress-responsive MAP 
kinases. Each of these subfamilies is subject to regulation in the myocardium, as 
illustrated in Figure 5.2, and the complex mechanisms responsible for this 
regulation are beginning to be unravelled (reviewed in Bueno and Molkentin, 
2002; Clerk and Sugden, 1999; Molkentin and Dorn II, 2001; Sugden, 1999; 
Sugden and Clerk, 1998).
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Figure 5.1: ERK, c-Myc and RB have the potential to regulate pol III 
transcription in cardiomyocytes. Hypertrophic stimulation o f cardiomyocytes leads 
to the activation o f ERK and c-Myc, and the phosphorylation o f RB. In proliferating 
cells, each o f these proteins regulates pol III transcription by targeting TFIIIB. Both 
ERK and c-Myc activate pol III transcription, whereas RB represses it. 
Hyperphosphorylation o f RB relieves this repression. Potentially, these same 
mechanisms may participate in controlling pol III transcription in cardiomyocytes, in 
order to regulate protein synthesis.
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Figure 5.2: Summary o f MAP kinase cascade activation in cardiomyocytes. MAP
kinase signalling pathways are activated by numerous hypertrophic agonists and stress 
stimuli in cardiomyocytes. Initial signals are transduced through mechanisms 
involving molecules such as PKC and ras, leading to the activation o f MAP kinase 
kinase kinase (MEKK) factors, which in turn activate MAP kinase kinase (MEK) 
enzymes. This culminates with the activation o f the MAP kinase effectors JNKs, 
ERKs and p38s. These kinases subsequently phosphorylate a variety o f downstream 
targets, including nuclear transcription factors. Each o f these pathways has a distinct 
set o f targets, but they may also share some common targets. Proteins specific to the 
ERK pathway are highlighted in red.
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The role of ERK in mediating cardiomyocyte hypertrophy has been particularly 
well studied. Many hypertrophic stimuli, including FCS, ET-1, PE and 
mechanical stress, activate the ERK pathway in cultured cardiomyocytes 
(Bogoyevitch, et al, 1993; Bogoyevitch, et al, 1994; Sadoshima and Izumo, 
1993a; Sadoshima et al, 1995). Signalling through both PKC and the small G- 
protein ras have been implicated in this activation (Bogoyevitch, et al, 1993; 
Bogoyevitch, et al, 1994; Braz et al, 2002; Clerk, et al, 1994; lijima et al, 2002; 
Pan et al, 2004; Sugden and Clerk, 2000; Thorburn, 1994). Several studies have 
demonstrated the relevance of this cascade to hypertrophy, by showing that ERK 
activation is both necessary and sufficient for the induction of many of the 
features of the hypertrophic response in culture, including an increase in protein 
synthesis, enhanced sarcomere organisation and foetal gene re-expression 
(Bueno et al, 2000; Gillespie-Brown et al, 1995; Glennon, et al, 1996; Ueyama et 
al, 2000; Wang and Proud, 2002b; Yue et al, 2000).
ERK is also activated by hypertrophic stimulation of the heart (Harris et al, 2004; 
lijima et al, 2002; Takeishi et al, 2001). As in cultured cells, the importance of 
this activation has been clearly shown. For example, transgenic mice expressing, 
in the myocardium, a constitutively activated form of MEKl, a specific upstream 
activator of ERK, display a hypertrophic phenotype. This is characterised by 
enlarged hearts and transcriptional changes that typically accompany 
hypertrophy (Bueno et al, 2000). Furthermore, cardiac-specific expression of a 
dominant negative form of Raf, which specifically inhibits ERK activation, 
blocks hypertrophic growth in response to pressure overload in mice (Harris et 
al, 2004). ERK activation has also been shown to correlate with hypertrophic
127
5 Regulation o f pol III transcription by ERK, c-Myc and RB in cardiomyocytes
severity in failing human hearts: a therapeutic intervention that reduces the level 
of active ERK also reduces cardiomyocyte size (Flesch et al, 2001). Studies such 
as these indicate a central role for the Raf/MEK/ERK pathway in determining the 
physiological hypertrophic state.
Thus, the ERK pathway appears to be a critical regulator of cardiomyocyte 
hyperti'ophy, both in culture and in the heart. ERK mediates its effects on cell 
function by phosphorylating a range of downstream targets (Chang and Karin, 
2001; Wilkinson and Millar, 2000). These targets vary depending on the cell type 
and initiating stimulus. In cardiomyocytes, several substrates for ERK have been 
identified. These include nuclear transcription factors, such as the tissue-specific 
factor G AT A4, and the transcriptional coactivators CBP and p300 (Babu et al, 
2000; Gusterson et al, 2002; Liang et al, 2001; Morimoto et al, 2000). By 
phosphorylating such factors, the ERK pathway is thought to contribute to the 
characteristic re-programming of mRNA production that occurs in 
cardiomyocytes during hypertrophy.
In addition to mediating typical hypertrophy-associated changes in class II gene 
expression, the Raf/MEK/ERK cascade also induces protein synthesis in 
cardiomyocytes (Bueno et al, 2001; Uemeya et al, 2000; Wang and Proud, 
2002b; Yue et al, 2000). However, the mechanisms by which ERK regulates this 
biosynthesis are poorly understood. Several recent studies using cultured 
cardiomyocytes have identified downstream targets of the ERK pathway that 
may contribute to this ability to stimulate protein synthesis. These include the 
ribosomal protein S6 kinases (S6Ks), eIF4E-binding protein 1 (4E-BP1) and the
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translation elongation factor eEF2 (lijima et al, 2002; Wang and Proud, 2002a, b; 
Wang et al, 2001). Each of these proteins is involved in regulating translational 
efficiency, and consequently, their activities are likely to influence the rate of 
protein synthesis. However, ERK activation is sufficient to induce sustained 
hypertrophic growth (Bueno et al, 2000), which, as discussed in Chapter 3, 
requires an increase in translational capacity. Therefore, it is highly probable that 
ERK will also target additional factors in order to increase the level of 
components of the protein synthetic machinery, such as rRNAs and tRNAs. In 
proliferating, immortalised cell lines, ERK induces rRNA and tRNA production 
by stimulating transcription by pols I and III (Felton-Edkins et al, 2003a; 
Stefanovsky, 2001; Zhao et al, 2003). ERK achieves this activation by 
phosphorylating the pol I-specific transcription factors UBF and TIF-IA, and the 
pol Ill-specific factor TFIIIB (Felton-Edkins et al, 2003a; Stefanovsky, 2001; 
Zhao et al, 2003). This induction of class I and III gene expression by ERK may 
also occur in cardiomyocytes, and would provide a mechanistic link between 
ERK activation and the increased protein synthesis that underlies hypertrophic 
growth. The potential mechanisms by which ERK could induce protein synthesis 
in cardiomyocytes are summarised in Figure 5.3. The role of ERK in pol III 
transcriptional activation in cardiomyocytes is addressed in this chapter.
5.1.2 c-Myc and cardiomyocyte hypertrophy
The c-Myc transcription factor is a member of a family of proteins, also 
including N-Myc, L-Myc, B-Myc and S-Myc (Dang, 1999). The Myc proteins 
play critical roles in the control of numerous cellular functions, including cell
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Figure 5.3: Mechanisms potentially involved in the activation of protein 
synthesis by ERK during cardiomyocyte hypertrophy. ERK has the potential 
to increase both translational efficiency and capacity. In response to hypertrophic 
stimulation, ERK-dependent mechanisms modulate the activities of S6Ks, 4E- 
BPl and eEF2. This is likely to increase cardiomyocyte translational efficiency. 
TFIIIB, UBF and TIF-IA are directly phosphorylated by ERK in proliferating 
cells, and this leads to the induction of pol I and III transcription, as indicated. 
This may also occur in cardiomyocytes, and hence facilitate an increase in 
translational capacity. Thus, several downstream targets of the ERK pathway are 
likely to mediate the increased protein synthesis required for cardiomyocyte 
hypertrophic growth.
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growth, proliferation, apoptosis and differentiation (Dang, 1999; Liischer, 2001; 
Schmidt, 1999; Zhou and Hurlin, 2001). These profound physiological effects 
are likely to reflect the ability of Myc to directly modulate the expression of 
multiple target genes (Coller, 2000; Dang, 1999). This is mediated by two 
domains: a C-terminal basic/helix-loop-helix/leucine zipper (b/HLH/z) DNA- 
binding domain, and an N-terminal transactivation domain (TAD) (Dang, 1999; 
Liischer, 2001). Many genes activated by c-Myc have a consensus c-Myc 
binding site (5’-CACGTG-3’), known as an E-box (Dang, 1999; Liischer, 2001). 
In order to bind these sites, c-Myc must heterodimerise with its binding partner 
Max, via the C-terminal b/HLH/z domain (Dang, 1999; Liischer, 2001). c-Myc 
then activates transcription. For at least some target genes, this occurs through 
the TAD-mediated recruitment of various chromatin remodelling activities 
(Amati et al, 2001). However, some genes are directly repressed by c-Myc in an 
E-box-independent manner (Amati et al, 2001; Liischer, 2001).
c-Myc activates the transcription of an array of genes whose products promote 
cell growth and division, while repressing the expression of negative regulators 
of these processes (Coller et al, 2000; Dang, 1999; Guo et al, 2000; O’Connell et 
al, 2003). Consequently, abnormal c-Myc expression is a common feature of 
human cancers. As a result, intensive research efforts have focused on 
delineating the mechanisms of c-Myc regulation and function. In non-tumour 
cells, the level of c-Myc is stringently controlled; c-Myc levels respond to 
mitogens and growth factors and are high in rapidly proliferating cells, but 
dramatically decline as cells differentiate (Grandori et al, 2000; Lüscher, 2001; 
Zhou and Hurlin, 2001). This regulation of c-Myc expression appears very
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complex, involving transcriptional, post-transcriptional, translational and post- 
translational controls (Dean et al, 1985; Jones and Cole, 1987; Kelly et al, 1983; 
Liischer, 2001; Sears et al, 1999; West et al, 1998). The mechanisms regulating 
these processes are ill-defined; however, several signalling cascades, including 
the Ras/Raf/ERK pathway, have been implicated in certain aspects of this control 
(Cheng et al, 1999; Kerkhoff and Rapp, 1998; Sears et al, 1999; Sears et al, 
2000).
Thus, c-Myc was initially characterised as a protein that promotes cellular 
proliferation and oncogenesis. An important prerequisite for cell division is 
attainment of a critical mass (Conlon and Raff, 1999; Schmidt, 1999). 
Accordingly, c-Myc is thought to induce proliferation not only by directing the 
expression of proteins involved in cell cycle progression and DNA synthesis, 
such as cyclins, CDKs, dihydrofolate reductase and thymidine kinase, but also by 
influencing the production of factors involved in protein synthesis, including 
translation factors and proteins involved in ribosome biogenesis (Coller et al, 
2000; Dang, 1999; Guo et al, 2000; O ’Connell et al, 2003; Schmidt, 1999). In 
fact, in some instances, c-Myc is now recognised as an important regulator of 
cell division-independent cell growth (Iritani and Eisenman, 1999; Johnston et al, 
1999; Kim et al, 2000; Schuhmacher et al, 1999).
As indicated above, terminally differentiated cells, such as cardiomyocytes, 
express c-Myc at very low levels, or not at all (Grandori et al, 2000; Komuro et 
al, 1988; Schneider et al, 1986; Zhou and Hurlin, 2001). However, studies of the 
molecular changes occurring during cardiomyocyte hypertrophy have revealed
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that various hypertrophic stimuli, which do not promote proliferation, rapidly 
increase c-Myc at the mRNA and protein levels (Izumo et al, 1988; Komuro et 
al, 1988; Sadoshima et al, 1992; Starsken et al, 1986; Chapter 4, Figure 4.6). The 
significance of this induction is only beginning to be appreciated, following 
reports that c-Myc expression is directly involved in promoting hypertrophy in 
the adult heart (Robbins and Swain, 1992; Xiao et al, 2001). Furthermore, 
clinical studies have demonstrated a correlation between the level of c-Myc 
expression and cardiomyocyte size in hypertrophic human hearts (Kai et al, 
1998).
The molecular events downstream of c-Myc induction in cardiomyocytes, which 
facilitate hypertrophic growth, have not been characterised. Candidate target 
genes include those encoding ribosomal proteins (L3, L23 and L35) and other 
proteins involved in ribosome biogenesis (nucleolin and nucleophosmin) (Xiao et 
al, 2001). Expression of these genes accompanies c-Myc activation in the adult 
myocardium, potentially contributing to an increase in protein synthesis (Xiao et 
al, 2001). Recent additions to the list of growth-promoting genes targeted by c- 
Myc in proliferating cells are the pol Ill-transcribed tRNA and 5S rRNA genes 
(Felton-Edkins et al, 2003b; Gomez-Roman et al, 2003). Although these genes 
do not have E-box sequences, they are bound and activated directly by c-Myc in 
vivo (Felton-Edkins et al, 2003b; Gomez-Roman et al, 2003). This is thought to 
be mediated through protein-protein interactions between c-Myc and TFIIIB 
(Gomez-Roman et al, 2003). Experiments described in this chapter aimed to 
determine whether c-Myc could also activate class III gene expression in
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cardiomyocytes, which would likely contribute to the ability of c-Myc to 
stimulate cardiomyocyte growth.
5.1.3 Cell cycle proteins and cardiomyocyte hypertrophy
In proliferating cells, mitogenic signals activate transduction cascades involving 
various proteins, including ERK and c-Myc, which regulate components of the 
cell cycle machinery (Hulleman and Boonstra, 2001). In this way, extracellular 
stimuli drive cell cycle progression. Despite the fact that cardiomyocytes become 
terminally differentiated in the neonate, and largely lose the ability to proliferate, 
emerging evidence suggests that certain components of this cell cycle machinery 
may also be involved in regulating the hypertrophic response (Busk et al, 2002; 
Nozato et al, 2001; Sadoshima et al, 1997; Tamamori-Adachi et al, 2002; 
Tamamori et al, 1998). For example, cyclin induction and CDK activation have 
been shown to accompany hypertrophic growth. In particular, several studies 
have shown that cyclins, normally connected with the G1 phase of the cell cycle 
(including cyclin D l, 2 and 3), and their associated kinases (CDKs 4 and 6), are 
induced by hypertrophic stimuli in culture and in situ (Busk et al, 2002; Nozato 
et al, 2001; Sadoshima et al, 1997; Tamamori-Adachi et al, 2002; Tamamori et 
al, 1998). Investigations into the relevance of these observations infer that these 
proteins promote hypertrophic growth. For instance, overexpressing cyclin D l 
and CDK4 in cultured cardiomyocytes increases protein synthesis and cell size, 
but does not provoke cell cycle reentry (Tamamori-Adachi et al, 2002). 
Conversely, inhibition of cyclin D-CDK4/6 complex activity blocks hypertrophic 
growth in cultured cells and in the heart (Busk et al, 2002; Nozato et al, 2001;
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Tamamori et al, 1998). Cyclin D-CDK4 complexes have also been implicated in 
promoting the hypertrophic growth of terminally differentiated cells in 
Drosophila (Datar et al, 2000), suggesting that this may be a conserved 
phenomenon.
The most extensively studied target of cyclin D-dependent kinases is the tumour 
suppressor protein RB (Sherr, 1996; Weinberg, 1995). Hypertrophic stimulation 
of cultured cardiomyocytes increases the proportion of hyperphosphorylated RB, 
as shown in Chapter 4 (Figure 4.3) and by other investigators (Nozato et al, 
2001; Sadoshima et al, 1997). However, it is not known whether this contributes 
to the induction of hypertrophic growth by cyclin D-CDK4/6. One of the most 
important functional consequences of RB phosphorylation in cycling cells is the 
promotion of S phase entry (Kaelin et al, 1999; Sherr, 1996; Weinberg, 1995). 
This is thought to be achieved through the regulation of class I, II and III gene 
expression (Graha et al, 1998; White, 1998). Hypophosphorylated RB binds the 
pol I-, II- and Ill-specific transcription factors UBF, E2F and TFIIIB, 
respectively (Dyson, 1998; Hannan et al, 2000; Scott et al, 2001). 
Phosphorylation of RB by CDKs correlates with the activation of these factors, 
and the subsequent induction of their tai'get genes (Dyson, 1998; Hannan et al, 
2000; Scott et al, 2001). In the case of UBF and TFIIIB, this would mean a 
general increase in class I and III gene expression, respectively, which is thought 
to facilitate the increase in cell mass necessary for S phase entry (White, 1998). 
E2F transcription factor complexes regulate the pol Il-dependent transcription of 
several genes required for DNA synthesis, including DNA polymerase a, 
thymidine kinase and dihydrofolate reductase (Dyson, 1998; White, 1998). Thus,
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such changes in gene expression provide several cellular components essential 
for the S phase of the cell cycle.
Terminally differentiated cardiomyocytes do not divide. Therefore, to appreciate 
the full significance of hypertrophy-associated RB phosphorylation, it is
'
important to characterise the downstream effects of this phosphorylation 
specifically in post-mitotic cardiomyocytes. Potentially, in terminally 
differentiated cells, RB phosphorylation may selectively induce the expression of 
genes involved in promoting cell growth, such as those transcribed by pols I and 
III, without activating those dedicated solely to DNA synthesis.
In order to understand the process of myocardial hypertrophy, it is important to 
delineate the molecular mechanisms contributing to its development. As such, 
the pathway of events leading from the initial hypertrophic stimulus, to changes 
in cellular phenotype, must be determined. This chapter aims to establish a link 
between several proteins shown to be responsive to hypertrophic stimuli, namely 
ERK, c-Myc and RB, and an increase in protein synthetic capacity through the 
regulation of pol III transcription.
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5.2 Results
5.2.1 Activation of pol III transcription by ERK in cardiomyocytes
As summarised in the introduction to this chapter, a large body of evidence 
indicates that the Raf/MEK/ERK cascade promotes the induction of hypertrophy 
in cardiomyocytes. To confirm the involvement of this pathway in the serum- 
induced hypertrophic response of the primary cells used in this study, a MEK- 
specific inhibitor (PD98059) was used. Cardiomyocytes were serum-starved for 
24 hours then either maintained in serum-free media, or exposed to 10% PCS, for 
a further 16 hours in the presence of PD98059 (50 pM) or vehicle. ERK 
activation by PCS is completely blocked in the presence of PD98059 (Figure 
5.4A, upper panel), indicating that this compound effectively inhibits MEKl/2 
(see Figure 5.2). The total level of ERK is unaffected by these treatments (Figure 
5.4A, lower panel). To determine the effects of this inhibition on hypertrophic 
growth, the rates of protein synthesis were measured (Figure 5.4B). This 
demonstrated that the characteristic induction of protein synthesis by serum is 
significantly attenuated in the presence of PD98059 (Figure 5.4B), thus 
indicating that ERK activation is necessary for the full induction of protein 
synthesis in response to hypertrophic stimuli. This is in agreement with the 
findings of several other studies (Ueyama et al, 2000; Wang and Proud, 2002b; 
Yue et al, 2000), and is consistent with a critical role for the ERK pathway in 
mediating cardiomyocyte hypertrophy. The rate of DNA synthesis was 
unaffected, as expected. Although the rate of protein synthesis is markedly 
reduced when serum-stimulated cardiomyocytes are incubated with PD98059, it 
is not completely abrogated to basal levels (Figure 5.4B, compare conditions 1
138
Figure 5.4: ERK inhibition impairs hypertrophie growth in cultured 
cardiomyocytes. Cardiomyocytes were cultured in the absence of serum for 24 
hours, then either maintained in serum-free media for a further 16 hours 
(conditions 1 and 4), or stimulated with 10% FCS for 16 hours (conditions 2 and 
3). 50 pM PD98059 (conditions 3 and 4) or vehicle alone (0.1% DMSO; 
conditions 1 and 2) were also included, as indicated. A. PD98059 blocks ERK 
activation. Whole cell lysates were analysed by Western blotting. Representative 
Western blots, performed with the antibodies specified, are shown. B. PD98059 
impairs protein synthesis. Cells were labelled with [^^S]methionine/cysteine or 
[^H]thymidine to determine protein or DNA synthesis rates, respectively. 
Relative [^ S^] and pH] incorporation were assessed by liquid scintillation 
counting. The fold increases represent the mean of four separate experiments, 
each with three replicates per condition. The error bars indicate the standard 
deviation from the mean (^significantly higher than condition 1, p<0.05; 
^significantly lower than condition 2, p<0.05; **not significantly different from 
condition 1).
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and 3). This suggests that ERK-independent mechanisms may also activate 
protein synthesis in cardiomyocytes.
To determine whether ERK is involved in the activation of pol III transcription in 
cardiomyocytes, the effects of both ERK inhibition (Figure 5.5) and activation 
(Figure 5.6) on class III gene expression were assessed. Northern blotting (Figure 
5.5A) and RT-PCR analysis (Figure 5.5B) revealed that inhibiting ERK with 
PD98059 diminishes the increase in B2 and tRNA transcripts in response to 
serum. Quantification of the levels of B2 under each condition suggests that, as 
with protein synthesis, ERK inhibition blocks the serum-stimulated induction of 
pol III transcription significantly, although not completely (Figure 5.5C). Thus, 
evidently, ERK-independent mechanisms also contribute to the activation of pol 
III transcription in response to hypertrophic stimuli. These data suggest that ERK 
is involved in stimulating both pol III transcription and protein synthesis in 
cardiomyocytes, and are consistent with the hypothesis that ERK induces 
hypertrophic growth in a pol Ill-dependent manner.
Several studies have shown that ERK activation is sufficient to induce the 
hypertrophic growth of cardiomyocytes (Bueno et al, 2000; Gillespie-Brown et 
al, 1995; Ueyama et al, 2000; Wang and Proud, 2002b; Yue et al, 2000). To 
determine whether the activation of ERK in the absence of hypertrophic stimuli 
could also induce pol III transcription, cultured cardiomyocytes were infected 
with adenoviruses expressing constitutively active MEKl (CAMEK) or p- 
galactosidase (p-gal), as a control. Other investigators have used such 
adenoviruses to demonstrate that ERK activation is sufficient to increase
141
Figure 5.5: ERK inhibition impairs pol III transcription in cultnred 
cardiomyocytes. Cardiomyocytes were treated as in Figure 5.4, then total 
cellular RNA extracted. A. 10 gg of RNA were analysed by Northern blotting. 
The upper panel shows the blot probed for B2, and the lower panel shows the 
same blot stripped and re-probed for ARPP PO. B. 3 gg of RNA were used to 
generate cDNAs by reverse transcription. Specific cDNAs were then amplified 
by PGR using pre-tRNA"^)'- and ARPP PO-specific primers. C. The levels of B2 
and ARPP PO in each sample (as determined by Northern analysis) were 
quantified using densitometry, and B2 levels normalised against ARPP PO levels. 
This was done for 4 separate experiments. The average fold increases obtained, 
along with standard deviations from the means, are represented in the graph 
0^significantly lower than condition 2, p<0.05).
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cardiomyocyte protein synthesis and size (Bueno et al, 2000; Ueyama et al, 2000; 
Wang and Proud, 2002b; Yue et al, 2000). Cardiomyocytes infected with varying 
amounts of control or CAMEK adenoviruses were cultured in serum-free 
conditions for 48 hours, then protein and RNA were extracted. For comparison, 
extracts were also prepared from uninfected cells cultured with or without 10% 
FCS, Western analysis confirmed that the CAMEK adenovirus effectively 
induces ERK phosphorylation, and hence activation (Figure 5.6A, upper panel). 
This is accompanied by a substantial increase in the level of B2 (Figure 5.6B) 
and tRNA (Figure 5.6C) transcripts, as determined by Northern blotting and RT- 
PCR analysis, respectively. These effects are specific, as the level of ARPP PO 
mRNA is unaffected by ERK activation (Figures 5.6B and C, lower panels). 
Thus, ERK can specifically increase pol III transcription in cultured 
cardiomyocytes, in the absence of hypertrophic stimuli.
Therefore, the pol III transcription machinery is clearly a downstream target of 
the ERK pathway in cardiomyocytes, and this is likely to contribute to ERK- 
induced protein synthesis. This provides one example of a mechanism involved 
in the activation of pol III transcription in response to hypertrophic stimulation. 
However, ERK-independent mechanisms also apparently contribute to this 
regulation. These may involve c-Myc, RB and/or Brfl induction, as postulated in 
Chapter 4. The role of c-Myc in pol III transcriptional activation is addressed in 
the following section.
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Figure 5.6: ERK activation is sufficient to induce pol III transcription in 
cultured cardiomyocytes. Cultured cardiomyocytes were infected with 
increasing amounts (0, 10, 25 or 40 \x\ for A and B; 0, 25 or 40 \x\ for C) of 
adenovirus expressing CAMEK or (3-gal (negative control), as indicated. Cells 
were serum-starved for 48 hours before extracting whole cell protein or RNA. As 
a positive control for ERK activation and pol III induction, uninfected cells were 
incubated without (SF) or with 10% FCS for 16 hours (A and B only). A. 75 gg 
of protein were resolved by SDS-PAGE and Western blotting was performed 
using the antibodies specified. B. RNA was analysed by Northern blotting. The 
upper panel shows the blot probed for B2, and the lower panel shows the same 
blot stripped and re-probed for ARPP PO. C. RNA was analysed by RT-PCR 
using pre-tRNA’^ “- and ARPP PO-specific primers. The viruses used for these 
analyses were a kind gift from Dr JD Molkentin, University of Cincinnati, USA.
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5.2.2 Activation of pol III transcription by c-Myc in cardiomyocytes
To determine whether c-Myc can activate pol III transcription in terminally 
differentiated cardiomyocytes, the effects of adenoviral-mediated c-Myc 
expression were investigated in culture. RNA was obtained from cardiomyocytes 
that had been infected (in the laboratory of Dr WR Maclellan, UCLA, USA) with 
adenoviruses expressing Lac Z, as a control, or c-Myc (Figure 5.7). RT-PCR 
analysis confirmed that the c-Myc adenovirus increased c-Myc expression in 
these cells, compared to cells infected with the control virus, as expected (Figure 
5.7, panel D). Panels A to C (Figure 5.7) demonstrate that c-Myc overexpression 
is accompanied by the induction of tRNAs tyrosine, leucine and arginine. These 
effects are specific, as the negative control mRNA (ARPP PO) does not change in 
response to c-Myc expression (Figure 5.7, panel E). Therefore, these data show 
that c-Myc can activate class III gene expression in cultured cardiomyocytes.
In order to study the role of c-Myc in the adult myocardium, Xiao et al (2001) 
developed a mouse model in which an oestrogen-responsive Myc fusion protein 
can be activated specifically in cardiomyocytes by administering 4- 
hydroxytamoxifen (OHT). Transgenic mice constitutively express this c-Myc- 
oestrogen receptor fusion protein (MycER) in cardiomyocytes; however, in the 
absence of an appropriate ligand, it is sequestered in the cytoplasm and hence 
inactive. OHT induces MycER nuclear translocation, and thus activates c-Myc. 
Using this model, these investigators demonstrated that activation of c-Myc in 
the heart is sufficient to induce several features of cardiac hypertrophy, including 
an increase in cell size without cell division (Xiao et al, 2001). Hearts were 
obtained from these mice, and relevant control mice, and tRNA levels analysed
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Figure 5.7: c-Myc can activate pol III transcription in cultured cardiomyocytes.
Cardiomyocytes were infected with equivalent amounts o f adenovirus expressing Lac 
Z (negative control) or c-Myc, as indicated, in the laboratory o f Dr WR MacLellan 
(UCLA, USA). Cells were grown in the absence o f hypertrophic stimuli, then total 
cellular RNA was extracted. This RNA was used in the current study to generate 
cDNAs in duplicate (Lac Z) or triplicate (c-Myc), as shown. cDNAs were amplified 
by PCR using primers specific for pre-tRNA^“, pre-tRNATy ,^ pre-tRNA^s, c-Myc and 
ARPP PO, as indicated.
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by RT-PCR (Figure 5.8). This revealed that c-Myc expression correlates with a 
substantial increase in the levels of pre-tRNA^^', pre-tRNA*"*"" and pre-tRNA'^ '^ ®, 
indicating that c-Myc activates pol III transcription in the heart (Figure 5.8, 
panels A to C). This is the first demonstration that c-Myc can induce pol III 
transcription in situ. As a positive control, the level of cyclin D2 mRNA was also 
measured (Figure 5.8, panel D). Cyclin D2 is a well-characterised direct target of 
c-Myc, and is known to respond to c-Myc in proliferating cells and 
cardiomyocytes (Bouchard et al, 1999; Bouchard et al, 2001; Coller et al, 2000; 
Xiao et al, 2001). As expected, c-Myc increases the expression of this gene. 
However, the induction of pol III transcripts by c-Myc appears to be stronger 
than the induction of cyclin D2. This observation is similar to effects described 
by Gomez-Roman et al (2003): in this previous study, c-Myc caused a much 
more robust activation of tRNA expression than cyclin D2 expression in 
fibroblasts.
In proliferating cells, c-Myc associates with class III genes, and this is assumed 
to explain the activation of pol III transcription by this transcription factor 
(Felton-Edkins et al, 2003b; Gomez-Roman et al, 2003). To test whether c-Myc 
was associated with class III gene promoters in cardiomyocytes in vivo, cultured 
cells were grown under hypertrophic conditions, then ChIP assays carried out 
using an anti-c-Myc antibody (Figure 5.9A). As a positive control, an antibody 
against the TFIIIB component TBP was employed, and as negative controls, a 
TFIIB antibody and beads alone were used. As expected, TBP associates with 
promoters utilised by pol III in cardiomyocytes, including tRNA^", as shown in 
Figure 5.9A (lane 1). However, no binding of c-Myc to tRNA’^ ”, tRNA’'^ *' nor 5S
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Figure 5.8: c-Myc can activate pol III transcription in the heart. RNA was
extracted from hearts derived from wild-type adult mice (lanes 1 and 2) or 
transgenic littermates expressing a MycER fusion protein specifically in 
cardiomyocytes (MycER Tg, lanes 3 and 4). Mice had either been exposed to OHT 
(lanes 2 and 4) or vehicle (peanut oil, lanes 1 and 3) for 1 week prior to removal o f  
hearts. RNA was analysed by RT-PCR using pre-tRNA^e"-, pre-tRNA^>^-, pre- 
tRNA-^x, cyclin D2- and ARPP PO-specific primers, as specified. The hearts used 
for these analyses were obtained from Dr WR MacLellan, UCLA, USA.
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Figure 5.9: Analysis of c-Myc binding to promoters in cardiomyocytes in
vivo. Cultured cardiomyocytes were grown in the presence of 10% FCS to induce 
hypertrophic growth. ChlPs were performed with antibodies against TBP, TFIIB, 
c-Myc or with beads alone. A. c-Myc binding to class III gene promoters cannot 
be detected in cultured cardiomyocytes. The association of each factor with the 
tRNA^" promoter is shown. Similar results were obtained for the tRNA^ '^' and 5S 
rRNA genes (data not shown), as determined by PCR with gene-specific primers. 
B. c-Myc binding to the nucleolin promoter cannot be detected in cultured 
cardiomyocytes, as determined by PCR with primers designed to amplify the 
nucleolin E-box. Input genomic DNA (10% and 2% of that used in the ChlPs) 
was analysed in the same PCR reactions (A and B, lanes 5 and 6). In the 
examples shown, the c-Myc antibody 9E10 was used. However, the data are also 
representative of results obtained using the N262 c-Myc antibody, which 
recognises a distinct epitope on the c-Myc protein.
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rRNA promoters could be detected in these cells. Similar results were obtained 
with two distinct c-Myc antibodies. Absence of c-Myc association with tRNA^““ 
promoters is shown in Figure 5.9A (lane 3) as an example. This may indicate that 
c-Myc does not interact with class III gene promoters in cardiomyocytes, thus 
inferring activation of pol III transcription by more indirect mechanisms. 
Alternatively, c-Myc may not have been effectively immunoprecipitated from 
these cells.
To test whether lack of c-Myc association was specific to pol III promoters, or 
likely to be as a result of inadequate c-Myc immunoprécipitation, the binding of 
c-Myc to another known tai'get gene, nucleolin, was investigated (Coller et al, 
2000; Greasley et al, 2000; O’Connell et al, 2003). Unlike class III genes, the pol 
Il-transcribed nucleolin gene contains the characteristic consensus E-box binding 
site for c-Myc (Frank et al, 2001; Greasley at al, 2000). Previous studies have 
demonstrated, by ChIP analyses, that c-Myc binds the nucleolin promoter in rat 
cells in vivo (Frank et al, 2001; Zeller et al, 2001). Furthermore, c-Myc induction 
activates nucleolin expression in cardiomyocytes (Xiao et al, 2001). Figure 5.9B 
shows that both TBP and TFIIB bind to the nucleolin promoter (lanes 1 and 2), 
as expected since both of these factors are required for pol Il-dependent 
transcription. In contrast, c-Myc binding to this promoter was not significantly 
above background levels (Figure 5.9B, compare lanes 3 and 4). This is consistent 
with a failure to immunoprecipitate c-Myc in this assay. Therefore, further work 
is required to determine the mechanisms by which c-Myc activates pol III 
transcription in cardiomyocytes.
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Nonetheless, the data clearly suggest that c-Myc activates the pol Ill-dependent 
transcription of essential components of the cellular biosynthetic machinery, both 
in cultured cardiomyocytes and in the heart. Potentially, this may contribute to 
the induction of hypertrophic growth by c-Myc.
5.2.3 Regulation of pol III transcription by RB in cardiomyocytes
To establish whether RB is necessary for restraining pol III activity in the heart, 
the effects of RB deletion were analysed. Dr WR MacLellan and colleagues 
(UCLA, USA) have created transgenic mice in which RB has been effectively 
deleted specifically from cardiomyocytes. These mice develop normally, and 
basal heart function is unaffected (MacLellan et al, unpublished results). 
However, in response to hypertrophic stimuli, RB-null mice display significantly 
exaggerated heart growth, compared to RB-expressing littermates. RNA was 
extracted from hearts derived from these mice, and analysed by RT-PCR (Figure 
5.10). This revealed a striking correlation between the level of pol III transcripts 
and heart growth. Thus, in the absence of hypertrophic stimulation (sham- 
operated hearts), tRNA levels are unaffected by RB deletion, as is heart size and 
function (MacLellan et al, unpublished results). However, the level of tRNA in 
hearts subjected to TAG is on average 30% higher in hearts lacking RB, than in 
wild-type control hearts. This effect is specific, as indicated by the constant level 
of ARPP PO in each heart. Similarly, the average TAC-induced increase in heart 
weight (normalised to body weight) was significantly enhanced (by 
approximately 25%) in the absence of RB (MacLellan et al, unpublished results). 
Therefore, loss of RB augments the increase in pol III transcription and
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Figure 5.10: Loss of RB augments the activation of pol III transcription in 
response to hypertrophic stimulation of the heart. Hearts were obtained from 
adult mice expressing wild-type RB (WT) or sibling mice lacking RB (KO) 
specifically in cardiomyocytes. Prior to heart removal, pressure-overload 
hypertrophy was induced by TAG for 2 weeks. Gontrol animals underwent sham 
operation (SHAM). RNA was extracted from whole hearts, then used for RT- 
PGR analysis with pre-tRNA^"-, pre-tRNA^^'- and ARPP PO-specific primers, as 
indicated. A. RT-PGRs, using RNA derived from 1 animal per condition, are 
shown. B. Densitometry was used to quantify the amounts of pre-tRNA^^" and 
ARPP PO in each heart. Four hearts were analysed for each condition, and the 
average level of pre-tRNA^^", normalised to ARPP PO, is shown in the graph. The 
error bars indicate the standard deviation from the mean (^significantly higher 
than WT SHAM, p<0.05; $ significantly higher than WT TAG, p<0.05; **not 
significantly different from WT SHAM). The hearts used for these analyses were 
provided by Dr WR MacLellan, UGLA, USA.
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hypertrophic growth in response to pressure-overload. This is consistent with a 
role for RB in restraining class III gene expression, and thus hypertrophy, in the 
heart under certain conditions. I
Having determined that RB can repress pol III transcription in cardiomyocytes, 
the next aim was to investigate whether RB phosphorylation contributes to the
j;;
derepression of pol III transcription during hypertrophy. Cyclin induction and
■il
RB phosphorylation characteristically accompany the serum stimulation of f
Sproliferating cells (Hulleman and Boonstra, 2001). As discussed in Chapter 3, a 
small pool of such cells is likely to be present in the primary cultures used here.
Therefore, before examining the role of RB phosphorylation in the upregulation 
of pol III transcription in cultured cardiomyocytes, it seemed pertinent to exclude 
the possibility that the observed increases in cyclin D1 and RB phosphorylation 
result from a proliferative, rather than a hypertrophic, response. To address this 
issue, cardiomyocytes were cultured in the presence or absence of BrdU, and the 
effects of serum stimulation on cyclin D1 levels and RB phosphorylation status 
were compared by Western blotting. As shown in Figure 5.11, BrdU has little 
effect on the induction of cyclin D1 or RB phosphorylation by FCS. This
I
I
confirms that these effects do indeed accompany cardiomyocyte hypertrophy.
CDKs are positively regulated by the appropriate cyclin partners. However, CDK 
activity is also negatively regulated by various CDK inhibitor (CKIs) proteins, 
belonging to the CIP/KIP and INK4 families (reviewed in Sherr and Roberts,
1999). Various CKIs are expressed in the heart, including p2U'^' and p27 
which belong to the CIP/KIP family (Brooks et al, 1998; Koh et al, 1998;
157
■Avi':- "VA;' ' An s,,' ■■;i- i : : ;  n n n
-B rdU
FCS: +~^
+ BrdU
35kDa-
30kDa
cyclin D1
l O S k D a - w
phos-RB
lOSkDa- total RB
Figure 5.11: RB phosphorylation in cultured cardiomyocytes is not due to 
proliferating cells. Following dissociation from neonatal rat hearts, cardiomyocytes 
were cultured in media containing 0.1 mM BrdU or vehicle alone (0.1% DMSO). 
BrdU and vehicle exposed cells were serum starved for 24 hours, then treated with or 
without 10% FCS for 16 hours to induce hypertrophy. BrdU or vehicle were present 
throughout the course o f the experiment. Whole cell lysates were prepared and 75 gg 
o f protein analysed by Western blotting using the antibodies indicated. The phos-RB 
antibody used specifically detects RB phosphorylated on thr 826.
158
5 Regulation o f  po l HI transcription by ERK, c-Myc and RB in cardiomyocytes
Poolman and Brooks, 1998). These proteins have been implicated in the 
development and maintenance of cardiomyocyte terminal differentiation (Brooks 
et al, 1998; Flink et al, 1998; Koh et al, 1998; Poolman and Brooks, 1998; 
Poolman et al, 1999). In contrast, members of the INK4 family, including 
pl^ iNK4a^  do not appear to be expressed in differentiated cardiomyocytes (Brooks 
et al, 1998; Koh et al, 1998; Nozato et al, 2001). INK4 CKIs specifically block 
cyclin D-dependent kinases, and thereby directly prevent RB phosphorylation on 
CDK4/6-specific sites. In proliferating cells, p i e x p r e s s i o n  is sufficient to 
induce cell cycle arrest, indicating that phosphorylation by p l6 ’' '^ '^*"-inhibited 
kinases is essential for the inactivation of RB in these cells (Medema et al, 1995). 
Accordingly, ribozyme-mediated depletion of p i i n  fibroblasts activates pol 
III transcription (Scott et al, 2001). To determine if RB phosphorylation is 
required for the activation of pol III transcription in cardiomyocytes, p i w a s  
overexpressed in cultured cells using adenoviral-mediated gene delivery. 
Western blotting confirmed that p i6 '™  was expressed in cells infected with the 
pl6iNK4a adenovirus, but not in those infected with a GFP-expressing control virus 
(Figure 5.12A, upper panel). Furthermore, p l6 '‘^ ’^'^ “ expression effectively blocked 
the phosphorylation of RB in response to FCS, without affecting the total level of 
RB (Figure 5.12A, lower two panels). To determine whether this influenced the 
induction of pol III transcription by FCS, Northern blotting was performed. 
Figure 5.12B demonstrates that the increase in B2 transcripts in response to 
serum was unaffected by p i e x p r e s s i o n .  This indicates that the activation of 
pol III transcription by FCS does not require RB phosphorylation in cultured 
cardiomyocytes, thus implying that active RB is not sufficient to block the 
induction of pol III transcription in response to hypertrophic stimulation.
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Figure 5.12: Inhibits RB phosphorylation, but not pol III
transcription, in cultured cardiomyocytes. Cultured cardiomyocytes were 
infected with or without (-) equivalent amounts of adenovirus expressing GFP 
(negative control) or p i ( p i 6), as indicated. Cells were serum starved (SF) 
or stimulated with 10% FCS for 16 hours prior to extracting whole cell protein or 
RNA. A. Proteins were resolved by SDS-PAGE and Western blotting was 
performed using antibodies against the proteins specified. The phos-RB antibody 
used specifically detects RB phosphorylated on thr 826. B. RNA was analysed by 
Northern blotting. The upper panel shows the blot probed for B2, and the lower 
panel shows the same blot stripped and re-probed for ARPP PO. The viruses used 
for these analyses were a kind gift from Dr S Mittnacht, Institute of Cancer 
Research, UK.
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5.2.4 Regulation of c-Myc and RB via ERK in cardiomyocytes
The data presented above suggest that ERK and c-Myc can activate pol III 
transcription in cardiomyocytes, whereas RB may be required to restrict this 
activation. ERK is a central regulator of cellular function, and is known to 
participate in the control of c-Myc and RB in various cell types (Cheng et al, 
1999; Carrington and Johnson, 1999; Hulleman and Boonstra, 2001; Sears et al, 
2000; Wilkinson and Millar, 2000). This raises the possibility that ERK not only 
induces pol III transcription directly, by phosphorylating TFIIIB, as occurs in 
proliferating cells (Felton-Edkins et al, 2003a), but also indirectly, by influencing 
the activity of c-Myc and/or RB. Therefore, the regulation of these proteins by 
ERK was investigated.
To determine whether c-Myc is induced by ERK in cultured cardiomyocytes, the 
CAMEK adenovirus was used to specifically activate ERK in the absence of 
hypertrophic stimuli. Western blotting of extracts derived from cells infected 
with CAMEK or control virus revealed that c-Myc was indeed induced at the 
protein level in response to ERK activation (Figure 5.13). Thus, this may 
contribute to ERK-induced pol III transcription.
To establish whether ERK signalling is necessary for the induction of c-Myc 
during hypertrophy, ERK activation was inhibited using PD98059. Although this 
inhibitor clearly blocks the phosphorylation of ERK, it does not influence the 
induction of c-Myc by FCS (Figure 5.14). This suggests that ERK-independent 
pathways are sufficient to induce c-Myc in cardiomyocytes. The induction of c- 
Myc by FCS in the presence of PD98059 may account for the previously
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Figure 5.13: ERK activation is suffîcient to induce c-Myc in cultured 
cardiomyocytes. Cultured cardiomyocytes were infected with equivalent amounts 
(25 fil) o f adenovirus expressing CAMEK or (3-gal (negative control), as indicated. 
Cells were serum starved for 48 hours prior to extracting whole cell protein. 75 gg 
o f protein were resolved by SDS-PAGE and Western blotting was performed using 
antibodies against the proteins specified. The viruses used for these analyses were 
a kind gift from Dr JD Molkentin, University o f Cincinnati, USA.
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Figure 5.14: ERK inhibition does not affect c-Myc levels. Cardiomyocytes were 
cultured in the absence o f serum for 24 hours, then either maintained in serum-free 
media for a further 16 hours (conditions 1 and 2), or stimulated with 10% FCS for 16 
hours (conditions 3 and 4). 50 pM PD98059 (conditions 2 and 4) or vehicle alone 
(0.1% DMSO; conditions 1 and 3) were also included, as indicated. Whole cell lysates 
were prepared and 75 ng o f protein resolved by SDS-PAGE. Western blotting was 
performed with antibodies against the proteins specified.
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described partial activation of pol III transcription in the presence of this 
inhibitor (Figure 5.5). However, ERK activation is clearly necessary for the full 
induction of pol III transcription.
Thus, although ERK may cause c-Myc induction under certain circumstances, 
which would likely contribute to its activation of pol III transcription, ERK also 
appears to induce pol III transcription independently of c-Myc, potentially by 
directly phosphorylating TFIIIB.
The Raf/MEK/ERK pathway also contributes to growth factor-dependent cyclin 
D induction, and thus RB phosphorylation, in proliferating cells (Hulleman and 
Boonstra, 2000; Lavoie et al, 1996; Weber et al, 1997; Wilkinson and Millar,
2000). ERK-dependent RB phosphorylation was examined in cultured 
cardiomyocytes in the present study. ERK inhibition blocks both cyclin D1 
induction and RB phosphorylation following 16 hours of serum stimulation, 
suggesting that the ERK pathway is involved in the regulation of these proteins 
in cardiomyocytes (Figure 5.15A, compare lanes 7 and 8). Thus, ERK-induced 
RB phosphorylation may contribute to the increase in pol III transcripts after 16 
hours of serum-stimulation.
However, as described previously, blocking RB phosphorylation with p l6 ’^ *^‘‘“ 
has no effect on the level of pol III transcripts induced by FCS (Figure 5.12). 
Therefore, it is unlikely that ERK inhibition impairs pol III transcription solely 
by preventing RB phosphorylation.
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Figure 5.15: Effects of ERK inhibition on cyclin D1 expression, RB 
phosphorylation and pol III transcription in cultured cardiomyocytes.
Cardiomyocytes were cultured in the absence of serum for 24 hours, then either 
maintained in serum-free (SF) media for a further 4 or 16 hours, or stimulated 
with 10% FCS for 4 or 16 hours, as indicated. 50 pM PD98059 (PD) or vehicle 
alone (0.1% DMSO) were also included for 4 or 16 hours, as specified. A. Whole 
cell lysates were analysed by Western blotting using the indicated antibodies. 
The phos-RB antibody used specifically detects RB phosphorylated on thr 826. 
B. Whole cell RNA was analysed by Northern blotting. The upper and lower 
panels show the blot probed for B2 then re-probed for ARPP PO, respectively. 
The figures shown are representative of three independent experiments.
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ERK is phosphorylated within 1 hour of hypertrophic stimulation, whereas RB 
phosphorylation is not apparent until after 12 hours (Figure 4.6). To confirm that 
ERK is required for the activation of pol III transcription, independently of its 
regulation of RB, the effects of PD98059 on blocking pol III transcription were 
also examined prior to RB phosphorylation (Figure 5.15B, compare lanes 5 and 
6). This revealed that ERK is involved in the early activation of pol III 
transcription during hypertrophic growth. Furthermore, Figure 5.16 demonstrates 
that ERK activation (by CAMEK expression), which is sufficient to induce pol 
III transcription in cardiomyocytes (Figure 5.6), is not sufficient to induce RB 
phosphorylation, despite increasing cyclin D1 levels. Thus, together, these data 
suggest that ERK activates pol III transcription independently of RB 
phosphorylation, and are consistent with the effects of pl6*'^ *^ '^ “ overexpression 
(Figure 5.12), which indicate that cyclin D-dependent RB phosphorylation is not 
essential for the activation of pol III transcription by hypertrophic stimuli. 
However, these experiments do not discount the possibility that RB limits the 
extent to which pol III transcription is activated during hypertrophic growth.
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Figure 5.16: ERK activation does not induce RB phosphorylation in cultured 
cardiomyocytes. Cultured cardiomyocytes were infected with increasing amounts o f 
adenovirus expressing CAMEK or (3-gal (negative control), as indicated. Cells were 
serum starved for 48 hours before extracting whole cell protein. As a positive control 
for ERK activation, cyclin induction and RB phosphorylation, uninfected cells were 
stimulated with or without (SF) 10% FCS for 16 hours. Proteins were resolved by 
SDS-PAGE and Western blotting was performed using the antibodies specified. The 
phos-RB antibody used specifically detects RB phosphorylated on thr 826. The viruses 
used for these analyses were a kind gift from Dr JD Molkentin, University o f  
Cincinnati, USA.
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5.3 Discussion
Chapter 4 implicated ERK, c-Myc and RB in the regulation of pol III 
transcription in cardiomyocytes. The data presented in this chapter confirm that, 
in these cells, class III gene expression is induced by ERK and c-Myc, but 
repressed by RB, at least under certain circumstances. There is a clear correlation 
between this regulation of pol III transcription and the involvement of each of 
these proteins in the hypertrophic growth response. For example, activation of 
ERK or c-Myc is sufficient to induce both pol III transcription and hypertrophic 
growth in terminally differentiated cardiomyocytes. Moreover, ERK inhibition 
partially diminishes the activation of both pol III transcription and protein 
synthesis by hypertrophic stimuli. Evidence for a role of RB in regulating 
hypertrophy is limited. However, the existing data (WR MacLellan, unpublished) 
from cai'diomyocyte-specific RB-deficient mice suggest that RB attenuates 
hypertrophic growth. The effects of RB loss on hypertrophy closely parallel the 
effects on pol III transcription. Therefore, the pol III transcription machinery 
appears to be a common downstream target of various proteins involved in the 
regulation of hypertrophy, strongly indicating the functional relevance of pol III 
transcriptional control during this growth response.
ERK directly phosphorylates TFIIIB in fibroblasts, and thus facilitates the rapid 
induction of pol III transcription following mitogenic stimulation (Felton-Edkins 
et al, 2003a). Phosphorylation of TFIIIB by ERK probably also participates in 
the early activation of pol III transcription in cardiomyocytes. However, further 
studies are required to confirm this. Other more indirect mechanisms are also 
likely to contribute to the ERK-mediated induction of class III gene expression.
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as ERK has numerous cellular targets that may impinge on the pol III 
transcription machinery. For example, c-Myc is known to be a downstream 
transcription factor target of ERK in certain cell types (Cheng et al, 1999; 
Carrington and Johnson, 1999; Sears et al, 2000). This study provides the first 
demonstration that c-Myc can be induced by ERK activation in cardiomyocytes 
(Figure 5.13). Given that c-Myc promotes pol III transcription and hypertrophic 
growth, this is likely to represent a functionally relevant step in the induction of 
these processes by ERK. However, ERK inhibition does not prevent c-Myc 
induction (Figure 5.14), thus questioning the importance of c-Myc activation by 
ERK. As mentioned in the introduction to this chapter, the regulation of c-Myc 
expression is highly complex, and not fully understood. The effects of ERK 
inhibition on c-Myc levels were examined after 16 hours of serum-stimulation. 
Potentially, c-Myc accumulation is only ERK-dependent at earlier timepoints, 
and other signalling pathways may determine the level of c-Myc at this later 
timepoint. A more thorough examination of c-Myc induction by ERK at various 
times following hypertrophic stimulation would be valuable. Introducing siRNA 
to c-Myc into cardiomyocytes in the presence of the CAMEK adenovirus may 
allow the involvement of c-Myc in the induction of pol III transcription by ERK 
to be tested more directly.
Another downstream target of ERK in cardiomyocytes is mTOR (mammalian 
target of rapamycin) (lijima et al, 2002; Proud, 2004; Wang and Proud, 2002b). 
This protein is involved in controlling the rate of translation in response to 
nutrients and growth factors in mammalian cells (Huang and Houghton, 2003; 
Shamji et al, 2003), and is thought to promote cardiomyocyte hypertrophy
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(Boluyt et al, 1997; McMullen et al, 2004; Sadoshima and Izumo, 1995; Shioi et 
al, 2003). The yeast homologue of mTOR (known simply as TOR) activates pol 
III transcription under favourable growth conditions (Zaragoza et al, 1998). 
Likewise, there is evidence to suggest that mTOR can promote pol III 
transcription in proliferating mammalian cells (Graham, White and Scott, 
unpublished results). Therefore, mTOR-dependent activation of pol III 
transcription may represent an additional indirect mechanism by which ERK 
could activate class III gene expression in cardiomyocytes.
The transcription factor c-Myc activates class III gene expression directly in 
proliferating cells (Gomez-Roman et al, 2003). Further analyses are required to 
determine whether this is also the case in cardiomyocytes. In an attempt to 
explore this possibility in the current study, ChIP assays were performed. 
However, as discussed previously, these assays were unsuccessful, possibly due 
to inefficient c-Myc immunoprécipitation (as suggested by the failure to detect c- 
Myc association with the positive control nucleolin promoter). Previous studies 
have used ChIP assays to demonstrate endogenous c-Myc binding to 5S iRNA 
and tRNA promoters. However, these analyses were performed using 
immortalised cell lines (Felton-Edkins et al, 2003b; Gomez-Roman et al, 2003), 
in which the level of c-Myc is likely to be higher than in the primary, terminally 
differentiated cells used in this study. Therefore, a more sensitive assay may be 
required to examine c-Myc promoter occupancy in cardiomyocytes.
Inactivation of RB enhances the hypertrophy-associated production of pol III 
transcripts in the heart, suggesting that, in addition to its established role as a
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negative regulator of class III gene expression in proliferating cells (Scott et al, 
2001; Sutcliffe et al, 2000; White et al, 1996), RB is also involved in restraining 
pol III transcription in terminally differentiated cardiomyocytes. However, unlike 
the situation in fibroblasts, where RB inactivation increases pol III transcription 
in both the presence and absence of growth factors (Scott et al, 2001), in 
cardiomyocytes, the effects of RB loss are only apparent under hypertrophic, not 
basal, conditions (see Figure 5.10). This discrepancy may be due to the fact that 
RB inactivation has only been investigated in cultured fibroblasts, whereas the 
effects of RB loss from cardiomyocytes were studied in situ. The more prolonged 
lack of RB during heart development may invoke mechanisms to compensate for 
the RB deficiency. It would be interesting to compare acute RB loss in different 
cell types more directly. This could be achieved by analysing the effects of RB 
knock down in culture using siRNA. It would also be informative to compare the 
effects of RB inactivation in a range of different tissue types.
Alternatively, the differential sensitivity of cardiomyocytes and fibroblasts to RB 
inactivation under basal conditions may reflect cell-type specific differences in 
the control of pol III transcription by RB. For example, the abundance of TFIIIB, 
which is the primary target of RB-mediated pol III transcriptional repression 
(Chu et al, 1997; Laiminie et al, 1997), may determine the contribution RB 
makes to the regulation of pol III transcription. The level of the TFIIIB subunit 
Brfl is relatively low in unstimulated cardiomyocytes, compared to fibroblasts, 
as discussed in Chapter 4. Therefore, whereas sequestration of TFIIIB by RB is 
necessary for the effective repression of pol III transcription in unstimulated 
fibroblasts (Scott et al, 2001), insufficient levels of functional TFIIIB may
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eliminate the requirement for RB under basal conditions in cardiomyocytes. 
Consistent with this model, Brfl levels increase following hypertrophic 
stimulation (Figures 4.4 and 4.7) and accordingly, RB is required to restrain pol 
III transcription under such circumstances.
As an alternative approach to investigate the involvement of RB in pol III 
transcriptional control, the CKI p l6 ’'^ '^ “^ was used to prevent the serum-stimulated 
inactivation (phosphorylation) of endogenous RB, and thus determine whether 
active (hypophosphorylated) RB is sufficient to repress pol III transcription in 
cardiomyocytes. However, p i e x p r e s s i o n  did not influence the induction of 
class III gene expression by FCS, thus indicating that active RB is not sufficient 
to ovemde the effects of positive pol III transcriptional regulators, such as ERK 
and c-Myc, and repress pol III transcription in these cells (Figure 5.12). 
However, this conclusion is based on the assumption that p i d o e s  
effectively block RB inactivation. As an indicator of RB inactivation, threonine 
826 phosphorylation was measured. The phosphorylation of this residue, which 
is specifically targeted by cyclin D-dependent kinases 4 and 6 (Zarkowska and 
Mittnacht, 1997), is markedly diminished in the presence of pl6 '^‘^'‘“ (Figure 
5.12). Cyclin D-dependent RB phosphorylation is commonly considered to be a 
necessary prerequisite for subsequent phosphorylation by cyclin E- and A- 
dependent kinases (Harbour et al, 1999; Lundberg and Weinberg, 1998). 
Therefore, it was presumed that pl6*'^ '^‘“ would block RB phosphorylation, not 
only by CDK4/6, but also by the cyclin E/A-dependent kinase CDK2, which is 
involved in rendering RB inactive with respect to pol III repression (Scott et al,
2001). However, this dogma of sequential RB phosphorylation has recently been
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challenged: mouse embryonic fibroblasts derived from knockout mice lacking D- 
type cyclins, or both CDK4 and 6, still show CDK2-dependent RB 
phosphorylation, and this appears to be sufficient for RB inactivation and cell 
cycle progression (Kozar et al, 2004; Malumbres et al, 2004; reviewed by Pagano 
and Jackson, 2004). Thus, conceivably, even in the presence of pl6'^"^^\ RB may 
still become phosphorylated on several sites following hypertrophic stimulation, 
leading to its dissociation from TFIIIB, and the resulting activation of pol III 
transcription. A more extensive comparison of RB phosphorylation in the 
presence and absence of would allow these issues to be addressed. Co-
immunoprecipitation experiments are also required to confirm an interaction 
between TFIIIB and RB in these cells, and to determine whether this interaction 
is responsive to different cellular conditions.
Thus, RB appears to repress pol III transcription in cardiomyocytes. However, 
there may be differences in the control of pol III transcription by RB in 
cardiomyocytes and undifferentiated fibroblasts, as discussed above. This 
highlights the importance of characterising cellular control mechanisms in 
different cell types and in situ, rather than assuming that mechanisms operating 
in cultured fibroblasts will be generally applicable. Further investigation is 
required to fully elucidate the role of RB in regulating class III gene expression 
in terminally differentiated cardiomyocytes. Such studies will likely make a 
valuable contribution to the limited understanding of RB targets in different cell 
types, and the involvement of this protein in cell growth control.
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In summary, the results presented in this chapter provide a mechanistic link 
between the activation of positive regulators of hypertrophy (ERK and c-Myc), 
and enhanced translational capacity, through increased pol III transcription. 
Additionally, recent findings implicating RB as a negative regulator of 
hypertrophy (MacLellan et al, unpublished results) can be at least partly 
explained by its ability to restrict class III gene expression in the heart. Not only 
do these findings contribute to the current understanding of processes governing 
hypertrophy, but also indicate that proliferating and terminally differentiated 
cells utilise common mechanisms to regulate pol III transcription and cell 
growth. However, there appear to be some cell-type specific differences in these 
shared control mechanisms, which warrant further investigation. The following 
chapter explores the regulation of Brfl expression in cardiomyocytes, and 
considers the possibility that the induction of this essential TFIIIB component is 
involved in activating pol III transcription during the hypertrophic growth of 
cardiomyocytes.
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CHAPTER 6 
Regulation of pol III transcription by changes in 
Brfl expression in cardiomyocytes
6.1 Introduction
Brfl along with TBP and Bdpl comprise the pol Ill-specific transcription factor 
TFIIIB. Brfl is a critical determinant of the integrity of TFIIIB; Brfl and TBP 
interact directly to form a stable complex, with which Bdpl is weakly associated 
in a Brfl-dependent manner (Geiduschek and Kassavetis, 2001). As discussed in 
Chapter 1, the primary purposes of TFIIIB are to recruit pol III to the appropriate 
promoters, as determined by TFIIIC, and to facilitate promoter opening. Brfl is 
essential for both of these TFIIIB functions. For example, Brfl mediates the 
initial interaction between TFIIIB and promoter-bound TFIIIC, which, at least in 
yeast, is the rate-limiting step for pol III transcription (Geiduschek and
Kassavetis, 2001; Moir et al, 1997; Rameau et al, 1994; Schramm and
Hernandez, 2002). In addition, Brfl makes direct contacts with pol III itself, thus 
participating in polymerase recruitment, and is necessary for the subsequent 
formation of an open promoter structure, competent for transcription initiation 
(Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002). Given these 
central roles of Brfl in TFIIIB function, it is perhaps not surprising that changes 
in class III gene expression are often achieved through the regulation of this
subunit, as discussed below. In fact, Brfl is the limiting factor for pol III
transcription under various circumstances in yeast and mammalian cells (Fairley 
et al, 2003; Felton-Edkins et al, 2003a; L6pez-de-Leôn et al, 1992; Sethy et al, 
1995).
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In S. cerevisiae, pol III transcription declines during the transition from 
logarithmic to stationary phase growth. This results from a specific reduction in 
the level, and possibly the activity, of Brfl (Sethy et al, 1995). Similarly, in 
mammalian cells, decreases in Brfl abundance contribute to the down-regulation 
of pol III transcription that occurs as F9 cells differentiate (Alzuherri and White, 
1998) and during p53-induced sustained cell cycle arrest (Eichhorn and Jackson, 
2001).
The activity of mammalian Brfl is also regulated by phosphorylation (Fairley et 
al, 2003; Felton-Edkins et al, 2003a; Johnston et al, 2002). In cycling cells, pol 
III transcription increases during late G1 and declines during mitosis (White et 
al, 1995b). Although the level of Brfl remains constant throughout the cell cycle -N
(Scott et al, 2001; Fairley et al, 2003), phosphorylation of this factor plays a key 
role in mediating these fluctuations in class III gene expression. For example,
Brfl becomes phosphorylated when quiescent fibroblasts are induced to enter the 
cell cycle by serum-stimulation (Johnston et al, 2002). This is at least partly 
mediated by ERK and CK2 (Felton-Edkins et al, 2003a; Johnston et al, 2002), 
kinases that promote cell growth and division. Phosphorylation of Brfl by either 
of these kinases increases the association of TFIIIB with TFIIIC and, in the case 
of ERK-mediated phosphorylation, TFIIIB with pol III, thus promoting 
transcription initiation (Felton-Edkins et al, 2003a; Johnston et al, 2002). Brfl is 
also phosphorylated during mitosis (Fairley et al, 2003). However, this 
modification is thought to disrupt the TFIIIB complex and thus repress, rather 
than activate, pol III transcription (Fairley et al, 2003). The kinase(s) responsible 
for this mitotic Brfl phosphorylation have yet to be identified.
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Therefore, regulation of the abundance and/or activity of this pivotal TFIIIB 
subunit can promote or disrupt critical interactions between components of the 
pol III transcription machinery and thereby activate or repress pol III 
transcription according to cellular requirements. The level of Brfl increases in 
response to the hypertrophic stimulation of cardiomyocytes, as shown in Chapter 
4. Given the critical role that B ifl plays in determining the rate of pol III 
transcription in other eukaryotic systems, it is likely that this elevated Brfl 
abundance will contribute to the enhanced class III gene expression that 
accompanies hypertrophic growth. This possibility is addressed in the current 
chapter, along with the mechanisms regulating the expression of this 
transcription factor.
179
6 Regulation o f  po l 111 transcription by changes in Brfl expression in cardiomyocytes
6.2 Results
6.2.1 Brfl is limiting for pol III transcription in unstimulated 
cardiomyocytes
To determine whether the increase in Brfl levels following hypertrophic 
stimulation of cardiomyocytes contributes to the activation of pol III 
transcription, the effects of raising the concentration of this TFIIIB subunit were 
assessed. Cultured cardiomyocytes were infected with adenoviruses expressing 
GFP alone, as a negative control, or HA-Brfl. Western analysis of protein lysates 
derived from these cells confirmed HA-Brfl overexpression where appropriate 
(Figure 6.1 A). To analyse the effects of increasing the level of Brfl on pol III 
transcription. Northern blotting was performed. As shown in Figures 6. IB and C, 
enhanced Brfl expression causes a significant induction of B2 transcripts (1.8- 
fold), compared to control infected cells, in the absence of hypertrophic stimuli. 
This indicates that Brfl is limiting for pol III transcription under basal conditions 
in terminally differentiated cardiomyocytes. Although in Figure 6.IB, B2 also 
seems to be elevated in serum-stimulated cells expressing HA-Brfl, compared to 
those expressing GFP alone, when normalised to ARPP PO in three separate 
experiments, it was apparent that B2 abundance does not increase significantly 
under these conditions (as displayed in Figure 6.1C). Therefore, in contrast to the 
situation in unstimulated cardiomyocytes, it was concluded that following 
hypertrophic stimulation, Brfl overexpression does not cause any further 
enhancement of pol III transcription (Figure 6.1C). This suggests that the level of 
Brfl no longer restricts class III gene expression, presumably due to the 
hypertrophy-associated increase in the abundance of this protein. These data are 
consistent with a model whereby enhanced Brfl expression promotes the
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Figure 6.1: Brfl induces pol III transcription in unstîmulated
cardiomyocytes. Cultured cardiomyocytes were infected with adenoviruses 
expressing HA-Brfl (B) or GFP (G) alone. Cells were serum-starved or 
stimulated with 10% FCS for 16 hours prior to extracting whole cell protein or 
RNA. A. Western blotting was performed using anti-HA and anti-actin 
antibodies. B. RNA was analysed by Northern blotting. The upper panel shows 
the blot probed for B2, and the lower panel shows the same blot stripped and re­
probed for ARPP PO. C. Northern blots were quantified by densitometry, and B2 
levels normalised to ARPP PO. This was done for 3 separate experiments. The 
average fold increases obtained, along with standard deviations from the means, 
are represented in the graph significantly different from SF GFP, p<0.05; **not 
significantly different from FCS GFP). The viruses used for these analyses were 
prepared by Dr F Cairns, University of Glasgow, UK.
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formation of functional TFIIIB complexes, which can then participate in the 
activation of pol III transcription during hypertrophic growth (Figure 6.2). 
However, overexpressing Brfl in unstimulated cardiomyocytes is not sufficient 
to induce pol III transcription to the same extent as FCS (Figure 6.1C). This 
suggests that other proteins, such as ERK and c-Myc, also play critical roles in 
activating the pol III transcription machinery in response to hypertrophic 
stimulation, consistent with the data presented in Chapter 5.
6.2.2 The regulation of Brfl expression in cardiomyocytes
Having determined that an increase in Brfl abundance is likely to be a 
functionally relevant step contributing to the activation of pol III transcription 
during hypertrophic growth, the mechanisms controlling this enhanced 
expression were investigated. Potentially, Brfl levels could be regulated at the 
level of transcription, mRNA processing, translation, or post-translationally 
through the control of protein stability. Only two previous studies have reported 
changes in Brfl abundance as a means for regulating pol III transcription in 
mammalian cells (Alzuherri and White, 1998; Eichhorn and Jackson, 2001). In 
the latter of these studies, Brfl levels were found to be controlled by ubiquitin- 
mediated proteolysis. The ubiquitin-proteasome pathway is a common means of 
regulating the function of numerous proteins involved in fundamental cellular 
processes including the cell cycle, differentiation and development, stress 
responses, DNA repair and apoptosis (Ciechanover, 1998; Jentsch and Schlenker, 
1995; Weissman, 2001). Eichhorn and Jackson (2001) demonstrated that Brfl 
destabilisation contributes to the decline in pol III transcription associated with a
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Figure 6.2: Model depicting B rfl-mediated activation o f class III gene 
expression during cardiomyocyte hypertrophy. Low levels o f Brfl in 
unstimulated cardiomyocytes are likely to restrict the formation o f TFIIIB 
complexes, and thereby limit the rate o f pol III transcription. Accordingly, 
increasing the level o f Brfl in these cells promotes pol III transcription. Thus, 
the hypertrophic stimulation o f cardiomyocytes is likely to activate class III gene 
expression by enhancing the availability o f this limiting factor. Inactive class III 
genes are represented by red boxes, whereas green boxes indicate active genes.
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sustained, p53-induced, cell cycle arrest. Brfl levels and pol III transcription 
could be restored in these arrested cells by inhibition of the proteasome. To test 
whether rapid protein turnover accounts for the low level of Brfl in unstimulated 
cardiomyocytes, the proteasome inhibitor MG132 was employed.
Cardiomyocytes were cultured in the absence of hypertrophic stimuli and, 4 
hours before harvesting, MG 132 or vehicle (0.1% DMSG) were added to the 
cells. Protein lysates were analysed by Western blotting. To ensure MG132 
efficacy, the effect of this proteasome inhibitor on the level of cyclin D l, which 
is known to have a short half-life due to rapid proteasome-mediated turnover
■|(Diehl et al, 1997), was assessed. As shown in Figure 6.3 (middle panel), MG132 |
caused a substantial accumulation of cyclin D l, thus confirming proteasome 
inhibition. However, Brfl levels were unaffected, suggesting that this protein is 
relatively stable in terminally differentiated cardiomyocytes (Figure 6.3, top 
panel). Therefore, ubiquitin-mediated proteolysis does not appear to regulate 
Brfl in these cells.
The most common means for controlling gene expression is through the 
regulation of transcription (White, 2001). To investigate whether hypertrophic 
stimuli increase the production of transcripts encoding Brfl, the level of Brfl 
mRNA was analysed by RT-PCR. Figure 6.4 shows that, along with the 
previously described increase in ANF and tRNA transcripts (Figures 3.4 and 3.7, 
respectively), hypertrophic stimulation also increases the level of Brfl mRNA.
ARPP PO levels were unaffected, demonstrating the specificity of these effects.
Thus, although the elevation in Brfl transcripts may be due to an increase in
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Figure 6.3: Brfl levels are not regulated by proteasome-mediated 
turnover in cardiomyocytes. Cardiomyocytes were cultured in serum- 
free medium. 4 hours before harvesting, 10 pM MG 132 or vehicle (0.1% 
DMSO) were added to the cells. 75 |ig o f protein lysates were then 
resolved by SDS-PAGE, and Western blotting was performed with 
antibodies against the proteins indicated.
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Figure 6.4: Hypertrophic stimulation of cardiomyocytes increases 
B rfl at the mRNA level. Cultured cardiomyocytes were serum-starved 
for 24 hours, then either maintained in serum-free media for a further 16 
hours, or exposed to 10% FCS. Total RNA was extracted from these 
cells and 3 pg used to generate cDNAs by reverse transcription. cDNAs 
were then amplified by PCR using primers specific for Brfl, pre- 
tRNA^“, ANF or ARPP PO, as indicated.
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mRNA stability, it most likely indicates that hypertrophic stimuli enhance Brfl 
expression by activating Brfl gene transcription.
As discussed in Chapter 3, hypertrophic growth is accompanied by characteristic 
changes in the transcription of several class 11 genes, including the induction of 
immediate early genes, the re-expression of certain foetal genes, and the 
upregulation of constitutively expressed contractile proteins (Figure 3.1). Many 
of these alterations in gene expression are mediated by ERK (Bueno et al, 2000; 
Gillespie-Brown et al, 1995; Glennon, et al, 1996; Harris et al, 2004; Ueyama et 
al, 2000; Yue et al, 2000), which phosphorylates a range of nuclear transcription 
factors (Babu et al, 2000; Bueno and Molkentin, 2002; Liang et al, 2001; 
Morimoto et al, 2000). Given that ERK can also activate class III gene 
expression (as demonstrated in Chapter 5), for which Brfl is essential, the 
involvement of this kinase in the induction of Brfl was investigated.
To explore the involvement of ERK in the induction of Brfl gene transcription, 
the effects of ERK activation on the level of Brfl transcripts were examined. 
Cultured cardiomyocytes were infected with control or CAMEK-expressing 
adenoviruses in the absence of hypertrophic stimuli. RT-PCR analysis, using 
RNA extracted from these cells, demonstrated that ERK activation does indeed 
induce Brfl at the mRNA level (Figure 6.5). ERK activation was also 
accompanied by an increase in tRNA transcripts, as found previously (Figure 
5.6). The level of the negative control mRNA (ARPP PO) was unchanged, 
confirming that these effects are specific. Thus, the Brfl gene is likely to
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Figure 6.5: ERK induces B rfl at the mRNA level in cardiomyocytes.
Cultured cardiomyocytes were infected with equivalent amounts o f  
adenovirus expressing CAMEK or p-gal (negative control), as indicated. 
Cells were serum starved for 48 hours prior to extracting whole cell 
RNA. 3 gg o f this RNA were used to generate cDNAs by reverse 
transcription. cDNAs were then amplified by PCR using Brfl -, pre- 
tRNA^“-, or ARPP PC-specific primers, as specified. The viruses used for 
these analyses were a kind gift from Dr JD Molkentin, University o f 
Cincinnati, USA.
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represent an additional transcriptional target of the ERK pathway in 
cardiomyocytes.
For this induction of Brfl mRNA by ERK to be functionally relevant, an increase 
in the abundance of the Brfl protein must also occur. Western analysis 
confirmed that ERK activation does induce Brfl at the protein level (Figure 6.6), 
and in addition, this effect is clearly specific to the Brfl subunit of TFIIIB, as 
TBP and Bdpl abundance do not respond to ERK activation. Therefore, given 
that Brfl is limiting for pol 111 transcription in the absence of hypertrophic 
stimuli, this induction of Brfl expression is likely to play a critical role in the 
activation of pol 111 transcription, and perhaps cell growth, by ERK in 
cardiomyocytes.
To determine whether ERK activation is necessary for the induction of Brfl by 
hypertrophic stimuli, the MEK inhibitor PD98059 was used. This inhibitor 
attenuates the induction of both pol 111 transcription and protein synthesis by FCS 
in cardiomyocytes (Figures 5.4 and 5.5). As shown in Figure 6.7, blocking ERK 
activation also reduces the FCS-induced increase in Brfl expression. This 
provides further evidence to support the proposed involvement of ERK in the 
induction of Brfl during hypertrophic growth. However, ERK inhibition does not 
completely abrogate Brfl induction, suggesting that other ERK-independent 
pathways also ensure that Brfl expression is increased during cardiomyocyte 
hypertrophy.
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Figure 6.6: ERK induces Brfl at the protein level in cardiomyocytes.
Cultured cardiomyocytes were infected with increasing amounts o f  
adenovirus expressing CAMEK or (3-gal (negative control), as indicated. 
Cells were serum starved for 48 hours before extracting whole cell protein. 
For comparison, uninfected cells were incubated without (SF) or with 10% 
FCS for 16 hours. 75 pg o f protein were resolved by SDS-PAGE and Western 
blotting was performed using the antibodies specified. The viruses used for 
these analyses were a kind gift from Dr JD Molkentin, University o f  
Cincinnati, USA.
* indicates a non-specific band.
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Figure 6.7: ERK inhibition attenuates the hypertrophy-associated 
increase in B rfl. Cultured cardiomyocytes were serum-starved for 24 
hours, then either maintained in serum-free medium, or exposed to 10% 
FCS, for 16 hours in the presence o f 50 pM PD98059 or vehicle (0.1% 
DMSO), as indicated. 75 pg o f  protein were resolved by SDS-PAGE and 
Western blotting was performed using the antibodies specified.
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6.3 Discussion
The induction of hypertrophic growth is accompanied by enhanced Brfl 
expression. The data presented in this chapter imply that this specific increase in 
Brfl abundance contributes to the activation of pol 111 transcription during 
hypertrophy: in the absence of hypertrophic stimuli, pol 111 transcription can be 
induced simply by raising the level of Brfl, suggesting that this TFIIIB subunit is 
rate-limiting for pol 111 transcription. Furthermore, the fact that hypertrophic 
cardiomyocytes do not respond to exogenous Brfl suggests that the hypertrophy- 
associated increase in the expression of this factor is sufficient to permit 
maximum levels of class 111 gene expression. This is the first indication that pol 
111 transcription can be activated by a growth factor-dependent increase in Brfl 
levels in mammalian cells. Studies aimed at determining the mechanisms 
regulating pol 111 transcription in other differentiated cell types may reveal that 
controlling Brfl abundance is a common means of determining pol 111 
transcriptional output following terminal differentiation.
Data presented in Chapter 5 demonstrate that ERK induces class 111 gene 
expression in cardiomyocytes. However, the mechanisms contributing to this 
induction were not determined. The results described in this chapter provide a 
mechanistic link between ERK activation and enhanced pol 111 transcription, 
through the induction of Brfl : active ERK can increase Brfl at the mRNA and 
protein levels in the absence of hypertrophic stimuli; in addition, the full 
induction of Brfl by FCS is dependent on ERK activation. ERK-regulated Brfl 
expression has not previously been reported, but is likely to make an important 
functional contribution to the induction of class 111 gene transcription, and hence
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hypertrophic growth, in cardiomyocytes. Again, examination of a variety of cell 
types is required to determine whether this ERK-mediated induction of Brfl 
expression is cardiomyocyte-specific, or a more generally employed mechanism 
for controlling pol III transcription. Another instance where ERK could 
potentially be involved in the induction of Brfl is discussed below.
HPV16 is a highly oncogenic strain of the human papillomavirus (HPV), and is a 
common cause of cervical cancer (zur Hausen, 2000). Although Brfl induction 
has not previously been shown to accompany normal cell growth or division, 
Brfl levels were found to be specifically elevated in HPV 16-transformed 
cervical epithelium, and this is thought to contribute to the abnormally high level 
of pol III transcripts found in tumours of the cervix (Daly et al, 2004, In press). 
HPV 16 oncoproteins have also been associated with aberrant activation of the 
ERK signalling pathway (Chakiabarti et aï, 2004; Gu and Matlashewski, 1995). 
Thus, the finding that ERK can enhance Brfl expression provides a possible 
explanation for this HPV-induced increase in Brfl abundance, and therefore may 
be of relevance, not only to the hypertrophic gi'owth of cardiomyocytes, but also 
to the development of this prevalent human cancer.
Although Brfl induction is likely to facilitate the activation of pol III 
transcription during hypertrophic growth, increasing Brfl alone is insufficient to 
attain levels of pol III transcription comparable to those induced by FCS (Figure 
6.1C). Furthermore, Brfl protein levels do not significantly increase until 3 to 6 
hours after hypertrophic stimulation, whereas pol III tianscription is activated 
after only I to 2 hours (Figures 4.7 and 4.5, respectively). Therefore, additional
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mechanisms must also contribute to pol III transcriptional regulation in 
cardiomyocytes. This is consistent with the data presented in Chapter 5, which 
suggest that multiple pathways are likely to converge on the pol III transcription 
machinery. For instance, c-Myc can positively regulate pol III transcription in 
cardiomyocytes, and this is likely to participate in the initial activation of class 
III gene expression. In addition, although the induction of Brfl by ERK is likely 
to partly explain the ability of this kinase to promote pol III transcription, it is 
probable that direct, ERK-mediated phosphorylation of B rfl, as occurs in 
fibroblasts (Felton-Edkins et al, 2003a), will also be involved, thus allowing a 
rapid response. Further investigations are required to confirm these possibilities. 
ERK is thought to phosphorylate Brfl on threonine 145 (Felton-Edkins et al, 
2003a). Mutating this residue to an aspartate would mimic such phosphorylation. 
If ERK-directed Brfl phosphorylation does contribute to pol III transcriptional 
induction in cardiomyocytes, adenoviral-mediated expression of this mutant 
would be expected to cause a more robust activation of pol III transcription in 
unstimulated cells than wild-type B rfl.
The increase in B ifl mRNA, in response to hypertrophic stimulation, implies an 
increase in Brfl gene transcription, although post-transcriptional control is also 
possible. To gain some insight into the transcription factors potentially involved 
in this regulation, the upstream region of the Brfl gene was analysed using the 
consensus binding site prediction programme CONSITE (available at 
www.phylofoot.org). This identified putative binding sites for various 
transcription factors known to be involved in determining the hypertrophic 
phenotype. For example, both the rat and human Brfl genes contain several
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potential c-Myc (E-boxes) and AP-1 binding sites, as shown in Figure 6.8. As 
discussed previously, c-Myc induces pol III transcription and hypertrophic 
growth in cardiomyocytes (see Chapter 5). Although c-Myc is likely to directly 
influence the pol III transcription machinery, as in other cell types (Gomez- 
Roman et al, 2003), it may also promote pol III transcription more indirectly by 
increasing the availability of Brfl. AP-1 transcriptional activators are dimers 
containing members of the Fos and Jun families (White, 2001). c-fos and c-jun 
are induced by hypertrophic stimuli (Iwaki et al, 1990; Izumo et al, 1988; 
Komuro et al, 1988; Komuro et al, 1990; Komuro et al, 1991; Sadoshima et al, 
1992; Sadoshima and Izumo, 1993a), leading to the transcriptional activation of 
genes characteristically upregulated during hypertrophy (Bishopric et al, 1992; 
Herzig et al, 1997; Omura et al, 2002; Paradis et al, 1996). Furthermore, both c- 
Myc and c-fos induction are regulated by the ERK pathway in cardiomyocytes 
(Chapter 5, Figure 5.13; Babu et al, 2000; Gillespie-Brown et al, 1995), hence 
providing a potential connection between ERK activation and Brfl accumulation. 
However, c-Myc can be induced independently of ERK activation (Figure 5.14), 
which may explain the partial FCS-stimulated increase in Brfl abundance in the 
presence of the MEK inhibitor PD98059 (Figure 6.7). Thus, it would be 
interesting to examine the binding of these transcription factors to the Brfl 
promoter, and directly test their effects on Brfl expression.
The abundance of Brfl is not altered in response to growth stimuli in 
proliferating cells. This suggests that Brfl expression is regulated in a cell-type 
specific manner. MEF2 is a transcription factor whose function is restricted to a 
few tissue types, including cardiac muscle, and is known to be a crucial regulator
196
X <No Ph
X ) w
w
■
s
■
c
g CL
w
□
<
□
sT
I
+
a
5<N
et
am
I
■SI
IT3
1
5
3OIO1
sI
■s
I
(L>
197
6 Regulation o f  po l III transcription by changes in Brfl expression in cardiomyocytes
of cardiomyocyte growth and gene expression (Akazawa and Komuro, 2003; 
Kolodziejczyk et al, 1999; Molkentin and Markham, 1993; Nadruz et al, 2003). 
A putative MEF2 binding site was identified upstream of the rat and human Brfl 
genes (Figure 6.8), making this factor a candidate for such cell-type specific 
regulation. In addition, intron 2 of the Brfl gene contains a consensus binding 
site for the transcriptional repressor REST (I Wood, personal communication; 
http://www.bioinformatics.leeds.ac.uk/group/online/REldb/reldb_home.htm), 
which is a negative regulator of cardiomyocyte hypertrophy (Kuwahara et al, 
2003). Potentially, this transcription factor may be involved in restraining Brfl 
expression under basal conditions in terminally differentiated cardiomyocytes. 
Further analyses of the mechanisms controlling Brfl expression are likely to 
uncover links between transcriptional regulators of hypertrophy and changes in 
protein synthesis.
In summary, the experiments described in this chapter have identified a novel 
mode for regulating pol III transcription during cell growth. Furthermore, this is 
the first study to examine the mechanisms regulating the expression of the central 
TFIIIB subunit B rfl, revealing an important role for the ERK signalling 
pathway. Further investigations are required to establish whether these 
mechanisms are a widespread means of controlling pol III transcription, for 
example during the growth of other differentiated cells or the abnormal 
proliferation of tumour cells. Future work aims to analyse the effects of blocking 
the hypertrophy-associated increase in Brfl, using antisense or siRNA 
technologies, to firmly establish the importance of this enhanced expression in 
the activation of class III gene expression and hypertrophic cell growth.
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CHAPTER 7 
Final Discussion
Cardiovascular disease is one of the leading causes of death in industrialised 
countries, with associated health care costs estimated to reach over £7 billion 
each year in the UK alone (statistics obtained from the British Heart Foundation: 
http://www.bhf.org.uk/news/index.asp?secondlevel=241&thirdlevel=751&artID 
=3362). Therefore, research into the mechanisms regulating heart function is of 
vital importance in order to improve our understanding of the causes of heart 
failure. Cardiomyocyte hypertrophy is associated with many cardiovascular 
disorders (Harjai et al, 1999; Kannel, 1990; Levy et al, 1990), and thus the 
molecular basis of this process has been the subject of intensive investigation. 
One of the cardinal features of this hypertrophy is an increase in cell size, 
without proliferation. However, the mechanisms responsible for this cell growth 
response have yet to be fully elucidated. In fact, although the mechanisms 
regulating cell division have attracted a considerable amount of interest over the 
years, comparatively little is known about the control of cell growth in general. 
Therefore, cardiomyocyte hypertrophy is not only worthy of study because of its 
relevance to heart disease, but also because it sheds light on the poorly 
understood mechanisms underlying cell growth.
Cell growth requires an accumulation of protein. In the case of cardiomyocyte 
hypertrophy, this is dependent on an increase in translational capacity 
(Brandenburger et al, 2001). Translational capacity is determined by the 
availability of numerous.molecules involved in biosynthesis, including ribosomal
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components, tRNAs and translation factors. Pol Ill-transcribed genes encode a 
variety of small, untranslated RNAs with essential roles in cellular biosynthesis 
(see Chapter 1). Therefore, it was hypothesised that an increase in class III gene 
expression would accompany cardiomyocyte hypertrophy. This was confirmed 
by the data presented in Chapter 3, which demonstrate that various hypertrophic 
stimuli enhance pol III transcription, both in culture and in the heart, leading to 
an increase in all the class III gene products tested, including 5S rRNA, tRNAs 
and U6 snRNA. This general increase in class III gene expression represents a 
previously unreported route to increase protein synthetic capacity, and hence 
hypertrophic growth, in cardiomyocytes. In addition, this is the first 
demonstration that pol III transcriptional activation accompanies cell growth 
independently of cell division. The subsequent chapters of this thesis aimed to 
elucidate the mechanisms responsible for this regulation. As discussed below, 
this revealed that several mechanisms contribute to the control of pol III 
transcription in terminally differentiated cardiomyocytes, suggesting that such 
regulation is of fundamental importance.
7.1 Mechanisms contributing to the regulation of pol III 
transcription in cardiomyocytes
The transcription of a class III gene is dependent on pol III reeruitment to the 
appropriate promoter. For the majority of genes transcribed by pol III, this is 
determined by the transcription factors TFIIIC and TFIIIB, which bind specific 
promoter sequences and directly recruit the polymerase, respectively 
(Geiduschek and Kassavetis, 2001; Schramm and Hernandez, 2002). ChIP assays
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were used to monitor pre-initiation complex assembly on class III genes in 
response to hypertrophic stimulation. This revealed a specific increase in TFIIIB 
promoter occupancy on tRNA and 5S rRNA genes, while the association of 
TFIIIC was unaffected (as illustrated in Figures 4.2 and 7.2). Therefore, it was 
concluded that polymerase binding, and hence transcription initiation, are 
regulated at the level of TFIIIB recruitment. This is consistent with the well- 
recognised role of TFIIIB as a central regulator of pol III transcription in other 
eukaryotic cell types (Gottesfeld et al, 1994; Sethy et al, 1995; Tower and 
Sollner-Webb, 1988; White et al, 1989; White et al, 1995a, b; White, 1998). The 
frequent targeting of TFIIIB by numerous control strategies likely reflects its 
essential role in various aspects of pol III transcription initiation.
7.1.1 Pol III transcription in cardiomyocytes is positively regulated by c- 
Myc, ERK and Brfl
TFIIIB function in dividing cells can be regulated through its interaction with 
various proteins. Some of these proteins have been implicated in controlling 
hypertrophy; therefore, their involvement in pol III transcriptional regulation was 
studied in cardiomyocytes. For instance, both ERK and c-Myc are involved in 
the control of pol III transcription during cellular proliferation (Felton-Edkins et 
al, 2003a, b; Gomez-Roman et al, 2003), and have previously been shown to 
promote the hypertrophic growth of heart muscle cells (Bueno et al, 2000; 
Glennon et al, 1996; Ueyama et al, 2000; Wang and Proud, 2002a; Xiao et al, 
2001; Yue et al, 2000). Following hypertrophie stimulation, c-Myc induction and 
ERK activation precede the initial increase in pol III transcription, as shown in 
Chapter 4. In addition, data presented in Chapter 5 reveal that c-Myc induction or
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ERK activation is sufficient to induce pol III transcription in the absence of 
hypertrophic stimuli. In the case of c-Myc, this was demonstrated both in culture 
and in the heart in situ. Furthermore, ERK inhibition attenuates the hypertrophy- 
associated induction of class III gene expression. Thus, this study has uncovered 
a connection between these molecules and their ability to enhance cardiomyocyte 
biosynthesis, by demonstrating that they can upregulate pol III transcription in 
these terminally differentiated cells.
Further work is required to establish the precise mechanisms by which ERK and 
c-Myc induce pol III transcription in caidiomyocytes. In proliferating cells, c- 
Myc interacts with TFIIIB, and is recruited to class III gene promoters (Gomez- 
Roman et al, 2003). This is presumed to underlie the activation of class III gene 
expression by c-Myc in such cells (Gomez-Roman et al, 2003). To determine 
whether this is also likely to explain the induction of pol III transcription by c- 
Myc in cardiomyocytes, co-immunoprecipitation analyses are required to 
demonstrate an interaction between endogenous c-Myc and TFIIIB. In addition, 
to examine the association of c-Myc with pol III promoters in vivo, a more 
sensitive assay for measuring c-Myc promoter occupancy needs to be developed, 
as Chip experiments were unsuccessful in this regard. Assuming that c-Myc does 
activate the transcription of class III genes directly by binding to pol Ill-specific 
promoters, studies aimed at elucidating how this facilitates transcriptional 
activation will be of interest. c-Myc induces the transcription of pol II- 
transcribed target genes through the recruitment of coactivator proteins such as 
HATs (Bouchard et al, 2001; Frank et al, 2001; Frank et al, 2003). These 
enzymes modify histones to create a more open chromatin structure, which
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facilitates access to the transcription machinery (Narlikar et al, 2002). Histone 
deacetylase (HDAC) enzymes antagonise the action of HATs, and maintain 
genes in an inactive state (Narlikar et al, 2002). HDACs have been shown to 
restrain class III gene expression in mammalian cells (Daly and White, 
unpublished results; Sutcliffe et al, 2000). Furthermore, HDACs play an 
important role in restricting the hypertrophic growth of cardiomyocytes (Chang 
et al, 2004; Zhang et al, 2002). Therefore, recruitment of HATs to class III genes 
by c-Myc would be expected to activate pol III transcription, and thus contribute 
to relieving the HD AC-mediated impairment of cardiomyocyte hypertrophy.
As demonstrated in Chapter 3 (Figure 3.8), extracts derived from hypertrophic 
cardiomyocytes transcribe pol III templates more actively in vitro than extracts 
from unstimulated cells. This suggests that, although chromatin structure may 
influence the rate of pol III transcription in vivo, hypertrophic stimulation also 
increases the inherent activity of the transcription machinery. To determine 
whether c-Myc directly participates in this chromatin-independent activation of 
pol III transcription, in vitro assays could be used. For example, if c-Myc 
activates pol III transcription solely by mediating changes in the chromatin 
environment, recombinant c-Myc would not be expected to activate pol III 
transcription in vitro. However, if c-Myc were to contribute to the direct 
activation of transcription by some other means, such as by promoting protein- 
protein interactions between components of the pol III transcription machinery, 
or by displacing the binding of a repressor protein, recombinant c-Myc would be 
predicted to augment pol III transcriptional activity in extracts derived from
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unstimulated cells. Such experiments could provide insights into c-Myc-induced 
class III gene expression.
As with C“Myc, ERK interacts directly with the pol III transcription machinery in 
proliferating cells. Specifically, ERK binds and phosphorylates the Brfl subunit 
of TFIIIB (Felton-Edkins et al, 2003a). This promotes transcription initiation by 
enhancing the interaction between TFIIIB and TFIIIC, and also TFIIIB and pol 
III, and is thought to account for the rapid induction of pol III transcription 
following the serum stimulation of fibroblasts (Felton-Edkins et al, 2003a). 
Although this is likely to contribute to the early activation of class III gene 
expression following hypertrophic stimulation (as depicted in Figure 7.2), 
phosphorylation of Brfl by ERK remains to be formally demonstrated in 
cardiomyocytes. The possibility that ERK could induce pol III transcription by 
more indirect means was also considered in this study. For example, the 
involvement of ERK in the induction of the pol Ill-activator c-Myc was 
explored. This revealed that ERK can indeed induce c-Myc expression in these 
cells, which is likely to contribute to the ability of ERK to promote 
cardiomyocyte protein synthesis, not only through the activation of pol III 
transcription, but also via the induction of several other growth-promoting c-Myc 
targets identified in other cell types (Coller et al, 2000; Dang, 1999; Guo et al, 
2000; O’Connell et al, 2003; Schmidt, 1999). In addition, ERK was shown to 
induce Brfl expression, which, as discussed below, is also involved in the 
upregulation of pol III transcription during cardiomyocyte hypertrophy. Thus, 
these data are indicative of a central role for ERK in pol III transcriptional 
control in cardiomyocytes, as illustrated in Figure 7.1.
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Figure 7.1: ERK is a central regulator of pol HI transcription in 
cardiomyocytes. The various ways in which ERK is likely to induce pol 111 
transcription in cardiomyocytes are illustrated in the diagram. These are as 
follows: 1. through the direct phosphorylation o f TFIIIB; 2. through the 
induction o f c-Myc; 3. through the activation o f Brfl expression. ERK- 
independent mechanisms also apparently contribute to c-Myc and Brfl 
induction. Furthermore, c-Myc potentially regulates Brfl expression via 
consensus E-box sequences found within or upstream o f the Brfl gene.
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TFIIIB is composed of three subunits, Bdpl, Brfl and TBP. Therefore, its 
activity will be influenced by the relative amounts of each of these components. 
In unstimulated cardiomyocytes, Brfl levels are relatively low, and this was 
shown to limit pol III transcription. However, hypertrophic stimulation 
specifically increases the amount of Brfl, such that the abundance of this factor 
no longer restricts class III gene expression. Brfl levels do not respond to the 
growth factor stimulation of fibroblasts (Figure 4.4A; Felton-Edkins et al, 2003a; 
Johnston et al, 2002; Scott et al, 2001). Therefore, this represents a novel 
mechanism for pol III transcriptional induction in mammalian cells, thus 
prompting an investigation into the mechanisms underlying this change in Brfl 
abundance. Hypertrophic stimulation increases Brfl at both the mRNA and 
protein level, consistent with enhanced transcription of the Brfl gene. However, 
further work is required to confirm that elevated Brfl transcripts do result from 
increased gene transcription, and not mRNA stability. As mentioned above, the 
induction of Brfl in cardiomyocytes was shown to be at least partly mediated by 
ERK: ERK activation is sufficient to increase the level of Brfl mRNA and 
protein, whereas ERK inhibition attenuates the induction of B rfl. This is the first 
study to report such ERK-controlled changes in Brfl abundance. By inducing the 
expression of this limiting factor, ERK will indirectly activate pol III 
transcription. Analysis of the genomic region spanning the upstream end of the 
Brfl gene suggested that c-Myc might also indirectly activate class III gene 
expression through the induction of Brfl (as illustrated in Figures 7.1 and 7.2), as 
several potential c-Myc binding sites were identified. However, this has yet to be 
tested experimentally.
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Further investigation is required to fully elucidate the mechanisms controlling the 
activation, or potentially the de-repression, of Brfl expression during 
hypertrophic growth. Moreover, it will be important to establish whether growth 
factor responsive changes in Brfl abundance are unique to cardiomyocytes, or a 
common feature of various different cell types. Conceivably, increased Brfl 
expression may only be required to facilitate enhanced pol III transcription if 
basal Brfl levels are relatively low, such as in differentiated cells (Alzuherri and 
White, 1998), or if demand for class III gene products is unusually high, for 
instance during tumour growth.
Thus, the hypertrophic stimulation of cardiomyocytes induces several molecular 
changes that can promote pol III transcription. It is likely that each of these 
changes, including ERK activation, c-Myc induction and increased Brfl 
expression, will cooperate to attain maximal levels of class III gene expression, 
as illustrated in Figure 7,2. It is also probable that other pathways which promote 
hypertrophic growth will converge on the pol III transcription machinery in 
cardiomyocytes, in order to increase the capability for biosynthesis. For instance, 
signalling through PI3K has been implicated in the hypertrophic process, as the 
activation of this pathway is necessary and sufficient for the induction of 
cardiomyocyte protein synthesis and growth (Boluyt et al, 1997; Conderelli et al, 
2002; Crackower et al, 2002; Schlüter et al, 1998; Schlüter et al, 1999; Shioi et 
al, 2000; Shioi et al, 2002). Consistent with the pol III transcription machinery 
being a common downstream taiget of growth-promoting signalling cascades, 
preliminary data indicate that PI3K regulates class III gene expression in 
cardiomyocytes; PI3K inhibition abrogates pol III transcription, whereas the
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Figure 7.2: Mechanisms contributing to the induction of pol III 
transcription following the hypertrophic stimulation of cardiomyocytes.
Hypertrophic stimulation leads to the rapid activation of ERK and c-Myc, which 
are likely to directly target TFIIIB, thus leading to the initial induction of pol III 
transcription. However, limiting levels of Brfl, and hence TFIIIB, potentially 
restrict the extent to which these molecules can activate the pol III transcription 
machinery at early timepoints. The increase in Brfl abundance by 6 hours would 
relieve this restriction, thus allowing the attainment of maximum class III gene 
expression. Decreased c-Myc levels might account for the downregulation of pol 
III transcription occumng 24 to 48 hours after hypertrophic stimulation. 
Abbreviations used: TFIIIB, IIIB; TFIIIC, IIIC; c-Myc, Myc. Bold arrows below 
transcription complexes indicate active class III gene transcription; dashed 
arrows indicate transcription at a reduced rate.
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constitutive activation of this kinase in the heart is accompanied by elevated 5S 
rRNA levels (data not shown). Additional work is required to verify these 
findings, but they support the proposal that increased pol III transcription is 
critical for hypertrophic growth,
7.1.2 Pol III transcription is negatively regulated by RB in cardiomyocytes
RB is another example of a protein that interacts with TFIIIB in proliferating 
cells (Chu et al, 1997; Larminie et al, 1997). However, unlike ERK and c-Myc, 
this interaction facilitates pol III transcriptional repression (Chu et al, 1997; 
Larminie et al, 1997; Sutcliffe et al, 2000). Experiments carried out by WR 
MacLellan and colleagues (unpublished) have shown that RB is involved in 
restricting cardiomyocyte growth following hypertrophic stimulation of the heart. 
This finding challenges the traditionally held view that RB is principally 
concerned with regulating cell division, by demonstrating that cell growth 
inhibition may be an equally important, and in some cases primary, function of 
RB. Data presented in Chapter 5 provide an explanation for this RB-mediated 
growth restraint, by demonstrating that RB negatively regulates pol III 
transcription in these cells. This is the first study to show that RB controls pol III 
transcription in situ and in a non-dividing cell type. Thus, by inhibiting class III 
gene expression, RB could restrict cell growth, whether it be a prerequisite for 
cell division, as in the case of fibroblasts, or the hypertrophic enlargement of 
terminally differentiated cells.
In fibroblasts, hyperphosphorylation of RB, induced by mitogenic stimulation, 
relieves pol III transcriptional repression (Scott et al, 2001). Exposure of
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cardiomyocytes to hypertrophie stimuli also induces RB phosphorylation 
(Figures 4.3 and 4.6; Nozato et al, 2001; Sadoshima et al, 1997). However, 
although RB is clearly involved in limiting the rate of pol III transcription under 
hypertrophic conditions in the heart, the relevance of RB phosphorylation to the 
induction of class III gene expression during hypertrophy has yet to be 
established. Adenoviral-mediated expression of a non-phosphorylatable RB 
mutant in cultured cardiomyocytes could be used to investigate this possibility.
7.2 Control of U6 snRNA and 7SK gene expression
The mechanisms described above are likely to regulate the expression of the 
majority of class III genes, by targeting a common component of the basal 
transcription machinery, namely TFIIIB, and thus will impact on the production 
of numerous RNAs involved in cellular metabolism. However, a small number of 
pol Ill-transcribed genes utilise a distinct TFIIIB complex. Specifically, those 
with a type 3 promoter, including the U6 snRNA and 7SK genes, do not require 
Brfl, but instead utilise the related factor Brf2 (Schramm and Hernandez, 2002; 
Schramm et al, 2000). Furthermore, this TFIIIB-like complex is recruited to type 
3 promoters through its interactions with SNAP^, rather than with TFIIIC 
(Schramm and Hernandez, 2002). In fact, TFIIIC is not involved in the 
expression of these genes at all (see Chapter 1). It would be interesting to 
determine whether the transcription of such genes is regulated by the same 
mechanisms that control transcription from type 1 and 2 promoters, or whether 
entirely different mechanisms are employed. Potentially, Brf2 may substitute for 
Brfl as a target for regulatory strategies, with the abundance and phosphorylation
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status of this subunit determining the rate of production of such transcripts. 
Alternatively, SNAPc may be an additional target of known pol III regulators, 
allowing the coordinate induction of all types of class III gene.
7.3 Potential for the coordinated production of 
components of the translational apparatus during 
cardiomvocvte hypertrophy
Pol III transcription is often coordinated with transcription by pol I, thus 
allowing the simultaneous production of essential components of the cellular 
biosynthetic machinery. In keeping with this, class I gene expression increases in 
response to the hypertrophic stimulation of cardiomyocytes (Hannan et al, 1995; 
Hannan et al, 1996a; Luyken et al, 1996; McDermott et al, 1989; McDermott et 
al, 1991). It is probable that this synchronous induction of class I and III gene 
transcription is achieved by the use of common regulatory mechanisms. Studies 
on the control of pol I transcription in cardiomyocytes have suggested that an 
increase in the phosphorylation and abundance of the pol I-specific transcription 
factor UBF regulates the activation of class I gene expression during hypertrophy 
(Brandenburger et al, 2001; Brandenburger et al, 2003; Hannan et al, 1995; 
Hannan et al, 1996a, b; Luyken et al, 1996). Although it has not yet been 
determined which signal transduction pathways are responsible for this control, 
ERK, c-Myc and RB are likely to be involved. For example, ERK-directed 
phosphorylation of UBF has been documented to mediate growth factor- 
stimulated increases in pol I transcription in other cell types (Stefanovsky et al.
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2001). Furthermore, UBF expression is controlled by c-Myc in differentiating 
granulocytes (Poortinga et al, 2004). In addition, RB interacts with UBF leading 
to pol I transcriptional repression in proliferating cells (Hannan et al, 2000). 
Thus, by targeting TFIIIB and UBF, these regulatory mechanisms could 
effectively coordinate class I and III gene expression in order to meet the 
biosynthetic needs of growing cardiomyocytes.
The activation of pol I transcription is essential for cardiomyocyte growth 
(Brandenburger et al, 2001). Given that pol III transcribes complementary 
components of the protein synthetic machinery, and that numerous regulatory 
mechanisms are involved in ensuring the appropriate expression of class III 
genes, it is highly probable that increased pol III transcription will also be a 
critical feature of cardiomyocyte hypertrophy, and indeed cell growth in general. 
Ultimately, further investigation is required to confirm this likelihood, by 
specifically preventing the hypertrophy-associated increase in pol III 
transcription, and analysing the effects of this inhibition on cell growth. Such 
exploration depends on the availability of agents that will specifically inhibit the 
expression of class III genes. This could be achieved by various means. For 
example, given that Brfl is essential for tRNA and 5S rRNA production, 
antisense mRNA or siRNA directed against this factor could be used to knock 
down Brfl during hypertrophy, and thus specifically diminish the expression of 
these and many other pol Ill-transcribed genes to basal levels. Furthermore, a 
recent study has demonstrated that the bacterial compound tagetitoxin, which had 
previously been shown to specifically abrogate pol III transcription in vitro and 
in Xenopus laevis oocytes (Steinberg et al, 1990), can also be used to inhibit pol
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III transcription in cultured mammalian cells (Allen et al, 2004). These 
approaches are likely to yield valuable information regarding the mechanisms 
underlying cell growth, with particular relevance to a process associated with 
heart disease.
In summary, this thesis describes an unprecedented investigation into the growth- 
associated regulation of pol III transcription in a non-dividing, terminally 
differentiated cell type. Moreover, the work presented contributes to the current 
understanding of the mechanisms underlying cardiomyocyte hypertrophy, by 
demonstrating that class III gene expression is subject to control during 
hypertrophic growth through the concerted action of several proteins. 
Appreciating the molecular basis of hypertrophic growth has important 
implications for the rational design of therapies aimed at treating and preventing 
sustained myocai’dial hypertrophy, and its associated human pathologies.
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